

```

HIGHLIGHT set on as ''
HIGHLIGHT set on as ''
? begin 5,73,155,399
    25may08 08:07:11 User208760 Session D2943.2
        $0.00    0.115 DialUnits File410
    $0.00 Estimated cost File410
    $0.06 TELNET
    $0.06 Estimated cost this search
    $0.61 Estimated total session cost    0.267 DialUnits

```

```

SYSTEM:OS - DIALOG OneSearch
File 5:Biosis Previews(R) 1926-2008/May W3
(c) 2008 The Thomson Corporation
File 73:EMBASE 1974-2008/May 22
(c) 2008 Elsevier B.V.
*File 73: The 2008 Emtree Thesaurus has been loaded. Please see
HELP NEWS 72 for details.
File 155:MEDLINE(R) 1950-2008/May 26
(c) format only 2008 Dialog
*File 155: MEDLINE has reloaded. Please see HELP NEWS 155
for details.
File 399:CA SEARCH(R) 1967-2008/UD=14821
(c) 2008 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

```

```

Set Items Description
---

```

```

? e au=amagai masayuki

```

Ref	Items	Index-term
E1	1	AU=AMAGAI MASAHIRO
E2	1	AU=AMAGAI MASAYUK
E3	208	*AU=AMAGAI MASAYUKI
E4	2	AU=AMAGAI MIEKO
E5	1	AU=AMAGAI MIKIKO
E6	8	AU=AMAGAI N
E7	9	AU=AMAGAI N.
E8	2	AU=AMAGAI NAKO
E9	4	AU=AMAGAI NAOMI
E10	3	AU=AMAGAI NORIKO
E11	1	AU=AMAGAI R
E12	5	AU=AMAGAI R.

```

Enter P or PAGE for more

```

```

? s e2,e3
    1 AU=AMAGAI MASAYUK
    208 AU=AMAGAI MASAYUKI
S1 209 E2,E3

```

```

? e au=nishikawa takeji ?

```

Ref	Items	Index-term
E1	1	AU=NISHIKAWA TAKEIJI
E2	266	AU=NISHIKAWA TAKEJI
E3	0	*AU=NISHIKAWA TAKEJI ?
E4	1	AU=NISHIKAWA TAKENOB
E5	2	AU=NISHIKAWA TAKEO
E6	108	AU=NISHIKAWA TAKESHI
E7	2	AU=NISHIKAWA TAKEYO
E8	1	AU=NISHIKAWA TAKU
E9	4	AU=NISHIKAWA TAKUJI

E10 4 AU=NISHIKAWA TAKURO
 E11 1 AU=NISHIKAWA TAKUROH
 E12 3 AU=NISHIKAWA TAKUSHI

Enter P or PAGE for more

? s el,e2
 1 AU=NISHIKAWA TAKEIJI
 266 AU=NISHIKAWA TAKEJI
 S2 267 E1,E2
 ? s (s1 or s2) and (pemphigus) and (cd40L or cd40(w)ligand or cd154 or gp39 or
 cd154)
 209 S1
 267 S2
 18072 PEMPHIGUS
 8469 CD40L
 34411 CD40
 539602 LIGAND
 16205 CD40(W)LIGAND
 3765 CD154
 798 GP39
 3765 CD154
 S3 2 (S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR
 CD154 OR GP39 OR CD154)
 ? rd s3
 S4 1 RD S3 (unique items)
 ? t s4/7/all

4/7/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980
 Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus
 vulgaris mouse model
 AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki;
 Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji;
 Amagai Masayuki (Reprint)
 AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35
 Shinanomachi, Tokyo 1608582, Japan**Japan
 AUTHOR E-MAIL ADDRESS: amagai@sc.itc.keio.ac.jp
 JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006
 2006
 ISSN: 0022-202X
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease
 caused by IgG autoantibodies against desmoglein 3 (Dsg3). We have
 recently developed an active disease mouse model for PV by adoptive
 transfer of splenocytes from Dsg3(-/-) mice. The purpose of this study
 was to determine the role of CD40/CD154 interaction in the pathogenic
 antibody production and development of the disease in PV model mice. When
 anti-CD154 monoclonal antibody (mAb) was administered to recipient mice
 prior to adoptive transfer, anti-CD154 mAb almost completely blocked the
 anti- Dsg3 IgG production and prevented blister formation. The blockade
 of CD40/CD154 interaction induced tolerance against Dsg3 as the
 suppression of antibody production was observed through day 70, and it
 was maintained even after challenge by immunization with recombinant
 mouse Dsg3 or by adoptive transfer of immunized Dsg3(-/-) splenocytes.
 Furthermore, the tolerance to Dsg3 was transferable because cotransfer of

splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/CD154 interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

? s (pemphigus) and (cd40L or cd40(w)ligand or cd154 or gp39 or cd154)
18072 PEMPHIGUS
8469 CD40L
34411 CD40
539602 LIGAND
16205 CD40(W)LIGAND
3765 CD154
798 GP39
3765 CD154
S5 37 (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
? rd s5
S6 25 RD S5 (unique items)
? t s6/7/all

6/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020104725 BIOSIS NO.: 200800151664
T-B cell interaction is crucial for the induction of desmoglein 3-specific IgG autoantibodies in an HLA-class II transgenic mouse model of pemphigus vulgaris
AUTHOR: Eming R (Reprint); Hertl M; Schmidt J; Podstawa E; Feliciani C; Sonderstrup G
AUTHOR ADDRESS: Univ Marburg, Marburg, Germany**Germany
JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT 2007 2007
CONFERENCE/MEETING: 37th Annual Meeting of the European-Society-for-Dermatological-Research Zurich, SWITZERLAND September 05 -08, 2007; 20070905
SPONSOR: European Soc Dermatol Res
ISSN: 0022-202X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

6/7/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019927481 BIOSIS NO.: 200700587222
Increased serum levels of circulating CD40 ligand in patients with bullous pemphigoid: Preliminary results
AUTHOR: Watanabe R (Reprint); Ishiura N; Nakashima H; Yazawa N; Kuwano Y; Tada Y; Okochi H; Fujimoto M; Tamaki K
AUTHOR ADDRESS: Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan**Japan
AUTHOR E-MAIL ADDRESS: fujimoto-m@umin.ac.jp
JOURNAL: Dermatology (Basel) 215 (3): p180-186 2007 2007
ITEM IDENTIFIER: doi:10.1159/000106573

ISSN: 1018-8665
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: Autoimmune bullous diseases are characterized by autoantibodies against specific adhesion molecules of the skin and/or mucous membrane. While these autoantibodies are known to play a primary role in the disease manifestation, it remains unknown how disease-specific autoreactive B cells and autoantibodies are induced. Recent studies have indicated the importance of the CD40 and CD40 ligand (CD40L) receptor-ligand pair in the immunopathogenesis of autoimmune diseases. ***CD40L*** circulates in soluble form, and some reports suggest that serum soluble CD40L (sCD40L) levels are increased in various autoimmune diseases. Objectives: To determine serum sCD40L levels in patients with pemphigus vulgaris (PV) and bullous pemphigoid (BP), and to determine their correlation with clinical findings and laboratory findings. Patients and Methods: Sera from 10 PV patients, 35 BP patients and 12 normal controls were subjected to ELISA assays to measure serum levels of sCD40L, anti-desmoglein-3 antibody and anti-BP180 antibody. Results and Conclusions: Circulating sCD40L levels were significantly elevated in BP patients, but not in PV patients. Serum sCD40L levels increased in the early stage of disease onset and recurrence in BP patients. In conclusion, circulating sCD40L levels may be a useful marker for early activation of autoimmune diathesis and, furthermore, an effective therapeutic target in patients with BP.
Copyright (C) 2007 S. Karger AG, Basel.

6/7/3 (Item 3 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019830322 BIOSIS NO.: 200700490063
The CD40/CD40 ligand system is involved in the pathogenesis of pemphigus
AUTHOR: Caproni Marzia; Antiga Emiliano; Torchia Daniele; Volpi Walter; del Bianco Elena; Cappetti Alessio; Feliciani Claudio; Fabbri Paolo (Reprint)
AUTHOR ADDRESS: Via Pergola, 58-60, I-50121 Florence, Italy**Italy
AUTHOR E-MAIL ADDRESS: fabbri@unifi.it
JOURNAL: Clinical Immunology (Orlando) 124 (1): p22-25 JUL 2007 2007
ITEM IDENTIFIER: doi:10.1016/j.clim.2007.04.007
ISSN: 1521-6616
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The CD40/CD40 ligand (CD40L) system has never been investigated in autoimmune bullous diseases belonging to the ***pemphigus*** group in humans. Skin biopsy specimens from 21 patients with pemphigus vulgaris, 10 with pemphigus foliaceus and healthy volunteers were studied by immunohistochemistry (for CD40 and CD40L) and reversal transcriptase polymerase-chain reaction (for CD40L), while sera were analyzed by enzyme-linked immunosorbent assay for soluble ***CD40L***. In all ***pemphigus*** specimens, the basal and suprabasal layers of the epidermis and perivascular infiltrating cells were CD40+. ***CD40L*** + cells moderately infiltrated the perivascular and interstitial dermis of ***pemphigus*** specimens. CD40L mRNA was strongly evident in all pemphigus samples while no signal was detected in the healthy controls. The expression of soluble CD40L was significantly greater in pemphigus sera

than in controls. We showed here that the CD40/ ***CD40L*** system is upregulated both in lesional skin and in serum of patients with ***pemphigus***. (c) 2007 Elsevier Inc. All rights reserved.

6/7/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980
Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model
AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki (Reprint)
AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan**Japan
AUTHOR E-MAIL ADDRESS: amagai@esc.itc.keio.ac.jp
JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006
2006
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3). We have recently developed an active disease mouse model for PV by adoptive transfer of splenocytes from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti- ***CD154*** monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti- Dsg3 IgG production and prevented blister formation. The blockade of CD40/ ***CD154*** interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day 70, and it was maintained even after challenge by immunization with recombinant mouse Dsg3 or by adoptive transfer of immunized Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/ ***CD154*** interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

6/7/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: A step toward antigen-specific therapy?
AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A
AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel Hill, NC 27599 USA**USA

AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu
JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006
2006
ISSN: 0022-202X
DOCUMENT TYPE: Article; Editorial
RECORD TYPE: Citation
LANGUAGE: English

6/7/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045
Blockade of CD40/CD40L interaction has therapeutic benefits in the pemphigus vulgaris mouse model
AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T; Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)
AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo, Japan**Japan
JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002
2002
MEDIUM: print
CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515
ISSN: 0022-202X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

6/7/7 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874
B cells move to centre stage: Novel opportunities for autoimmune disease treatment
Browning J.L.
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02445, United States
AUTHOR EMAIL: Jeff.Browning@biogenidec.com
CORRESP. AUTHOR: Browning J.L.
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02445, United States
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery (Nat. Rev. Drug Discov.) (United Kingdom)
July 1, 2006, 5/7 (564-576)
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784
PUBLISHER ITEM IDENTIFIER: N2085
DOI: 10.1038/nrd2085
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 173

The B-cell arm of the immune system has long been appreciated for its crucial role in pathogen resistance, but in the study of many autoimmune diseases, T cells have dominated the limelight for decades. However, the development of the B-cell-depleting antibody rituximab as a lymphoma therapy has provided a tool to probe the contribution made by B cells in several immune disorders. Recently, the success of B-cell depletion with

rituximab in the treatment of rheumatoid arthritis has stimulated investigation of its effects in several other immune disorders, and considerable interest in the potential of drugs that can modulate B-cell function for the treatment of such diseases in general. This article discusses the role of B cells in a range of autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus, and analyses approaches to therapeutic B-cell manipulation.

6/7/8 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

148306456 CA: 148(14)306456e PATENT

Methods of identifying a marker of regulatory CD4+ T cells

INVENTOR(AUTHOR): Dromey, James A.; Mannering, Stuart I.; Harrison,

Leonard C.

LOCATION: Australia

ASSIGNEE: The Walter and Eliza Hall Institute of Medical Research

PATENT: PCT International; WO 200828229 A1 DATE: 20080313

APPLICATION: WO 2007AU1302 (20070905) *US 2006PV842548 (20060905)

PAGES: 78pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

C12N-0005/08

A I F B 20060101

H AU

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA215010 Immunochemistry

IDENTIFIERS: regulatory T lymphocyte CD52 immunotherapy autoimmune disease cancer infection

DESCRIPTORS:

Apoidea... Cat... Dermatophagoides... Felis catus...

allergy; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Transplant rejection...

allotransplant; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Inflammation... Spinal column,disease...

ankylosing spondylitis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Kidney,disease...

anti-tubular basement membrane disease; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Blood transfusion...

apheresis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Antigens...

autoantigens; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Autoimmune disease... Inflammation... Thyroid gland,disease...

autoimmune thyroiditis; regulatory CD4+CD52+ T cells and their use in

immunotherapy for autoimmune disease, infection, and cancer

Myocarditis... Thyroid gland,disease...
autoimmune; regulatory CD4+CD52+ T cells and their use in immunotherapy
for autoimmune disease, infection, and cancer

CD antigens...
CD52; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Uterus,neoplasm...
cervix; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Inflammatory bowel disease...
Crohn's disease; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...
desmoglein 1; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...
desmoglein 3; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Cardiomyopathy...
dilated, familial; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Ileitis...
distal; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Interferons...
γ; regulatory CD4+CD52+ T cells and their use in immunotherapy
for autoimmune disease, infection, and cancer

Kidney,disease...
Goodpasture's syndrome; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...
gp39; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Transplant and Transplantation...
graft-vs.-host reaction; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Lymphatic system...
gut-assocd.; regulatory CD4+CD52+ T cells and their use in
immunotherapy for autoimmune disease, infection, and cancer

Aggreccans...
G1; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Heat-shock proteins...
HSP 60; regulatory CD4+CD52+ T cells and their use in immunotherapy for
autoimmune disease, infection, and cancer

Proteins...
IGRP (islet-specific glucose-6-phosphate catalytic subunit-related
protein); regulatory CD4+CD52+ T cells and their use in immunotherapy
for autoimmune disease, infection, and cancer

Cell proliferation...
inhibition; regulatory CD4+CD52+ T cells and their use in immunotherapy
for autoimmune disease, infection, and cancer

Autoimmune disease...
insulin autoimmune syndrome; regulatory CD4+CD52+ T cells and their use
in immunotherapy for autoimmune disease, infection, and cancer

Autoimmune disease...
insulin-dependent diabetes mellitus; regulatory CD4+CD52+ T cells and
their use in immunotherapy for autoimmune disease, infection, and
cancer

Diabetes mellitus...

insulin-dependent; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Dermatomyositis...
juvenile; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Plasmapheresis...
leukapheresis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Infection...
measles; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Glycoproteins...
MOG (myelin oligodendrocyte glycoprotein); regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Lymphatic system...
mucosa-assocd.; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Skin,disease...
pemphigus; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Bone,disease... Inflammation...
polychondritis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Arthritis...
psoriatic arthritis; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Addison's disease... Allergy... Antigens... Autoimmune disease...
Autoimmune hepatitis... Biomarkers... Bladder,neoplasm... Bone marrow...
CD4-positive T cell... Celiac disease... Cholinergic receptors... Cord blood... Cytokines... Diagnosis... Filaggrin... Food allergy... Gliadins...
Glutenins... Graves' disease... Hematopoietic neoplasm... Hepatitis...
Human immunodeficiency virus... Human... Immunotherapy... Infection...
Inflammatory bowel disease... Interleukin 17... Liver... Lung,neoplasm...
Lupus erythematosus... Lyme disease... Lymph node... Lymphatic system...
Lymphoma... Malaria... Mammary gland,neoplasm... Meningitis... Mononuclear cell(leukocyte)... Multiple sclerosis... Myasthenia gravis... Myelin basic protein... Neoplasm... Ovary,neoplasm... Pancreas,neoplasm... Pertussis...
Phenotypes... Prostate gland,neoplasm... Proteolipid protein... Rheumatoid arthritis... Scleroderma... Sjogren syndrome... Skin,neoplasm... Spleen...
Tetanus... Thymus gland... Thyroglobulin... Thyrotropin receptors...
Tuberculosis... Vimentins...
regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Toxoids...
tetanus; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Autoimmune disease...
thyroid; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

Collagens...
type II; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer

CAS REGISTRY NUMBERS:
7440-41-7 biological studies, syndrome; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer
9024-58-2 GAD65; regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and cancer
9031-28-1 9035-68-1 80449-01-0 302355-25-5 regulatory CD4+CD52+ T cells and their use in immunotherapy for autoimmune disease, infection, and

cancer

6/7/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148055086 CA: 148(3)55086n PATENT
Preparation of pyrrolopyrimidine compounds as protein kinase inhibitors
INVENTOR(AUTHOR): Brain, Christopher Thomas; Thoma, Gebhard; Sung, Moo Je
LOCATION: Switz.
ASSIGNEE: Novartis A.-G.; Novartis Pharma G.m.b.H.
PATENT: PCT International ; WO 2007/140222 A2 DATE: 2007/1206
APPLICATION: WO 2007/US69595 (20070524) *US 2006PV808605 (20060526)
PAGES: 213pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA228016 Heterocyclic Compounds (More Than One Hetero Atom)

CA201XXX Pharmacology

CA263XXX Pharmaceuticals

IDENTIFIERS: pyrrolopyrimidine prepn protein kinase inhibitor
proliferative disease treatment

DESCRIPTORS:

Transplant rejection...

acute; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful
in treatment and prevention of diseases as well as in combination
therapy

Drug resistance...

adrenergic; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Nervous system,disease...

amyotrophic lateral sclerosis, familial; prepn. of pyrrolopyrimidines
as protein kinase inhibitors useful in treatment and prevention of
diseases as well as in combination therapy

Antibodies and Immunoglobulins...

anti- CD45RB; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...

anti-CD2; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...

anti-CD3; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...

anti-CD4; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in

combination therapy

Antibodies and Immunoglobulins...
anti-CD80; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...
anti-CD86; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...
anti-ICAM-3; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...
anti-IL-2 receptor; prepn. of pyrrolopyrimidines as protein kinase
inhibitors useful in treatment and prevention of diseases as well as in
combination therapy

Antibodies and Immunoglobulins...
anti-TNF; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Dermatitis...
atopic; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Mental and behavioral disorders...
autism; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in
combination therapy

Anemia(disease)... Anemia(disease)... Autoimmune disease... Autoimmune
disease...
autoimmune hemolytic anemia; prepn. of pyrrolopyrimidines as protein
kinase inhibitors useful in treatment and prevention of diseases as
well as in combination therapy

Autoimmune disease...
autoimmune thrombocytopenia, neonatal; prepn. of pyrrolopyrimidines as
protein kinase inhibitors useful in treatment and prevention of
diseases as well as in combination therapy

Autoimmune disease... Inflammation... Thyroid gland,disease...
autoimmune thyroiditis; prepn. of pyrrolopyrimidines as protein kinase
inhibitors useful in treatment and prevention of diseases as well as in
combination therapy

Skin,disease...
bullous pemphigoid; prepn. of pyrrolopyrimidines as protein kinase
inhibitors useful in treatment and prevention of diseases as well as in
combination therapy

Disease,animal...
cardiotomy syndrome; prepn. of pyrrolopyrimidines as protein kinase
inhibitors useful in treatment and prevention of diseases as well as in
combination therapy

Viral hepatitis...
chronic active; prepn. of pyrrolopyrimidines as protein kinase
inhibitors useful in treatment and prevention of diseases as well as in
combination therapy

Intestine,neoplasm...
colon; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful
in treatment and prevention of diseases as well as in combination
therapy

Intestine,neoplasm...
colorectal; prepn. of pyrrolopyrimidines as protein kinase inhibitors
useful in treatment and prevention of diseases as well as in

combination therapy

Diabetes mellitus...
 complications from; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Fusion proteins(chimeric proteins)...
 constructed from CD40 and gp39; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Inflammation...
 Crohn's disease; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Intestine,disease...
 Crohn's; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Fusion proteins(chimeric proteins)...
 CTLA4-Ig; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Blood,disease...
 cytopenia, autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Nervous system,disease...
 degeneration; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Platelet(blood)...
 disease, autoimmune thrombocytopenia, neonatal; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Blood cell...
 disease, cytopenia, autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Immunity...
 disorders; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Macrolides...
 epothilones; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Autoimmune disease...
 exptl. autoimmune encephalomyelitis; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Encephalomyelitis...
 exptl. autoimmune; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Enzymes...
 FLK-4 kinase; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Inflammation... Kidney,disease...
 glomerulonephritis; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Kidney,disease...
Goodpasture's syndrome; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Glycoproteins...
gp39; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Transplant and Transplantation...
graft-vs.-host reaction; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Nervous system,disease...
Guillain-Barre syndrome; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Neoplasm...
head and neck; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Anemia(disease)...
hemolytic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Cytoprotective agents...
hepatoprotective agents; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Allergy...
hypersensitivity, T-cell mediated; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Purpura(disease)...
idiopathic thrombocytopenic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Addison's disease...
idiopathic; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Allergy...
immediate hypersensitivity; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Tumor necrosis factors...
inhibitors; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Reperfusion...
injury, incurred during organ transplantation; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Autoimmune disease...
insulin-dependent diabetes mellitus; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Diabetes mellitus...
insulin-dependent; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Kidney...

mesangium, proliferative disorders; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Connective tissue,disease...

mixed connective tissue disease; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

Antibodies and Immunoglobulins...

monoclonal, OKT3; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

(etc.)...

CAS REGISTRY NUMBERS:

7440-57-5D compds., prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

150977-45-0D fusion with Gst, GST-Flk1; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

9031-44-1 329900-75-6 inhibitors; prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in treatment and prevention of diseases as well as in combination therapy

50-07-7 50-44-2 51-21-8 54-62-6 57-22-7 59-05-2 96-22-0 99-05-8
107-11-9 109-01-3 109-04-6 147-94-4 148-82-3 364-76-1 402-67-5
518-28-5 577-72-0 616-24-0 617-89-0 801-52-5 927-80-0 2028-63-9
2410-93-7 2955-88-6P 4744-08-5 7154-73-6 9059-09-0 10160-87-9
13889-98-0 14254-57-0 15228-71-4 15663-27-1 20830-81-3 23214-92-8
23326-27-4 23360-92-1 23499-01-6P 26905-03-3 27301-54-8 29767-20-2
33069-62-4 33419-42-0 34334-19-5P 36082-50-5 39856-50-3 41575-94-4
49845-33-2 50609-01-3P 50935-04-1 53123-88-9 53643-48-4 59865-13-3
64099-82-7 64724-29-4 75706-12-6 79079-06-4 79421-45-7 80449-02-1
88201-45-0 92394-00-8 95058-81-4 98037-52-6 101463-26-7
103843-29-4 104775-65-7P 104987-11-3 108891-60-7 112677-72-2P
114051-78-4 114899-77-3 117091-64-2 128794-94-5 137632-03-2
137632-06-5 137632-09-8 138238-67-2 138359-29-2 139691-76-2
140208-17-9 141349-86-2 141349-87-3 141349-89-5 141349-91-9
141350-03-0 141436-78-4 141460-90-4 142243-02-5 143375-65-9
143597-35-7 144114-11-4 144114-16-9 144697-17-6 144941-32-2
144941-35-5 145539-86-2 146702-84-3 147014-95-7 147014-96-8
147014-97-9 148047-29-4 148047-34-1 149146-03-2 149146-92-9
149147-12-6 149147-16-0 150027-15-9 150316-06-6 150428-23-2
150977-45-0 151769-13-0 152478-56-3 152478-57-4 152743-99-2
153190-51-3 153190-61-5 153190-71-7 153570-69-5 155215-87-5
155948-74-6 157482-36-5 160647-73-4P 161384-16-3 165245-96-5
165245-99-8 170780-46-8 170911-92-9 182372-13-0 182938-13-2
221198-99-8 303014-92-8 330197-29-0 372092-80-3 373824-30-7P
386705-49-3 403652-37-9 519003-68-0P 571188-59-5 571189-49-6P
657410-79-2P 733039-20-8 885693-22-1P 890652-00-3P 900507-37-1P
909562-81-8P 926200-11-5P 926211-47-4P 926227-55-6P 959795-56-3P
959795-57-4P 959795-58-5P 959795-59-6P 959795-60-9P 959795-61-0P
959795-62-1P 959795-63-2P 959795-64-3P 959795-65-4P 959795-66-5P
959795-67-6P 959795-68-7P 959795-69-8P 959795-70-1P 959795-71-2P
959795-72-3P 959795-73-4P 959795-74-5P 959795-75-6P 959795-76-7P
959795-77-8P 959795-78-9P 959795-79-0P 959795-80-3P 959795-81-4P
959795-82-5P 959795-83-6P 959795-84-7P 959795-85-8P 959795-86-9P
959795-87-0P 959795-88-1P 959795-89-2P 959795-90-5P 959795-91-6P
959795-92-7P 959795-93-8P 959795-94-9P 959795-95-0P 959795-96-1P
959795-97-2P 959795-98-3P 959795-99-4P 959796-00-0P 959796-01-1P
959796-02-2P 959796-03-3P 959796-04-4P 959796-05-5P 959796-06-6P
959796-07-7P 959796-08-8P 959796-09-9P 959796-10-2P 959796-11-3P
959796-12-4P 959796-13-5P 959796-14-6P 959796-15-7P 959796-16-8P

959796-17-9P	959796-18-0P	959796-19-1P	959796-20-4P	959796-21-5P
959796-22-6P	959796-23-7P	959796-24-8P	959796-25-9P	959796-26-0P
959796-27-1P	959796-28-2P	959796-29-3P	959796-30-6P	959796-31-7P
959796-32-8P	959796-33-9P	959796-34-0P	959796-35-1P	959796-36-2P
959796-37-3P	959796-38-4P	959796-39-5P	959796-40-8P	959796-41-9P
959796-42-0P	959796-43-1P	959796-44-2P	959796-45-3P	959796-46-4P
959796-47-5P	959796-48-6P	959796-49-7P	959796-50-0P	959796-51-1P
959796-52-2P	959796-53-3P	959796-54-4P	959796-55-5P	959796-56-6P
959796-57-7P	959796-58-8P	959796-59-9P	959796-60-2P	959796-61-3P
959796-62-4P	959796-63-5P	959796-64-6P	959796-65-7P	959796-66-8P
959796-67-9P	959796-68-0P	959796-69-1P	959796-70-4P	959796-71-5P
959796-72-6P	959796-73-7P	959796-74-8P	959796-75-9P	959796-76-0P
959796-77-1P	959796-78-2P	959796-79-3P	959796-80-6P	959796-81-7P
959796-82-8P	959796-83-9P	959796-84-0P	959796-85-1P	959796-86-2P
959796-87-3P	959796-88-4P	959796-89-5P	959796-90-8P	959796-91-9P
959796-92-0P	959796-93-1P	959796-94-2P	959796-95-3P	959796-96-4P
959796-97-5P	959796-98-6P	959796-99-7P	959797-00-3P	959797-01-4P
959797-02-5P	959797-03-6P	959797-04-7P	959797-05-8P	959797-06-9P
959797-07-0P	959797-08-1P	959797-09-2P	959797-10-5P	959797-11-6P
959797-12-7P	959797-13-8P	959797-14-9P	959797-15-0P	959797-16-1P
959797-17-2P	959797-18-3P	959797-19-4P	959797-20-7P	959797-21-8P
959797-22-9P	959797-23-0P	959797-24-1P	959797-25-2P	959797-26-3P
959797-27-4P	959797-28-5P	959797-29-6P	959797-30-9P	959797-31-0P
959797-32-1P	959797-33-2P	959797-34-3P	959797-35-4P	959797-36-5P
959797-37-6P	959797-38-7P	959797-39-8P	959797-40-1P	959797-41-2P
959797-42-3P	959797-43-4P	959797-44-5P	959797-45-6P	959797-46-7P
959797-47-8P	959797-48-9P	959797-49-0P	959797-50-3P	959797-51-4P
959797-52-5P	959797-53-6P	959797-54-7P	959797-55-8P	959797-56-9P
959797-57-0P	959797-58-1P	959797-59-2P	959797-60-5P	959797-61-6P
959797-62-7P	959797-63-8P	959797-64-9P	959797-65-0P	959797-66-1P
959797-67-2P	959797-68-3P	959797-69-4P	959797-70-7P	959797-71-8P
959797-72-9P	959797-73-0P	959797-74-1P	959797-75-2P	959797-76-3P
959797-77-4P	959797-78-5P	959797-79-6P	959797-80-9P	959797-81-0P
959797-82-1P	959797-83-2P	959797-84-3P	959797-85-4P	959797-86-5P
959797-87-6P	959797-88-7P	959797-89-8P	959797-90-1P	959797-91-2P
959797-92-3P	959797-93-4P	959797-94-5P	959797-95-6P	959797-96-7P
959797-97-8P	959797-98-9P	959797-99-0P	959798-00-6P	959798-01-7P
959798-02-8P	959798-03-9P	959798-04-0P	959798-05-1P	959798-06-2P
959798-07-3P	959798-08-4P	959798-09-5P	959798-10-8P	959798-11-9P
959798-12-0P	959798-13-1P	959798-14-2P	959798-15-3P	959798-16-4P
959798-17-5P	959798-18-6P	959798-19-7P	959798-20-0P	959798-21-1P
959798-22-2P	959798-23-3P	959798-24-4P	959798-25-5P	959798-26-6P
959798-27-7P	959798-28-8P	959798-29-9P	959798-30-2P	959798-31-3P
959798-32-4P	959798-33-5P	959798-34-6P	959798-35-7P	959798-36-8P
959798-37-9P	959798-38-0P	959798-40-4P	959798-42-6P	959798-43-7P
959798-44-8P	959798-45-9P	959798-46-0P	959798-47-1P	959798-48-2P
959798-49-3P	959798-50-6P	959798-51-7P	959798-52-8P	959798-53-9P
959798-54-0P	959798-55-1P	959798-56-2P	959798-57-3P	959798-58-4P
959798-59-5P	959798-60-8P	959798-61-9P	959798-62-0P	959798-63-1P
959798-64-2P	959798-65-3P	959798-66-4P	959798-67-5P	959798-68-6P
959798-69-7P	959798-70-0P	959798-71-1P	959798-72-2P	959798-73-3P
959798-74-4P	959798-75-5P	959798-76-6P	959798-77-7P	959798-78-8P
959798-79-9P	959798-80-2P	959798-81-3P	959798-82-4P	959798-83-5P
959798-84-6P	959798-85-7P	959798-86-8P	959798-87-9P	959798-88-0P
959798-89-1P	959798-90-4P	959798-91-5P	959798-92-6P	959798-93-7P
959798-94-8P	959798-95-9P	959798-96-0P	959798-97-1P	959798-98-2P
959798-99-3P	959799-00-9P	959799-01-0P	959799-02-1P	959799-03-2P
959799-04-3P	959799-05-4P	959799-06-5P	959799-07-6P	959799-08-7P
959799-09-8P	959799-10-1	959799-11-2	959799-12-3P	959799-13-4P
959799-14-5P	959799-15-6P	959799-16-7P	959799-17-8P	959799-18-9P
959799-19-0P	959799-20-3P	959799-22-5P	959799-24-7P	959799-26-9P

959799-28-1P 959799-30-5P 959799-31-6 959799-32-7P 959799-33-8P
 prepn. of pyrrolopyrimidines as protein kinase inhibitors useful in
 treatment and prevention of diseases as well as in combination therapy
 100-02-7 reactions, prepn. of pyrrolopyrimidines as protein kinase
 inhibitors useful in treatment and prevention of diseases as well as in
 combination therapy

6/7/10 (Item 3 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 2008 American Chemical Society. All rts. reserv.

147534655 CA: 147(26)534655d PATENT
 Use of a compound with receptor activator of nuclear factor-kB ligand
 (RANKL) activity
 INVENTOR(AUTHOR): Penninger, Josef; Loser, Karin; Beissert, Stefan
 LOCATION: Austria
 ASSIGNEE: Imba-Institut Fuer Molekulare Biotechnologie GmbH
 PATENT: PCT International ; WO 2007128564 A2 DATE: 2007/1115
 APPLICATION: WO 2007/EP4045 (2007/0508) *EP 2006450071 (2006/0508)
 PAGES: 44pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/00	A	I	F	B	20060101	H	EP
A61P-0037/00	A	I	L	B	20060101	H	EP
A61P-0017/00	A	I	L	B	20060101	H	EP
A61K-0038/20	A	I	L	B	20060101	H	EP
A61K-0038/16	A	I	L	B	20060101	H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
 BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
 GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
 KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;
 NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;
 SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH;
 ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
 MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
 ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
 ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA201007 Pharmacology

IDENTIFIERS: RANKL regulatory T cell modulation antiinflammatory skin
 disease treatment

DESCRIPTORS:

Keratosis...

actinic; compd. with RANKL activity for treatment of inflammatory and
 skin disease

Allergy...

allergic contact dermatitis; compd. with RANKL activity for treatment
 of inflammatory and skin disease

Dermatitis...

allergic contact; compd. with RANKL activity for treatment of
 inflammatory and skin disease

Interleukin 2 receptors...

α chain; compd. with RANKL activity for treatment of inflammatory
 and skin disease

Antiarteriosclerotics...

antiatherosclerotics; compd. with RANKL activity for treatment of
 inflammatory and skin disease

Alopecia...

areata, ophiasis-type; compd. with RANKL activity for treatment of
 inflammatory and skin disease

Alopecia...
 areata; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...
 atopic; compd. with RANKL activity for treatment of inflammatory and skin disease

Autoimmune disease... Inflammation... Thyroid gland,disease...
 autoimmune thyroiditis; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis... Liver,disease...
 autoimmune; compd. with RANKL activity for treatment of inflammatory and skin disease

Infection...
 bacterial, bacterial inflammation; compd. with RANKL activity for treatment of inflammatory and skin disease

Cirrhosis...
 biliary; compd. with RANKL activity for treatment of inflammatory and skin disease

Psoriasis...
 capitis; compd. with RANKL activity for treatment of inflammatory and skin disease

CD antigens...
 CD103; compd. with RANKL activity for treatment of inflammatory and skin disease

Glycoproteins...
 CD40-L (antigen CD40 ligand); compd. with RANKL activity for treatment of inflammatory and skin disease

Acne... Allergy inhibitors... Allergy... Antidiabetic agents...
 Antirheumatic agents... Antitumor agents... Anti-inflammatory agents...
 Atherosclerosis... Autoimmune disease... Autoimmune hepatitis...
 Cardiovascular agents... CD45RB(antigen)... CD4(antigen)... CD4-positive T cell... CD86(antigen)... CTLA-4(antigen)... Dermatitis... Dermatomyositis ... Drug toxicity... Eczema... Gastrointestinal agents... Genetic engineering... Human herpesvirus... Human... Immunomodulators...
 Inflammation... Interleukin 10... Interleukin 17... Interleukin 1...
 Interleukin 6... Interleukins... Keloid... Multiple sclerosis...
 Myocarditis... Nervous system agents... Prophylaxis... Psoriasis...
 Rheumatoid arthritis... Scleroderma... Skin,disease... Skin,neoplasm...
 Sunburn... Tumor necrosis factors... Urticaria... Uveitis... Vitiligo...
 compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...
 contact, irritative; compd. with RANKL activity for treatment of inflammatory and skin disease

Dermatitis...
 contact; compd. with RANKL activity for treatment of inflammatory and skin disease

Drug delivery systems...
 creams; compd. with RANKL activity for treatment of inflammatory and skin disease

Lupus erythematosus...
 cutaneous; compd. with RANKL activity for treatment of inflammatory and skin disease

Antigen receptors...
 DEC-205 (dendritic epidermal cell, 205 kDa); compd. with RANKL activity for treatment of inflammatory and skin disease

Alopecia...
 diffusa; compd. with RANKL activity for treatment of inflammatory and skin disease

Eczema...
 dihidrotic; compd. with RANKL activity for treatment of inflammatory

- and skin disease
- Drug delivery systems...
 - emulsions; compd. with RANKL activity for treatment of inflammatory and skin disease
- Keratosis...
 - epidermolytic hyperkeratosis; compd. with RANKL activity for treatment of inflammatory and skin disease
- Skin,disease...
 - erythema nodosum; compd. with RANKL activity for treatment of inflammatory and skin disease
- Drug delivery systems...
 - foams; compd. with RANKL activity for treatment of inflammatory and skin disease
- Interferons...
 - γ ; compd. with RANKL activity for treatment of inflammatory and skin disease
- Drug delivery systems...
 - gels; compd. with RANKL activity for treatment of inflammatory and skin disease
- Inflammation... Kidney,disease...
 - glomerulonephritis; compd. with RANKL activity for treatment of inflammatory and skin disease
- Transplant and Transplantation...
 - graft-vs.-host reaction; compd. with RANKL activity for treatment of inflammatory and skin disease
- Psoriasis...
 - guttata; compd. with RANKL activity for treatment of inflammatory and skin disease
- Autoimmune disease...
 - hepatic; compd. with RANKL activity for treatment of inflammatory and skin disease
- Dermatitis...
 - herpetiformis, Duhring; compd. with RANKL activity for treatment of inflammatory and skin disease
- Keratosis...
 - hyperkeratosis, hyperkeratosis lenticularis perstans; compd. with RANKL activity for treatment of inflammatory and skin disease
- Keratosis...
 - hyperkeratosis; compd. with RANKL activity for treatment of inflammatory and skin disease
- Allergy...
 - hypersensitivity; compd. with RANKL activity for treatment of inflammatory and skin disease
- Histocompatibility antigens...
 - I-A; compd. with RANKL activity for treatment of inflammatory and skin disease
- Skin,disease...
 - ichthyosis; compd. with RANKL activity for treatment of inflammatory and skin disease
- Antibodies and Immunoglobulins...
 - IgA, linear IgA dermatosis; compd. with RANKL activity for treatment of inflammatory and skin disease
- Irritants... Radiation... UV radiation...
 - inflammation caused by; compd. with RANKL activity for treatment of inflammatory and skin disease
- Intestine,disease...
 - inflammatory; compd. with RANKL activity for treatment of inflammatory and skin disease
- Autoimmune disease...
 - insulin-dependent diabetes mellitus; compd. with RANKL activity for treatment of inflammatory and skin disease

Diabetes mellitus...
insulin-dependent; compd. with RANKL activity for treatment of
inflammatory and skin disease

Psoriasis...
inversa; compd. with RANKL activity for treatment of inflammatory and
skin disease

Skin...
keratinocyte; compd. with RANKL activity for treatment of inflammatory
and skin disease

Skin...
Langerhans cell; compd. with RANKL activity for treatment of
inflammatory and skin disease

Skin,disease...
lichen planus; compd. with RANKL activity for treatment of inflammatory
and skin disease

Skin,disease...
lichen sclerosus et atrophicans; compd. with RANKL activity for
treatment of inflammatory and skin disease

Skin,disease...
lichen vidal; compd. with RANKL activity for treatment of inflammatory
and skin disease

Skin,disease...
lichen; compd. with RANKL activity for treatment of inflammatory and
skin disease

Skin,disease...
linear IgA dermatosis; compd. with RANKL activity for treatment of
inflammatory and skin disease

Drug delivery systems...
liposomes; compd. with RANKL activity for treatment of inflammatory and
skin disease

Drug delivery systems...
lotions; compd. with RANKL activity for treatment of inflammatory and
skin disease

Alopecia...
male pattern; compd. with RANKL activity for treatment of inflammatory
and skin disease

Skin,disease...
morphea; compd. with RANKL activity for treatment of inflammatory and
skin disease

Skin,disease...
necrobiosis lipoidica; compd. with RANKL activity for treatment of
inflammatory and skin disease

Drug delivery systems...
ointments; compd. with RANKL activity for treatment of inflammatory and
skin disease

Drug delivery systems...
pastes; compd. with RANKL activity for treatment of inflammatory and
skin disease

Skin,disease...
pemphigoid, bullous; compd. with RANKL activity for treatment of
inflammatory and skin disease

Skin,disease...
pemphigoid, mucous; compd. with RANKL activity for treatment of
inflammatory and skin disease

Skin,disease...
pemphigoid, scarring mucosal; compd. with RANKL activity for treatment
of inflammatory and skin disease

Skin,disease...
pemphigus foliaceus; compd. with RANKL activity for treatment of
inflammatory and skin disease

Skin,disease...

pemphigus, vegetans; compd. with RANKL activity for treatment of inflammatory and skin disease

CAS REGISTRY NUMBERS:

53-06-5 67-97-0 363-24-6 207621-35-0 214210-47-6 compd. with RANKL activity for treatment of inflammatory and skin disease
53-06-5D derivs., compd. with RANKL activity for treatment of inflammatory and skin disease
956655-07-5 956655-08-6 956655-09-7 956655-10-0 956655-11-1
956655-12-2 956655-13-3 956655-15-5 unclaimed sequence; use of a compd. with receptor activator of nuclear factor- κ B ligand (RANKL) activity

6/7/11 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT

Biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad
LOCATION: USA

ASSIGNEE: Novartis AG; Xoma Technology

PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123

APPLICATION: WO 2006US19325 (20060518) *US 2005PV682575 (20050518) *US 2005PV749336 (20051209)

PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

G01N-0033/564 A I F B 20060101 H EP

G01N-0033/68 A I L B 20060101 H EP

A61P-0037/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

SECTION:

CA215008 Immunochemistry

CA201XXX Pharmacology

IDENTIFIERS: autoimmune inflammatory disease diagnosis treatment CD40 signaling, monoclonal antibody CD40 autoimmune disease inflammation, biomarker apoptosis survival signaling CD40 autoimmune inflammation

DESCRIPTORS:

Inflammation... Spinal column,disease...

ankylosing spondylitis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Dermatitis...

atopic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Anemia(disease)... Autoimmune disease...

autoimmune hemolytic anemia; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive

- to anti-CD40 monoclonal antibodies
- Autoimmune disease... Inflammation... Thyroid gland,disease...
 - autoimmune thyroiditis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Hepatitis...
 - autoimmune; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Proteins...
 - Bcl-xL, biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Proteins...
 - Bcl-2, biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Immunoassay... Nucleic acid hybridization... Radioimmunoassay...
 - biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- DNA fragmentation...
 - biomarker for apoptosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Cytokines... Interleukin 10... Interleukin 6... Interleukin 8... Macrophage inflammatory protein 1 β ... Monocyte chemoattractant protein-1... Tumor necrosis factors...
 - biomarker for CD40 signaling; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Allergy... Alzheimer's disease... Asthma... Atherosclerosis... Autoimmune disease... Biomarkers... cDNA sequences... CD40(antigen)... Celiac disease ... Dermatomyositis... Gout... Graves' disease... Hemolysis... Human... Immune disease... Inflammation... Multiple sclerosis... Myasthenia gravis ... Prognosis... Protein sequences... Psoriasis... Rheumatoid arthritis... Sarcoidosis... Thrombolysis... Transplant rejection... Urticaria...
 - biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Apoptosis... Cell proliferation...
 - biomarkers; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Heart,disease...
 - cardiomyopathy; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Signal transduction,biological...
 - CD40-CD40L-mediated biomarkers; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Glycoproteins...
 - CD40-L (antigen CD40 ligand); biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Phosphatidylserines...
 - cell surface-expressed biomarker for apoptosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies
- Fatigue,biological...

chronic fatigue syndrome; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Nerve,disease...
chronic inflammatory demyelinating polyneuropathy; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Blood vessel,disease...
Churg-Strauss syndrome; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Proteins...
cIAP-1 (cellular inhibitor of apoptosis protein 1), biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to ant

Dermatitis...
contact; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Inflammation...
Crohn's disease; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Intestine,disease...
Crohn's; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Cryoglobulins...
cryoglobulinemia; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...
delayed hypersensitivity; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Lupus erythematosus...
discoid; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Chemiluminescence...
electrochemiluminescence, biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Immunoassay...
enzyme-linked immunosorbent assay, biomarker detn. by; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibody

Antibodies and Immunoglobulins...
fragments; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Transplant and Transplantation...
graft-vs.-host reaction; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Heat-shock proteins...
HSP 75, biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Disease,animal...
hyperimmunoglobulinemia E syndrome; biomarkers for diagnosis and

treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 2; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 3; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

hypersensitivity, type 4; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Transcription factors...

I κ B (inhibitor of NF- κ B), phosphorylated, biomarker for CD40 signaling pathway; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component respon

Proteins...

IAP (inhibitor of apoptosis proteins), biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Purpura(disease)...

idiopathic thrombocytopenic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Myositis...

idiopathic; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

IgE-mediated; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Allergy...

immediate hypersensitivity; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Intestine,disease...

inflammatory; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Autoimmune disease...

insulin-dependent diabetes mellitus; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Diabetes mellitus...

insulin-dependent; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Lung,disease...

interstitial fibrosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Rheumatoid arthritis...

juvenile; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Inflammation... Kidney,disease...

lupus nephritis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to

anti-CD40 monoclonal antibodies

Proteins...
Mcl-1 (myeloid cell leukemia sequence-1), biomarker for cell survival;
biomarkers for diagnosis and treatment of diseases having an autoimmune
and/or inflammatory component responsive to anti-CD40 mon

Diagnosis...
mol.; biomarkers for diagnosis and treatment of diseases having an
autoimmune and/or inflammatory component responsive to anti-CD40
monoclonal antibodies

Antibodies and Immunoglobulins...
monoclonal; biomarkers for diagnosis and treatment of diseases having
an autoimmune and/or inflammatory component responsive to anti-CD40
monoclonal antibodies

Transcription factors...
NF- κ B (nuclear factor of κ light chain gene enhancer in
B-cells), biomarker for CD40 signaling pathway; biomarkers for
diagnosis and treatment of diseases having an autoimmune and/or infla

Diabetes mellitus...
non-insulin-dependent; biomarkers for diagnosis and treatment of
diseases having an autoimmune and/or inflammatory component responsive
to anti-CD40 monoclonal antibodies

Skin,disease...
pemphigus vulgaris; biomarkers for diagnosis and treatment of diseases
having an autoimmune and/or inflammatory component responsive to
anti-CD40 monoclonal antibodies

Artery,disease... Inflammation...
periarteritis nodosa; biomarkers for diagnosis and treatment of
diseases having an autoimmune and/or inflammatory component responsive
to anti-CD40 monoclonal antibodies

Anemia(disease)...
pernicious anemia; biomarkers for diagnosis and treatment of diseases
having an autoimmune and/or inflammatory component responsive to
anti-CD40 monoclonal antibodies

Myositis...
polymyositis; biomarkers for diagnosis and treatment of diseases having
an autoimmune and/or inflammatory component responsive to anti-CD40
monoclonal antibodies

Biliary tract,disease...
primary biliary cirrhosis; biomarkers for diagnosis and treatment of
diseases having an autoimmune and/or inflammatory component responsive
to anti-CD40 monoclonal antibodies

Arthritis...
psoriatic arthritis; biomarkers for diagnosis and treatment of diseases
having an autoimmune and/or inflammatory component responsive to
anti-CD40 monoclonal antibodies

Fibrosis...
pulmonary interstitial; biomarkers for diagnosis and treatment of
diseases having an autoimmune and/or inflammatory component responsive
to anti-CD40 monoclonal antibodies

Arthritis...
Reiter's syndrome; biomarkers for diagnosis and treatment of diseases
having an autoimmune and/or inflammatory component responsive to
anti-CD40 monoclonal antibodies

Epitopes...
residues 82-87 of human CD40; biomarkers for diagnosis and treatment of
diseases having an autoimmune and/or inflammatory component responsive
to anti-CD40 monoclonal antibodies

PCR (polymerase chain reaction)...
RT-PCR (reverse transcription-PCR), biomarker detn. by; biomarkers for
diagnosis and treatment of diseases having an autoimmune and/or
inflammatory component responsive to anti-CD40 monoclonal antibod

Connective tissue,disease...

scleroderma; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

Antibodies and Immunoglobulins...

single chain; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

CAS REGISTRY NUMBERS:

915425-15-9 915425-17-1 915425-18-2 915425-19-3 915425-20-6

915425-21-7 915425-22-8 915425-23-9 amino acid sequence; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

142243-02-5 148640-14-6 165245-96-5 biomarker for CD40 signaling pathway; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

83869-56-1 127464-60-2 biomarker for CD40 signaling; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

371761-91-0 biomarker for cell survival; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

173296-31-6 176630-81-2 220138-87-4 220153-31-1 225541-59-3

331696-20-9 384417-51-0 384522-15-0 384522-17-2 384581-28-6

384585-58-4 384661-90-9 384771-52-2 384779-76-4 389189-13-3

391544-63-1 391961-37-8 391964-48-0 391965-83-6 391965-84-7

391973-87-8 391974-16-6 392055-61-7 392079-74-2 459530-42-8

459552-50-2 459598-47-1 459656-13-4 459690-00-7 480530-68-5

480760-82-5 480954-56-1 520893-87-2 520894-47-7 520896-15-5

624651-71-4 624653-99-2 biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

9055-67-8D 169592-56-7D 180189-96-2D 186322-81-6D 189258-14-8D cleaved, biomarker for apoptosis; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

915425-14-8 915425-16-0 nucleotide sequence; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

115926-52-8D 191808-15-8D 362516-16-3D 362517-43-9D phosphorylated, biomarker for CD40 signaling pathway; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

915425-75-1 915425-76-2 915425-77-3 915425-79-5 unclaimed nucleotide sequence; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

915425-78-4 915425-80-8 unclaimed protein sequence; biomarkers for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component responsive to anti-CD40 monoclonal antibodies

6/7/12 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

145055995 CA: 145(4)55995w PATENT

Modulation of Fc gamma receptors for optimizing immunotherapy

INVENTOR(AUTHOR): Boruchov, Adam; Young, James W.

LOCATION: USA

ASSIGNEE: Memorial Sloan-Kettering Cancer Center
PATENT: European Pat. Appl. ; EP 1674479 A1 DATE: 20060628
APPLICATION: EP 2005250446 (20050128) *US 2004PV638422 (20041222) *US
2004PV640685 (20041230) *US 2005PV647616 (20050127)
PAGES: 77 pp. CODEN: EPXXDW LANGUAGE: English
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK;
BA; HR; IS; YU

SECTION:

CA201012 Pharmacology
CA202XXX Mammalian Hormones
CA214XXX Mammalian Pathological Biochemistry
CA215XXX Immunochemistry

IDENTIFIERS: Fc gamma receptor modulator dendritic cell maturation
immunotherapy autoimmune disease, antitumor antiinfective dendritic
cell maturation prevention cancer infection vaccine

DESCRIPTORS:

Monocyte...

-derived dendritic cell; modulation of Fc gamma receptors for
optimizing immunotherapy

Antibodies and Immunoglobulins...

agammaglobulinemia, primary; modulation of Fc gamma receptors for
optimizing immunotherapy

Immunity... Disease, animal...

agglutinin disease, cold; modulation of Fc gamma receptors for
optimizing immunotherapy

Interferons...

α; modulation of Fc gamma receptors for optimizing immunotherapy

Spinal column, disease... Inflammation...

ankylosing spondylitis; modulation of Fc gamma receptors for optimizing
immunotherapy

Antibodies and Immunoglobulins...

anti-CD32a; modulation of Fc gamma receptors for optimizing
immunotherapy

Antibodies and Immunoglobulins...

anti-CD32b; modulation of Fc gamma receptors for optimizing
immunotherapy

Vaccines...

antiinfectives; modulation of Fc gamma receptors for optimizing
immunotherapy

Alopecia...

areata; modulation of Fc gamma receptors for optimizing immunotherapy

Artery, disease... Inflammation...

arteritis, giant cell; modulation of Fc gamma receptors for optimizing
immunotherapy

Artery, disease... Inflammation...

arteritis, takayasu; modulation of Fc gamma receptors for optimizing
immunotherapy

Artery, disease... Inflammation...

arteritis, temporal; modulation of Fc gamma receptors for optimizing
immunotherapy

Immunosuppression...

assocd. with alc. consumption prior to burn injuries; modulation of Fc
gamma receptors for optimizing immunotherapy

Muscle, disease...

atrophy, cancer-related; modulation of Fc gamma receptors for
optimizing immunotherapy

Anemia(disease)... Autoimmune disease...

autoimmune hemolytic anemia; modulation of Fc gamma receptors for
optimizing immunotherapy

Autoimmune disease... Ovary, disease... Inflammation...

- autoimmune oophoritis; modulation of Fc gamma receptors for optimizing immunotherapy
- Autoimmune disease...
 - autoimmune thrombocytopenia; modulation of Fc gamma receptors for optimizing immunotherapy
- Thyroid gland,disease... Autoimmune disease... Inflammation...
 - autoimmune thyroiditis; modulation of Fc gamma receptors for optimizing immunotherapy
- Addison's disease... Adrenal gland,disease... Hepatitis...
 - autoimmune; modulation of Fc gamma receptors for optimizing immunotherapy
- Immunity...
 - autoimmunity; modulation of Fc gamma receptors for optimizing immunotherapy
- Interferons...
 - β ; modulation of Fc gamma receptors for optimizing immunotherapy
- Transforming growth factors...
 - β -; modulation of Fc gamma receptors for optimizing immunotherapy
- Transplant and Transplantation...
 - bone marrow; modulation of Fc gamma receptors for optimizing immunotherapy
- Skin,disease...
 - bullous pemphigoid; modulation of Fc gamma receptors for optimizing immunotherapy
- Immunosuppression...
 - burn-induced; modulation of Fc gamma receptors for optimizing immunotherapy
- Cachexia... Anorexia...
 - cancer-related; modulation of Fc gamma receptors for optimizing immunotherapy
- Heart,disease...
 - cardiomyopathy; modulation of Fc gamma receptors for optimizing immunotherapy
- Lymph node,disease...
 - Castleman's; modulation of Fc gamma receptors for optimizing immunotherapy
- Glycoproteins...
 - CD40-L (antigen CD40 ligand); modulation of Fc gamma receptors for optimizing immunotherapy
- CD antigens...
 - CD83; modulation of Fc gamma receptors for optimizing immunotherapy
- Fatigue,biological...
 - chronic fatigue syndrome; modulation of Fc gamma receptors for optimizing immunotherapy
- Blood vessel,disease...
 - Churg-Strauss syndrome; modulation of Fc gamma receptors for optimizing immunotherapy
- Cryoglobulins...
 - cryoglobulinemia; modulation of Fc gamma receptors for optimizing immunotherapy
- Lupus erythematosus...
 - discoid; modulation of Fc gamma receptors for optimizing immunotherapy
- Platelet(blood)...
 - disease, autoimmune thrombocytopenia; modulation of Fc gamma receptors for optimizing immunotherapy
- Flow cytometry...
 - FACS (fluorescence-activated cell sorting); modulation of Fc gamma receptors for optimizing immunotherapy
- Muscle,disease...
 - fibromyalgia; modulation of Fc gamma receptors for optimizing immunotherapy

- Lung,disease...
 - fibrosis; modulation of Fc gamma receptors for optimizing immunotherapy
- Interferons...
 - γ ; modulation of Fc gamma receptors for optimizing immunotherapy
- Kidney,disease... Inflammation...
 - glomerulonephritis; modulation of Fc gamma receptors for optimizing immunotherapy
- Transplant and Transplantation...
 - graft-vs.-host reaction; modulation of Fc gamma receptors for optimizing immunotherapy
- Nervous system,disease...
 - Guillain-Barre syndrome; modulation of Fc gamma receptors for optimizing immunotherapy
- Dermatitis...
 - herpetiformis; modulation of Fc gamma receptors for optimizing immunotherapy
- Purpura(disease)...
 - idiopathic thrombocytopenic; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgA; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG, complexed; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG, immobilized; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG, sol. monomers of; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG2; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG3; modulation of Fc gamma receptors for optimizing immunotherapy
- Antibodies and Immunoglobulins...
 - IgG4; modulation of Fc gamma receptors for optimizing immunotherapy
- Gene,animal...
 - IL1B; modulation of Fc gamma receptors for optimizing immunotherapy
- Diabetes mellitus...
 - immune-mediated; modulation of Fc gamma receptors for optimizing immunotherapy
- Autoimmune disease...
 - insulin-dependent diabetes mellitus; modulation of Fc gamma receptors for optimizing immunotherapy
- Diabetes mellitus...
 - insulin-dependent; modulation of Fc gamma receptors for optimizing immunotherapy
- Rheumatoid arthritis...
 - juvenile; modulation of Fc gamma receptors for optimizing immunotherapy
- Skin...
 - Langerhans cell; modulation of Fc gamma receptors for optimizing immunotherapy
- Skin,disease... Mouth,disease...
 - lichen planus; modulation of Fc gamma receptors for optimizing immunotherapy
- Disease,animal...
 - Menibre's; modulation of Fc gamma receptors for optimizing immunotherapy
- Connective tissue,disease...

mixed connective tissue disease; modulation of Fc gamma receptors for optimizing immunotherapy
 FcγR receptors... Immunotherapy... Autoimmune disease... Antitumor agents... Anti-infective agents... Combination chemotherapy... Infection... Lipopolysaccharides... FcγRIIb receptors... Immunomodulators... FcγRIIa receptors... Signal transduction, biological... Antiphospholipid syndrome... Population genetics... Behcet's syndrome... Dermatitis... Human... Cytokines... Interleukin 8... Tumor necrosis factors... Drug targets... Celiac disease... Graves' disease... Multiple sclerosis... Myasthenia gravis... Psoriasis... Sarcoidosis... Sjogren syndrome... Dendritic cell... Vitiligo... Vaccines... T cell(lymphocyte)... CD4-positive T cell... CD8-positive T cell... Interleukin 10... Interleukin 6... Anti-AIDS agents... AIDS(disease)... Lymphoma... Transplant and Transplantation... Prostate gland, neoplasm... Amyloidosis... Interleukin 2... Mus musculus... B cell(lymphocyte)... Blood... FcγRIII receptors... FcγRI receptors... Monocyte... Neutrophil... Antifibrotic agents... Antirheumatic agents... Antidiabetic agents... Dermatomyositis... Arthritis... Rheumatoid arthritis... Human immunodeficiency virus... Multiple myeloma... Burn... Cytotoxic agents... Neoplasm... Sepsis... Alcoholism... Human immunodeficiency virus 1... modulation of Fc gamma receptors for optimizing immunotherapy
 Antibodies and Immunoglobulins... monoclonal, IV3; modulation of Fc gamma receptors for optimizing immunotherapy
 Antibodies and Immunoglobulins... monoclonal, 2B6; modulation of Fc gamma receptors for optimizing immunotherapy
 CAS REGISTRY NUMBERS:
 363-24-6 modulation of Fc gamma receptors for optimizing immunotherapy

6/7/13 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT
 Inhibition of T cell activation in the treatment of immunological disease by blocking class II MHC antigen function
 INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi, Ki-Wan
 LOCATION: S. Korea
 ASSIGNEE: Medexgen Inc.
 PATENT: PCT International ; WO 200577415 A1 DATE: 20050825
 APPLICATION: WO 2005KR457 (20050218) *KR 10835 (20040218)
 PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: A61K-039/395A
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA201007 Pharmacology

CA215XXX Immunochemistry

IDENTIFIERS: T lymphocyte activation inhibition MHCII antigen receptor

binding, immune disorder T lymphocyte activation inhibition

DESCRIPTORS:

T cell(lymphocyte)...
activation of; inhibition of T cell activation in treatment of immunol.
disease by blocking class II MHC antigen function

T cell(lymphocyte)...
activation; inhibition of T cell activation in treatment of immunol.
disease by blocking class II MHC antigen function

Brain,disease...
adrenoleukodystrophy, treatment of; inhibition of T cell activation in
treatment of immunol. disease by blocking class II MHC antigen function

Interferon receptors...
 α -interferon, inhibition of ligand binding by; inhibition of T
cell activation in treatment of immunol. disease by blocking class II
MHC antigen function

Integrins...
 $\alpha 4 \beta 1$, inhibition of ligand binding by; inhibition of T cell
activation in treatment of immunol. disease by blocking class II MHC
antigen function

Spinal column,disease... Inflammation...
ankylosing spondylitis, treatment of; inhibition of T cell activation
in treatment of immunol. disease by blocking class II MHC antigen
function

Thyroid gland,disease... Autoimmune disease... Inflammation...
autoimmune thyroiditis, treatment of; inhibition of T cell activation
in treatment of immunol. disease by blocking class II MHC antigen
function

Anemia(disease)...
autoimmune, treatment of; inhibition of T cell activation in treatment
of immunol. disease by blocking class II MHC antigen function

Interferon receptors...
 β , inhibition of ligand binding by; inhibition of T cell
activation in treatment of immunol. disease by blocking class II MHC
antigen function

CD4(antigen)...
blocking MHC antigen interaction with; inhibition of T cell activation
in treatment of immunol. disease by blocking class II MHC antigen
function

CD antigens...
CD106, inhibition of receptor binding by; inhibition of T cell
activation in treatment of immunol. disease by blocking class II MHC
antigen function

CD antigens...
CD27, inhibition of ligand binding by; inhibition of T cell activation
in treatment of immunol. disease by blocking class II MHC antigen
function

Glycoproteins...
CD40-L (antigen CD40 ligand), inhibition of receptor binding by;
inhibition of T cell activation in treatment of immunol. disease by
blocking class II MHC antigen function

CD antigens...
CD54, inhibition of receptor binding by; inhibition of T cell
activation in treatment of immunol. disease by blocking class II MHC
antigen function

Disease models...
collagen induced arthritis, control of inflammation in; inhibition of T
cell activation in treatment of immunol. disease by blocking class II
MHC antigen function

Inflammation...
Crohn's disease, treatment of; inhibition of T cell activation in
treatment of immunol. disease by blocking class II MHC antigen function

Intestine,disease...
 Crohn's, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cryoglobulins...
 cryoglobulinemia, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Arthritis...
 disease model, control of inflammation in; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Immunity...
 disorder, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Antibodies and Immunoglobulins...
 fusion products, with MHC antigen receptors; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD2(antigen)... CTLA-4(antigen)...
 fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interferon receptors...
 γ-interferon, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...
 gene LAG3, blocking MHC antigen interaction with; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Kidney,disease...
 Goodpasture's syndrome, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Transplant and Transplantation...
 graft-vs.-host reaction, treatment of, control of inflammation in; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...
 ICAM-1 (intercellular adhesion mol. 1), inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...
 ICOS (inducible co-stimulator), inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD28(antigen)... CD40(antigen)... Fas antigen... LFA-1(antigen)...
 Interleukin 1 receptors... Interleukin 2 receptors... Interleukin 3 receptors... Interleukin 4 receptors... Interleukin 5 receptors...
 Interleukin 6 receptors... Interleukin 7 receptors... Tumor necrosis factor receptors... Transforming growth factor receptors... Interferon receptors...
 ... Granulocyte-macrophage colony-stimulating factor receptors...
 Granulocyte colony-stimulating factor receptors... Macrophage colony-stimulating factor receptors... Erythropoietin receptors... MPL receptor...
 inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CD80(antigen)... Fas ligand... Cell adhesion molecules... LFA-3(antigen)...
 Interleukin 1... Interleukin 2... Interleukin 3... Interleukin 4...
 Interleukin 5... Interleukin 6... Interleukin 7... Tumor necrosis factors...
 ... Transforming growth factors... Interferons...
 inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Autoimmune disease...
insulin-dependent diabetes mellitus, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Diabetes mellitus...
insulin-dependent, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...
LIGHT, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Histocompatibility antigens...
MHC (major histocompatibility complex), class II, blocking action of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...
nectin-1, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Antigens...
OX40L, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...
PD-1, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Proteins...
PDL-1, inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Skin,disease...
pemphigus vulgaris, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Interleukin 6 receptors...
receptor-assocd. glycoprotein gp130, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Connective tissue,disease...
scleroderma, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Lupus erythematosus...
systemic, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell activation...
T cell; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Purpura(disease)...
thrombocytopenic, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Autoimmune disease... Transplant rejection... Rheumatoid arthritis... Multiple sclerosis... Myasthenia gravis... Graves' disease... Addison's disease... Vitiligo... Behcet's syndrome...
treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Tumor necrosis factor receptors...
type 1, fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Tumor necrosis factor receptors...
type 2, fusion protein with Igs; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Eye, disease... Inflammation...

uveitis, treatment of; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Cell adhesion molecules...

VCAM-1 (vascular cell adhesion mol. 1), inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

Receptors...

4-1BB, inhibition of ligand binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function

CAS REGISTRY NUMBERS:

83869-56-1 143011-72-7 81627-83-0 11096-26-7 9014-42-0 inhibition of receptor binding by; inhibition of T cell activation in treatment of immunol. disease by blocking class II MHC antigen function
863278-37-9 863278-38-0 863278-39-1 863278-40-4 863278-41-5 863278-42-6 863278-43-7 863278-45-9 863278-47-1 863278-49-3 863278-51-7 863278-53-9 863278-56-2 863278-59-5 unclaimed nucleotide sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function
863278-44-8 863278-46-0 863278-48-2 863278-50-6 863278-52-8 863278-54-0 863278-55-1 863278-57-3 863278-58-4 863278-60-8 unclaimed protein sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function
863281-19-0 863281-20-3 unclaimed sequence; inhibition of T cell activation in the treatment of immunol. disease by blocking class II MHC antigen function

6/7/14 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT

Antagonistic monoclonal antibodies and derivatives specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

INVENTOR(AUTHOR): Long, Li; Lugman, Mohammad; Yabannavar, Asha; Zaror,

Isabel

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200544306 A2 DATE: 20050519

APPLICATION: WO 2004US36957 (20041104) *US 2003PV517337 (20031104) *US

2003PV525579 (20031126) *US 2004PV565710 (20040427)

PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA201XXX Pharmacology

CA203XXX Biochemical Genetics

CA209XXX Biochemical Methods

CA263XXX Pharmaceuticals

IDENTIFIERS: human CD40 antigen monoclonal antibody autoimmune disease
inflammation allergy

DESCRIPTORS:

Allergy...

allergic asthma; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Allergy...

allergic contact dermatitis; antagonistic monoclonal antibodies and
derivs. specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Dermatitis...

allergic contact; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Asthma...

allergic; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Spinal column,disease... Inflammation...

ankylosing spondylitis; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Human... Corticosteroids,biological studies... CD40(antigen)... Sarcoidosis

... Affinity... Dissociation constant... Nucleic acids... Gout...

Transplant rejection... Autoimmune disease... Rheumatoid arthritis...

Multiple sclerosis... Myasthenia gravis... Drug delivery systems... Celiac

disease... Psoriasis... Graves' disease... Dermatomyositis... Thrombolysis

... Allergy... Asthma... Molecular cloning... DNA sequences... Protein

sequences... Urticaria... Atherosclerosis... Hemolysis... Alzheimer's

disease... Immunosuppressants... Signal transduction,biological...

antagonistic monoclonal antibodies and derivs. specific to human CD40
antigen for treatment of autoimmune and inflammatory diseases

Structure-activity relationship...

antibody-binding, epitope mapping; antagonistic monoclonal antibodies
and derivs. specific to human CD40 antigen for treatment of autoimmune
and inflammatory diseases

Dermatitis...

atopic; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Anemia(disease)... Autoimmune disease...

autoimmune hemolytic anemia; antagonistic monoclonal antibodies and
derivs. specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Thyroid gland,disease... Autoimmune disease... Inflammation...

autoimmune thyroiditis; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Hepatitis...

autoimmune; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Heart,disease...

cardiomyopathy; antagonistic monoclonal antibodies and derivs. specific
to human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Animal cell...

CD40-expressing; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and

inflammatory diseases

Glycoproteins...
CD40-L (antigen CD40 ligand); antagonistic monoclonal antibodies and
derivs. specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Antibodies and Immunoglobulins...
chimeric; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Hybridoma...
CHIR-12.12 or 153.8E2D10D6.12.12 or ATCC No. PTA-5543; antagonistic
monoclonal antibodies and derivs. specific to human CD40 antigen for
treatment of autoimmune and inflammatory diseases

Hybridoma...
CHIR-5.9 or 131.2F8.5.9 or ATCC No. PTA-5542; antagonistic monoclonal
antibodies and derivs. specific to human CD40 antigen for treatment of
autoimmune and inflammatory diseases

Fatigue,biological...
chronic fatigue syndrome; antagonistic monoclonal antibodies and
derivs. specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Nerve,disease...
chronic inflammatory demyelinating polyneuropathy; antagonistic
monoclonal antibodies and derivs. specific to human CD40 antigen for
treatment of autoimmune and inflammatory diseases

Blood vessel,disease...
Churg-Strauss syndrome; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Immunoassay...
competitive binding assay; antagonistic monoclonal antibodies and
derivs. specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Dermatitis...
contact, irritant; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Inflammation...
Crohn's disease; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Intestine,disease...
Crohn's; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Cryoglobulins...
cryoglobulinemia; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Antibodies and Immunoglobulins...
CTLA-4 fusion proteins; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Fusion proteins(chimeric proteins)...
CTLA-4-Ig; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Allergy...
delayed hypersensitivity, type 1, 2, 3 and 4; antagonistic monoclonal
antibodies and derivs. specific to human CD40 antigen for treatment of
autoimmune and inflammatory diseases

Nerve,disease...
 demyelination, chronic inflammatory polyneuropathy; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Lupus erythematosus...
 discoid; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Immune complexes...
 disease; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Protein motifs...
 Domain 2 of CD40; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 fragments; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Transplant and Transplantation...
 graft-vs.-host reaction; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 heavy chain; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 humanized; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Disease,animal...
 hyperimmunoglobulinemia E syndrome, hyper IgE syndrome; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Purpura(disease)...
 idiopathic thrombocytopenic; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Myositis...
 idiopathic; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

CTLA-4(antigen)...
 Ig fusion proteins; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 IgE, -mediated allergy; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 IgG; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Antibodies and Immunoglobulins...
 IgG1; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Autoimmune disease...
 insulin-dependent diabetes mellitus; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune

- and inflammatory diseases
- Diabetes mellitus...
 - insulin-dependent; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Lung,disease...
 - interstitial fibrosis; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Rheumatoid arthritis...
 - juvenile; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Antibodies and Immunoglobulins...
 - light chain; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Kidney,disease... Inflammation...
 - lupus nephritis; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Epitopes...
 - mapping; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Antibodies and Immunoglobulins...
 - monoclonal; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Diabetes mellitus...
 - non-insulin-dependent; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Skin,disease...
 - pemphigus vulgaris; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Artery,disease... Inflammation...
 - periarteritis nodosa; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Anemia(disease)...
 - pernicious anemia; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Myositis...
 - polymyositis; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Nerve,disease...
 - polyneuropathy, chronic inflammatory demyelinating; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Biliary tract,disease...
 - primary biliary cirrhosis; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases
- Arthritis...
 - psoriatic arthritis; antagonistic monoclonal antibodies and derivs. specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

Fibrosis...

pulmonary interstitial; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Arthritis...

Reiter's syndrome; antagonistic monoclonal antibodies and derivs.
specific to human CD40 antigen for treatment of autoimmune and
inflammatory diseases

Connective tissue,disease...

scleroderma; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

B cell(lymphocyte)...

stimulator; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

Lupus erythematosus...

systemic; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

CAS REGISTRY NUMBERS:

852007-27-3P 852007-29-5P 852007-30-8P 852007-31-9P 852007-32-0P
852007-33-1P 852007-35-3P 852007-37-5P amino acid sequence;
antagonistic monoclonal antibodies and derivs. specific to human CD40
antigen for treatment of autoimmune and inflammatory diseases
59865-13-3 104987-11-3 53123-88-9 356547-88-1 852006-91-8 851779-28-7
851779-29-8 antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases
852007-26-2P 852007-28-4P 852007-34-2P 852007-36-4P nucleotide
sequence; antagonistic monoclonal antibodies and derivs. specific to
human CD40 antigen for treatment of autoimmune and inflammatory
diseases

6/7/15 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142409698 CA: 142(22)409698r PATENT

Vaccines for cancer, autoimmune disease and infections

INVENTOR(AUTHOR): Mollidrem, Jeffrey

LOCATION: USA

ASSIGNEE: Board of Regents, the University of Texas System

PATENT: PCT International ; WO 200535714 A2 DATE: 20050421

APPLICATION: WO 2004US27792 (20040826) *US 2003PV498238 (20030826)

PAGES: 235 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA;
SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

SECTION:

CA215002 Immunochemistry

CA201XXX Pharmacology
CA202XXX Mammalian Hormones
CA208XXX Radiation Biochemistry
CA214XXX Mammalian Pathological Biochemistry
IDENTIFIERS: peptide vaccine cancer autoimmune disease infection
DESCRIPTORS:

Leukemia...
acute myeloid; HLA class I-restricted peptides for protective
vaccination against
Mycobacterium BCG...
adjuvant for HLA class I-restricted peptide vaccines
Immunostimulants...
adjuvants, Freund's incomplete; for HLA class I-restricted peptide
vaccines
Immunostimulants...
adjuvants, Freund's; for HLA class I-restricted peptide vaccines
Transplant rejection...
allograft; HLA class I-restricted peptides for protective
vaccination against
Interferons...
α; in combination therapy with HLA class I-restricted peptide
vaccines
Spinal column,disease... Inflammation...
ankylosing spondylitis; HLA class I-restricted peptides for protective
vaccination against
Antibodies and Immunoglobulins...
anti-TRAIL receptor; in combination therapy with HLA class I-restricted
peptide vaccines
Anemia(disease)...
aplastic; HLA class I-restricted peptides for protective vaccination
against
Autoimmune disease... Stomach,disease... Inflammation...
autoimmune gastritis; HLA class I-restricted peptides for protective
vaccination against
Hepatitis...
autoimmune; HLA class I-restricted peptides for protective vaccination
against
Hepatitis...
B; HLA class I-restricted peptides for protective vaccination against
Hepatitis...
C; HLA class I-restricted peptides for protective vaccination against
Glycoproteins...
CD40-L (antigen CD40 ligand); in combination therapy with HLA class
I-restricted peptide vaccines
Fatigue,biological...
chronic fatigue syndrome; HLA class I-restricted peptides for
protective vaccination against
Leukemia...
chronic myelocytic; HLA class I-restricted peptides for protective
vaccination against
Intestine,neoplasm...
colon; HLA class I-restricted peptides for protective vaccination
against
Inflammation...
Crohn's disease; HLA class I-restricted peptides for protective
vaccination against
Intestine,disease...
Crohn's; HLA class I-restricted peptides for protective vaccination
against
Agranulocytosis...
cyclic neutropenia; HLA class I-restricted peptides for protective

- vaccination against
- T cell(lymphocyte)...
 - cytotoxic; protective vaccination with HLA class I-restricted peptides for
- Cyclins...
 - D; protective vaccination with HLA class I-restricted peptides from
- Cytokine receptors...
 - DR4 (death receptor 4), agonists; in combination therapy with HLA class I-restricted peptide vaccines
- Cytokine receptors...
 - DR5 (death receptor 5), agonists; in combination therapy with HLA class I-restricted peptide vaccines
- Cyclins...
 - E; protective vaccination with HLA class I-restricted peptides from
- TCR(T cell receptors)...
 - engineering of cytotoxic T-cells for tumor peptide specificity by transfection with
- Cyclins...
 - E2; protective vaccination with HLA class I-restricted peptides from
- Muscle,disease...
 - fibromyalgia; HLA class I-restricted peptides for protective vaccination against
- Cytometry...
 - flow; for isolation of cytotoxic T-cells specific for HLA class I-restricted peptides
- Genetic vectors...
 - for expression of HLA class I-restricted peptides
- Microspheres...
 - for prepn. of cytotoxic T-cells specific for HLA class I-restricted peptides
- Interferons...
 - γ; in combination therapy with HLA class I-restricted peptide vaccines
- Immunization...
 - genetic; with HLA class I-restricted peptides
- Kidney,disease...
 - Goodpasture's syndrome; HLA class I-restricted peptides for protective vaccination against
- Transplant and Transplantation...
 - graft-vs.-host reaction; HLA class I-restricted peptides for protective vaccination against
- Leukemia...
 - hair-cell; HLA class I-restricted peptides for protective vaccination against
- Infection...
 - hepatitis B; HLA class I-restricted peptides for protective vaccination against
- Infection...
 - hepatitis C; HLA class I-restricted peptides for protective vaccination against
- CD28(antigen)... CTLA-4(antigen)...
 - HLA class I-restricted peptide vaccines in combination therapy with antibodies to
- Human... Dendritic cell...
 - HLA class I-restricted peptides for protective vaccination
- Neoplasm... Myelodysplastic syndromes... Bladder,neoplasm... Mammary gland,neoplasm... Lung,neoplasm... Prostate gland,neoplasm... Liver,neoplasm... Pancreas,neoplasm... Stomach,neoplasm... Testis,neoplasm... Brain,neoplasm... Ovary,neoplasm... Skin,neoplasm... Bone,neoplasm... Autoimmune disease... Infection... Addison's disease... Alopecia... Antiphospholipid syndrome... Behcet's syndrome... Celiac disease... Graves'

disease... Lupus erythematosus... Multiple sclerosis... Myasthenia gravis
 ... Psoriasis... Rheumatoid arthritis... Rheumatic fever... Sarcoidosis...
 Vitiligo...

HLA class I-restricted peptides for protective vaccination against
 Histocompatibility antigens...

HLA-A11; HLA class I-restricted peptides for protective vaccination
 Histocompatibility antigens...

HLA-A2.1; HLA class I-restricted peptides for protective vaccination
 Histocompatibility antigens...

HLA-A3; HLA class I-restricted peptides for protective vaccination
 Histocompatibility antigens...

HLA-B27; HLA class I-restricted peptides for protective vaccination
 Histocompatibility antigens...

HLA-B35; HLA class I-restricted peptides for protective vaccination
 Histocompatibility antigens...

HLA-B7; HLA class I-restricted peptides for protective vaccination
 Purpura(disease)...

idiopathic thrombocytopenic; HLA class I-restricted peptides for
 protective vaccination against

Angiogenesis inhibitors... Interleukin 2... Interleukin 12...

Oligonucleotides...

in combination therapy with HLA class I-restricted peptide vaccines

Radiotherapy...

in combination with HLA class I-restricted peptides for protective
 vaccination

Autoimmune disease...

insulin-dependent diabetes mellitus; HLA class I-restricted peptides
 for protective vaccination against

Diabetes mellitus...

insulin-dependent; HLA class I-restricted peptides for protective
 vaccination against

Leukemia...

large granular lymphocytic; HLA class I-restricted peptides for
 protective vaccination against

Leukemia...

lymphocytic; HLA class I-restricted peptides for protective vaccination
 against

Animal tissue culture...

mammalian; expansion of cytotoxic T-cells to HLA class I-restricted
 peptides in

Ear,disease...

Meniere's; HLA class I-restricted peptides for protective vaccination
 against

Cell adhesion molecules...

modifiers; adjuvant for HLA class I-restricted peptide vaccines

Leukemia...

monocytic; HLA class I-restricted peptides for protective vaccination
 against

Lipid A...

monophosphates; adjuvant for HLA class I-restricted peptide vaccines

Leukemia...

myeloblastic; HLA class I-restricted peptides for protective
 vaccination against

Leukemia... Leukemia...

myelogenous; HLA class I-restricted peptides for protective vaccination
 against

Skin,disease...

pemphigus vulgaris; HLA class I-restricted peptides for protective
 vaccination against

Biliary tract,disease...

primary biliary cirrhosis; HLA class I-restricted peptides for

protective vaccination against
 Leukemia...
 promyelocytic; HLA class I-restricted peptides for protective
 vaccination against
 CAS REGISTRY NUMBERS:
 99011-02-6 141256-04-4 adjuvant for HLA class I-restricted peptide
 vaccines
 7722-84-1 biological studies, in combination therapy with HLA class
 I-restricted peptide vaccines
 225478-04-6 225478-05-7 for prep. of cytotoxic T-cells specific for HLA
 class I-restricted peptides
 182253-77-6 182253-78-7 847201-80-3 847201-81-4 847201-82-5
 847201-83-6 847201-86-9 847201-87-0 847201-88-1 847201-89-2
 847201-90-5 847201-91-6 847201-92-7 847201-94-9 204391-91-3
 850146-69-9 850146-70-2 HLA class I-restricted peptides for
 protective vaccination
 23214-92-8 20830-81-3 50-76-0 65271-80-9 15663-27-1 671-16-9
 1404-00-8 41575-94-4 11056-06-7 33419-42-0 29767-20-2 51-75-2
 50-18-0 3778-73-2 148-82-3 305-03-3 645-05-6 76-75-5 55-98-1
 154-93-8 13010-47-4 13909-09-6 18883-66-4 4342-03-4 25316-40-9
 51-21-8 7689-03-4 13010-20-3 18378-89-7 10540-29-1 33069-62-4
 14913-33-8 57-22-7 865-21-4 110417-88-4 100629-51-4 92689-49-1
 220578-59-6 114-70-5 156-54-7 59-05-2 2353-33-5 220127-57-1
 216974-75-3 205923-56-4 50-35-1 179324-69-7 184475-35-2
 183321-74-6 320-67-2 191732-72-6 83869-56-1 in combination therapy
 with HLA class I-restricted peptide vaccines
 9003-99-0 9004-06-2 128028-50-2 protective vaccination with HLA class
 I-restricted peptides from
 7429-90-5D salts, adjuvant for HLA class I-restricted peptide vaccines
 850280-40-9 850280-41-0 850280-42-1 850280-43-2 850280-44-3
 850280-45-4 850280-46-5 850280-47-6 850280-48-7 850280-49-8
 850280-50-1 850280-51-2 850280-52-3 850280-53-4 850280-54-5
 850280-55-6 unclaimed nucleotide sequence; vaccines for cancer,
 autoimmune disease and infections
 153045-21-7 847201-84-7 847201-85-8 847201-93-8 847201-95-0
 847201-96-1 847201-97-2 847201-98-3 847201-99-4 847202-00-0
 847202-01-1 847202-02-2 847202-03-3 847202-04-4 847202-05-5
 847202-06-6 847202-07-7 847202-08-8 847202-09-9 847202-10-2
 847202-11-3 847202-12-4 847202-13-5 847202-14-6 847202-15-7
 847202-16-8 847202-17-9 847202-18-0 847202-19-1 847202-20-4
 unclaimed sequence; vaccines for cancer, autoimmune disease and
 infections

6/7/16 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142334937 CA: 142(18)334937g PATENT
 Regulatory leukocytes repressing B cell autoantibody secretion
 INVENTOR(AUTHOR): Vilen, Barbara J.; Kilmon, Michelle; Rutan, Jennifer A.
 LOCATION: USA
 ASSIGNEE: University of North Carolina At Chapel Hill
 PATENT: PCT International ; WO 200527841 A2 DATE: 20050331
 APPLICATION: WO 2004US30325 (20040916) *US 2003PV503534 (20030916)
 PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;

LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA202XXX Mammalian Hormones

IDENTIFIERS: B cell autoantibody Sm antigen regulatory leukocyte

DESCRIPTORS:

CD40(antigen)... Tumor necrosis factor receptors...

activation of regulatory immune cells by

Interferons...

α; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

Transforming growth factors...

α-; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

Integrins...

αM; expression by immune cells mediating peripheral anergy of
autoreactive B-cells

Integrins...

αX; expression by immune cells mediating peripheral anergy of
autoreactive B-cells

Immune tolerance...

anergy; interleukin-6- and contact-dependent mechanisms for regulatory
immune cells mediating peripheral anergy of autoreactive B-cells

CD20(antigen)...

antibodies to B-cells in treatment of autoimmune disease

Cytokines...

APRIL; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

Kidney,disease... Autoimmune disease... Inflammation...

autoimmune glomerulonephritis; regulatory immune cells repress
autoreactive B-cell antibody prodn. in relation to treatment of

Thyroid gland,disease... Autoimmune disease... Inflammation...

autoimmune thyroiditis; regulatory immune cells repress autoreactive
B-cell antibody prodn. in relation to treatment of

Cytokines...

BAFF; expression by regulatory immune cells mediating peripheral anergy
of autoreactive B-cells

Interferons...

β; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

Transforming growth factors...

β-; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

CD antigens...

CD11B; expression by immune cells mediating peripheral anergy of
autoreactive B-cells

CD antigens...

CD11C; expression by immune cells mediating peripheral anergy of
autoreactive B-cells

Cytokines...

CD30 ligand; expression by regulatory immune cells mediating peripheral
anergy of autoreactive B-cells

Glycoproteins...

CD40-L (antigen CD40 ligand); expression by regulatory immune cells
mediating peripheral anergy of autoreactive B-cells

CD antigens...
 CD70; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Inflammation...
 Crohn's disease; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Intestine,disease...
 Crohn's; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Antigens...
 DX5; expression by immune cells mediating peripheral anergy of autoreactive B-cells

Interleukin 1... Interleukin 2... Interleukin 3... Interleukin 4...
 Interleukin 5... Interleukin 6... Interleukin 7... Interleukin 8...
 Interleukin 10... Interleukin 12... Interleukin 13... Interleukin 14...
 Interleukin 15... Interleukin 18... Interleukin 24... Macrophage migration inhibitory factor... Monocyte chemoattractant protein-1... Lymphotoxin...
 Fas ligand...
 expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Interferons...
 γ; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Proteins...
 GTR ligand; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Kidney,disease...
 Goodpasture's syndrome; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Antibodies and Immunoglobulins...
 IgM autoantibodies; prodn. is lupus model is repressed by regulatory leukocytes

Dendritic cell... Macrophage... Animal tissue culture... Human...
 Immunotherapy...
 interleukin-6- and contact-dependent mechanisms for regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Chemokines...
 macrophage inflammatory protein 1; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Lymphocyte...
 natural killer cell; interleukin-6- and contact-dependent mechanisms for regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Antigens...
 nuclear antigens; surface expression by immune cells mediating peripheral anergy of autoreactive B-cells

Proteins...
 OX40L; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

Skin,disease...
 pemphigus vulgaris; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Artery,disease... Inflammation...
 periarteritis nodosa; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Lymphocyte...
 plasma cell; regulatory leukocytes repress autoantibody secretion by

Arthritis...
 psoriatic arthritis; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of

Diagnosis...

regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to
 Rheumatoid arthritis... Psoriasis... Antiphospholipid syndrome... Sjogren's syndrome...
 regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of
 B cell(lymphocyte)...
 regulatory leukocytes repress autoantibody secretion by
 Autoimmune disease...
 regulatory leukocytes repress autoantibody secretion in lupus model
 Connective tissue,disease...
 scleroderma; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of
 Antigens...
 Sm; regulatory leukocytes repress B-cell prodn. of autoantibodies to
 Lupus erythematosus...
 systemic; regulatory leukocytes repress autoantibody secretion in model for
 Receptors...
 TLR (Toll-like receptor); activation of regulatory immune cells by
 Cytokines...
 TNFSF7 (tumor necrosis factor superfamily member 7); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Antibodies and Immunoglobulins...
 to B-cells in treatment of autoimmune disease
 Proteins...
 TRAIL (tumor necrosis factor-related apoptosis-inducing ligand); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Cytokines...
 TWEAK (TNF-like weak inducer of apoptosis); expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Blood vessel,disease... Inflammation...
 vasculitis, autoimmune, ANCA-assocd.; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of
 Blood vessel,disease... Inflammation...
 vasculitis, necrotizing; regulatory immune cells repress autoreactive B-cell antibody prodn. in relation to treatment of
 Interleukins...
 23; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Interleukins...
 25; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Interleukins...
 26; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 Proteins...
 4-1BBL; expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells
 CAS REGISTRY NUMBERS:
 81627-83-0 207621-35-0 expression by regulatory immune cells mediating peripheral anergy of autoreactive B-cells

6/7/17 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142259982 CA: 142(14)259982n PATENT

Compositions comprising autoantigen and antigen-specific multivalent antibody for treating cancer, infection and autoimmune disease
INVENTOR(AUTHOR): Barabas, Arpad Z.

LOCATION: Can.,

ASSIGNEE: The Governors of the University of Calgary

PATENT: PCT International ; WO 200516379 A1 DATE: 20050224

APPLICATION: WO 2004CA1494 (20040812) *US 2003PV495804 (20030815)

PAGES: 104 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A; A61K-039/00B; A61P-037/00B; A61P-037/02B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

CA263XXX Pharmaceuticals

IDENTIFIERS: antigen autoantigen antibody IgM IgG cancer infection autoimmune disease

DESCRIPTORS:

Immunostimulants...

adjuvants, Freund's; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Immunostimulants...

adjuvants; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Eubacteria... Animal virus... Fungi... Yeast...

antigen; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Drug delivery systems...

aq.; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...

autoantibodies, downregulation; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens... Antibodies and Immunoglobulins... Mammalia... Human... Tumor

antigens... Antitumor agents... Vaccines... Infection... Mycosis...

Parasite... Protozoa... Fusion proteins(chimeric proteins)... Buffers...

Myelin basic protein... Animal cell... Animal tissue... Organ,animal...

Rheumatoid arthritis... Myasthenia gravis... Sjogren's syndrome... Multiple

sclerosis... Melanoma... Prostate gland,neoplasm... Thyroid gland,neoplasm

... Pancreas,neoplasm... Liver,neoplasm... Mammary gland,neoplasm...

Lung,neoplasm... Stomach,neoplasm... Pathogen... Staphylococcus...

Streptococcus... Escherichia coli... Influenza virus... Hepatitis A virus

... Hepatitis B virus... Hepatitis C virus... Malaria... Alums... Haptens

...

autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

autoantigens, 70 kD mitochondrial biliary; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease

Antigens...

autoantigens; autoantigens and antigen-specific multivalent antibodies

for treating cancer, infection and autoimmune disease

Anemia(disease)... Autoimmune disease...
 autoimmune hemolytic anemia; autoantigens and antigen-specific
 multivalent antibodies for treating cancer, infection and autoimmune
 disease

Thyroid gland,disease... Autoimmune disease... Inflammation...
 autoimmune thyroiditis; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Kidney,disease... Hypoparathyroidism... Blister... Addison's disease...
 autoimmune; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Infection...
 bacterial; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...
 bispecific; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Glycoproteins...
 cartilage GP39, human; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...
 chimeric; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Proteins... Haptens...
 conjugates; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Dermatitis...
 contact, sensitivity; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Fertility...
 disorder, autoimmune; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Uterus,disease...
 endometriosis; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...
 fragments; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Drug delivery systems...
 freeze-dried; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Antigens...
 glomerular nephritogenic; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Basement membrane...
 glomerular; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Kidney,disease... Inflammation...
 Heymann nephritis; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Gene,animal...
 human Ig; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Antigens...
 human placental Hp-8; autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

Antibodies and Immunoglobulins...
 humanized; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Antigens...
 IBL; endometrial; autoantigens and antigen-specific multivalent

- antibodies for treating cancer, infection and autoimmune disease
- Antibodies and Immunoglobulins...
 - IgG; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Antibodies and Immunoglobulins...
 - IgM; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Autoimmune disease...
 - insulin-dependent diabetes mellitus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Diabetes mellitus...
 - insulin-dependent; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Antigens...
 - kidney tubular nephritogenic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Antigens...
 - La/SSB; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Kidney,disease... Inflammation...
 - lupus nephritis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Kidney,disease... Inflammation...
 - membranous glomerulonephritis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Drug delivery systems...
 - nasal, intra; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Antigens...
 - nucleolar ASE-1; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Drug delivery systems...
 - ophthalmic; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Drug delivery systems...
 - oral; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Drug delivery systems...
 - parenterals; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Skin,disease...
 - pemphigoid, bolus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Skin,disease...
 - pemphigus foliaceus; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Skin,disease...
 - pemphigus vulgaris; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Biliary tract,disease...
 - primary biliary cirrhosis; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Kidney...
 - proximal tubule; autoantigens and antigen-specific multivalent antibodies for treating cancer, infection and autoimmune disease
- Proteins...
 - recombinant; autoantigens and antigen-specific multivalent antibodies

for treating cancer, infection and autoimmune disease

Antigens...
 repro-EN-1.0; endometrial; autoantigens and antigen-specific
 multivalent antibodies for treating cancer, infection and autoimmune
 disease

Antigens...
 Ro/SSA; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Connective tissue,disease...
 scleroderma; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Antigens...
 Sm; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Ribonucleoproteins...
 snRNP (small nuclear ribonucleoprotein); autoantigens and
 antigen-specific multivalent antibodies for treating cancer, infection
 and autoimmune disease

Proteins...
 Sp17; human; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Lupus erythematosus...
 systemic; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Mus musculus...
 transgenic; autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

Vaccines...
 tumor; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Antitumor agents...
 vaccines; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

Infection...
 viral; autoantigens and antigen-specific multivalent antibodies for
 treating cancer, infection and autoimmune disease

CAS REGISTRY NUMBERS:

9024-58-2 9014-46-4 autoantigens and antigen-specific multivalent
 antibodies for treating cancer, infection and autoimmune disease

7732-18-5 biological studies, sterile; autoantigens and antigen-specific
 multivalent antibodies for treating cancer, infection and autoimmune
 disease

98-50-0D 63-74-1D conjugates, autoantigens and antigen-specific
 multivalent antibodies for treating cancer, infection and autoimmune
 disease

7429-90-5D salts, autoantigens and antigen-specific multivalent antibodies
 for treating cancer, infection and autoimmune disease

6/7/18 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

141122334 CA: 141(8)122334n PATENT
 Immunotherapy of B cell malignancies and autoimmune disease using
 unconjugated and conjugated antibodies, fragments or fusion proteins
 INVENTOR(AUTHOR): Goldenberg, David M.; Hansen, Hans
 LOCATION: USA
 ASSIGNEE: Immunomedics, Inc.; Mccall, John Douglas
 PATENT: PCT International ; WO 200458298 A1 DATE: 20040715
 APPLICATION: WO 2003GB5700 (20031231) *US PV437145 (20021231)

PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A; A61K-041/00B; A61K-051/10B; A61K-039/395B;
A61P-005/00B; A61P-037/06B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;
RO; RU; SC; SD; SE; SG; SK; SL; SI; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD
; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG;
CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO;
SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;
TG

SECTION:

CA215003 Immunochemistry
CA209XXX Biochemical Methods
CA263XXX Pharmaceuticals

IDENTIFIERS: immunotherapy B cell malignancy autoimmune disease conjugate
unconjugate antibody

DESCRIPTORS:

Leukemia...

acute lymphocytic; unconjugated and conjugated antibodies, fragments or
antibody fusion proteins for immunotherapy and immunodiagnosis of B
cell malignancies and autoimmune disease

Sulfonic acids, biological studies...

alkanesulfonic, salts; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...

α ; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Toxins...

α ; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Interleukin 2 receptors...

α chain; unconjugated and conjugated antibodies, fragments or
antibody fusion proteins for immunotherapy and immunodiagnosis of B
cell malignancies and autoimmune disease

Integrins...

αX ; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Nervous system, disease...

amyotrophic lateral sclerosis; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Spinal column, disease...

ankylosing spondylitis; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Cytotoxic agents...

antimetabolites; unconjugated and conjugated antibodies, fragments or
antibody fusion proteins for immunotherapy and immunodiagnosis of B
cell malignancies and autoimmune disease

Inflammation... Artery, disease...

arteritis, giant cell; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Artery,disease...
arteritis, Takayasu's; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Autoimmune disease... Thyroid gland,disease...
autoimmune thyroiditis; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Lymphoma...
B-cell; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Disease,animal...
B-lymphocyte, malignancy; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...
 β ; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Skin,disease...
bullous pemphigoid; unconjugated and conjugated antibodies, fragments
or antibody fusion proteins for immunotherapy and immunodiagnosis of B
cell malignancies and autoimmune disease

CD antigens...
CD11c; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Antigens...
CD126; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

CD antigens...
CD33; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

CD antigens...
CD37; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Glycoproteins...
CD40-L (antigen CD40 ligand); unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

CD antigens...
CD52; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Antibodies and Immunoglobulins...
chimeric; unconjugated and conjugated antibodies, fragments or antibody
fusion proteins for immunotherapy and immunodiagnosis of B cell
malignancies and autoimmune disease

Leukemia...
chronic lymphocytic; unconjugated and conjugated antibodies, fragments
or antibody fusion proteins for immunotherapy and immunodiagnosis of B
cell malignancies and autoimmune disease

Infection...
chronic viral hepatitis; unconjugated and conjugated antibodies,
fragments or antibody fusion proteins for immunotherapy and
immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...

conjugates; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...
diphtheria; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

T cell(lymphocyte)...
disease; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Blood vessel...
endothelium, antigen; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...
enterotoxin A, Staphylococcal; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...
enterotoxins, staphylococcal A; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Toxins...
exotoxins, Pseudomonas; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Lung,disease...
fibrosis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...
fragments; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Mycosis...
fungoides; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Interferons...
γ; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...
glomerulonephritis, rapidly progressive; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Kidney,disease...
Goodpasture's syndrome; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Purpura(disease)...
Henoch-Schoenlein's; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Histocompatibility antigens...
HLA-DR; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antigens...
HMI.24; unconjugated and conjugated antibodies, fragments or antibody

fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...
humanized; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Histocompatibility antigens...
I-A; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Cell adhesion molecules...
ICAM-1 (intercellular adhesion mol. 1); unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Purpura(disease)...
idiopathic thrombocytopenic, acute and chronic; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Kidney,disease...
IgA nephropathy; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Immunoglobulin receptors...
IgE type II; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...
IgG; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Drug delivery systems...
immunoconjugates; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Diagnosis...
immunodiagnosis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Drug delivery systems...
immunotoxins; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Apoptosis...
inducer; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Mitosis...
inhibitors; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Fluorescent substances... Heavy metals...
label; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...
lupus nephritis; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

Proteins...
MCP (membrane cofactor protein); unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and

immunodiagnosis of B cell malignancies and autoimmune disease

Inflammation... Kidney,disease...
 membranous glomerulonephritis; unconjugated and conjugated antibodies,
 fragments or antibody fusion proteins for immunotherapy and
 immunodiagnosis of B cell malignancies and autoimmune disease

Antibodies and Immunoglobulins...
 monoclonal; unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

Mucins...
 MUC1; unconjugated and conjugated antibodies, fragments or antibody
 fusion proteins for immunotherapy and immunodiagnosis of B cell
 malignancies and autoimmune disease

Erythema...
 multiforme; unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

Skin,neoplasm...
 mycosis fungoides; unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

Inflammation... Kidney,disease...
 nephritis, post-streptococcal; unconjugated and conjugated antibodies,
 fragments or antibody fusion proteins for immunotherapy and
 immunodiagnosis of B cell malignancies and autoimmune disease

Erythema...
 nodosum; unconjugated and conjugated antibodies, fragments or antibody
 fusion proteins for immunotherapy and immunodiagnosis of B cell
 malignancies and autoimmune disease

Lymphoma...
 non-Hodgkin's; unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

CAS REGISTRY NUMBERS:
 55-86-7D analogs, unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

14596-37-3 15749-66-3 14391-96-9 14596-12-4 13981-25-4 15757-86-5
 14265-71-5 14687-61-7 14158-27-1 10098-91-6 14119-15-4 14913-89-4
 14981-64-7 15760-04-0 14158-31-7 10043-66-0 14191-64-1 14981-79-4
 15765-31-8 15766-00-4 14391-19-6 13967-65-2 15840-13-8 14265-75-9
 15765-78-3 14378-26-8 14158-35-1 10043-49-9 14391-11-8 15816-77-0
 15092-94-1 15776-20-2 13981-38-9 14119-09-6 378253-43-1
 378784-45-3 378784-00-0 15750-15-9 14914-68-2 14391-20-9
 378782-88-8 14694-69-0 14265-85-1 15755-39-2 15904-62-8 14913-49-6
 15623-45-7 14835-02-0 15706-52-2 15229-37-5 15756-41-9 17239-90-6
 15750-24-0 14798-12-0 14391-32-3 15117-96-1 biological studies,
 unconjugated and conjugated antibodies, fragments or antibody fusion
 proteins for immunotherapy and immunodiagnosis of B cell malignancies
 and autoimmune disease

12586-31-1 capture; unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

7440-42-8D compds., unconjugated and conjugated antibodies, fragments or
 antibody fusion proteins for immunotherapy and immunodiagnosis of B
 cell malignancies and autoimmune disease

7440-66-6D 7429-90-5D 7440-55-3D 7439-94-3D 7440-05-3D complexes,
 unconjugated and conjugated antibodies, fragments or antibody fusion
 proteins for immunotherapy and immunodiagnosis of B cell malignancies
 and autoimmune disease

7440-06-4D coordination complexes and analogs, unconjugated and conjugated

antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease
 151-56-4D 13010-20-3D 15056-34-5D 59-30-3D 1605-68-1D 289-95-2D
 120-73-0D 60-34-4D 187888-07-9D 33069-62-4D 7689-03-4D 23214-92-8D
 derivs. and analogs, unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease
 329900-75-6 inhibitors; unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease
 57-13-6D substituted derivs. and analogs, unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease
 127464-60-2 352423-07-5 50-18-0 33419-42-0 671-16-9 53-03-2 154-93-8
 59-05-2 11056-06-7 50-02-2 4346-18-3 83314-01-6 58-05-9 9001-99-4
 9003-98-9 62683-29-8 11096-26-7 9014-42-0 143011-72-7 83869-56-1
 67-43-6 60239-18-1 60239-22-7 56491-86-2 138612-85-8 4375-07-9
 57-22-7 75037-46-6 unconjugated and conjugated antibodies, fragments or antibody fusion proteins for immunotherapy and immunodiagnosis of B cell malignancies and autoimmune disease

6/7/19 (Item 12 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

139317445 CA: 139(21)317445r PATENT

Remedies for pemphigus containing CD40l antagonist as the active ingredient

INVENTOR(AUTHOR): Amagai, Masayuki; Nishikawa, Takeji

LOCATION: Japan,

ASSIGNEE: Keio University; Eisai Co., Ltd.

PATENT: PCT International; WO 200386463 A1 DATE: 20031023

APPLICATION: WO 2003JP4219 (20030402) *JP 2002101886 (20020403)

PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: Japanese

PATENT CLASSIFICATIONS:

CLASS: A61K-045/00A; A61K-039/395B; A61P-017/00B; A61P-037/06B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; NO; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GN; GQ; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA201007 Pharmacology

IDENTIFIERS: pemphigus vulgaris foliaceus CD40l receptor antagonist

antiCD40L

DESCRIPTORS:

Glycoproteins...

CD40-L (antigen CD40 ligand); remedies for pemphigus contg. CD40l antagonist as the active ingredient

T cell(lymphocyte)...

helper cell; remedies for pemphigus contg. CD40l antagonist as the active ingredient

Skin,disease...

pemphigus foliaceus; remedies for pemphigus contg. CD40l antagonist as the active ingredient

Skin,disease...

pemphigus vulgaris; remedies for pemphigus contg. CD40l antagonist as the active ingredient
Skin,disease...
pemphigus; remedies for pemphigus contg. CD40l antagonist as the active ingredient
CD40(antigen)... Human... Antigen-presenting cell...
remedies for pemphigus contg. CD40l antagonist as the active ingredient
CAS REGISTRY NUMBERS:
252662-47-8D MRI antibody, remedies for pemphigus contg. CD40l antagonist as the active ingredient

6/7/20 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

137228962 CA: 137(16)228962y PATENT
CD4+CD25+ regulatory T cells from human blood
INVENTOR(AUTHOR): Schuler, Gerold
LOCATION: Germany,
PATENT: European Pat. Appl. ; EP 1241249 A1 DATE: 20020918
APPLICATION: EP 2001106033 (20010312)
PAGES: 26 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-005/06A; A61K-035/14B; G01N-033/50B; A61P-037/06B;
A61P-037/04B
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR
SECTION:
CA209016 Biochemical Methods
CA215XXX Immunochemistry
IDENTIFIERS: CD4 CD25 regulatory T cell blood
DESCRIPTORS:
Antigens...
alloantigens; CD4+CD25+ regulatory T cells from human blood
Interferons...
a; CD4+CD25+ regulatory T cells from human blood
Antigens...
autoantigens; CD4+CD25+ regulatory T cells from human blood
Acrylic fibers,analysis... Adoptive immunotherapy... Animal tissue...
Antigens... Apoptosis... Autoimmune disease... Blood... CD28(antigen)...
CD2(antigen)... CD3(antigen)... CD4(antigen)... Cell... Composition...
CTLA-4(antigen)... Dendritic cell... Drugs... Hepatitis... Human...
Immunity... Interleukin 10... Interleukin 2 receptors... Interleukin 2...
Interleukin 5... Interleukin 7... Interleukin 9... Magnetic separation...
Molecules... Necrosis... Pathogen... RNA... T cell(lymphocyte)...
Thyroglobulin... Transplant and Transplantation... Transplant rejection...
Vitiligo...
CD4+CD25+ regulatory T cells from human blood
Glycoproteins...
CD40-L (antigen CD40 ligand); CD4+CD25+ regulatory T cells from human blood
Transplant and Transplantation...
graft-vs.-host reaction; CD4+CD25+ regulatory T cells from human blood
Adsorption...
immunoadsorption; CD4+CD25+ regulatory T cells from human blood
Antibodies...
monoclonal; CD4+CD25+ regulatory T cells from human blood
Skin,disease...
pemphigus vulgaris; CD4+CD25+ regulatory T cells from human blood
Thyroid gland,disease...

thyroiditis; CD4+CD25+ regulatory T cells from human blood
CAS REGISTRY NUMBERS:
7440-70-2 analysis, ionophor; CD4+CD25+ regulatory T cells from human
blood
9002-10-2 CD4+CD25+ regulatory T cells from human blood
17673-25-5D esters, CD4+CD25+ regulatory T cells from human blood

6/7/21 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136246408 CA: 136(16)246408f PATENT
Combination therapy for treatment of autoimmune diseases using B cell
depleting/immunoregulatory antibody combination.
INVENTOR(AUTHOR): Hanna, Nabil
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals
PATENT: PCT International ; WO 200222212 A2 DATE: 20020321
APPLICATION: WO 2001US29026 (20010918) *US PV257147 (20001222)
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61P-037/00; A61K-039/39
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;
CH; CN; CO; CU; CZ; EE; ES; FI; GB; GE; GM; HU; ID; IL; IN; KP; KR; LK; LR;
MN; MW; MX; NO; NZ; PL; PT; RO; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE;
IT; MC; NL; PT; SE; TR; CG; CI; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215008 Immunochemistry
IDENTIFIERS: autoimmune disease immunotherapy antibody B lymphocyte
DESCRIPTORS:
Immune complexes...
-mediated diseases; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Leukocyte...
adhesion deficiency; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Respiratory distress syndrome...
adult; combination therapy for treatment of autoimmune diseases using B
cell depleting/immunoregulatory antibody combination
Nerve,disease...
allergic neuritis; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Encephalitis...
allergic; combination therapy for treatment of autoimmune diseases
using B cell depleting/immunoregulatory antibody combination
Phospholipids,biological studies...
antibodies to, antiphospholipid syndrome; combination therapy for
treatment of autoimmune diseases using B cell
depleting/immunoregulatory antibody combination
Artery,disease...
arteritis, giant cell; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Antibodies...
autoantibodies; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Ovary,disease...
autoimmune oophoritis; combination therapy for treatment of autoimmune
diseases using B cell depleting/immunoregulatory antibody combination
Platelet(blood)...

autoimmune thrombocytopenia; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Thyroid gland,disease...
autoimmune thyroiditis; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Skin,disease...
bullous pemphigoid; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CDw75; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CDw76; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CDw78; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CDw84; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD24; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD37; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Glycoproteins...
CD40-L (antigen CD40 ligand); combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD53; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD72; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD73; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD77; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD79a; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD81; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD83; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

CD antigens...
CD85; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Nervous system...
central, inflammation; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Antibodies...
chimeric, humanized; combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

Inflammation...
 chronic; combination therapy for treatment of autoimmune diseases using
 B cell depleting/immunoregulatory antibody combination

Intestine,disease...
 colitis; combination therapy for treatment of autoimmune diseases using
 B cell depleting/immunoregulatory antibody combination

Autoimmune disease... B cell(lymphocyte)... Antibodies... CD80(antigen)...
 CD86(antigen)... CD19(antigen)... CD20(antigen)... CD22(antigen)...
 CD40(antigen)... CD4(antigen)... Invariant chain(class II antigen)... Human
 ... Psoriasis... Dermatitis... Respiratory distress syndrome... Meningitis
 ... Encephalitis... Allergy... Eczema... Asthma... Atherosclerosis...
 Rheumatoid arthritis... Diabetes mellitus... Multiple sclerosis...
 Sjogren's syndrome... Tuberculosis... Sarcoidosis... Granulomatous disease
 ... Multiple organ failure... Myasthenia gravis... Graves' disease...
 Behcet's syndrome... Immunosuppressants... Immunotherapy...
 combination therapy for treatment of autoimmune diseases using B cell
 depleting/immunoregulatory antibody combination

Cytotoxic agents... Radionuclides,biological studies...
 conjugates with antibody; combination therapy for treatment of
 autoimmune diseases using B cell depleting/immunoregulatory antibody
 combination

Anemia(disease)...
 Coombs pos.; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination

Intestine,disease...
 Crohn's; combination therapy for treatment of autoimmune diseases using
 B cell depleting/immunoregulatory antibody combination

Cryoglobulins...
 cryoglobulinemia; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination

Allergy...
 delayed hypersensitivity; combination therapy for treatment of
 autoimmune diseases using B cell depleting/immunoregulatory antibody
 combination

Cell migration...
 diapedesis, leukocyte; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination

Endocrine system...
 disease, autoimmune; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination

Muscle,disease...
 Eaton-Lambert syndrome; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination

Proteins...
 gene B29; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination

Glycoproteins...
 gene KAll; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination

Kidney,disease...
 glomerulonephritis, anti-glomerular basement membrane; combination
 therapy for treatment of autoimmune diseases using B cell
 depleting/immunoregulatory antibody combination

Kidney,disease...
 glomerulonephritis; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination

Anemia(disease)...
 hemolytic; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination

Antibodies...
 humanized; combination therapy for treatment of autoimmune diseases

using B cell depleting/immunoregulatory antibody combination
 Purpura(disease)...
 idiopathic thrombocytopenic; combination therapy for treatment of
 autoimmune diseases using B cell depleting/immunoregulatory antibody
 combination
 Kidney,disease...
 IgA nephropathy; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Immunoglobulin receptors...
 IgE type II; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Kidney,disease...
 immune complex nephritis; combination therapy for treatment of
 autoimmune diseases using B cell depleting/immunoregulatory antibody
 combination
 T cell(lymphocyte)...
 infiltration; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Intestine,disease...
 inflammatory; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Drug delivery systems...
 infusions; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Drug delivery systems...
 injections, i.v.; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Diabetes mellitus...
 insulin-dependent; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Skin,disease...
 pemphigus; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Anemia(disease)...
 pernicious anemia; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Muscle,disease...
 polymyositis; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Nerve,disease...
 polyneuropathy, IgM; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Blood vessel,disease...
 Raynaud's phenomenon; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Arthritis...
 Reiter's syndrome; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 Connective tissue...
 scleroderma; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Nervous system...
 sclerosis; combination therapy for treatment of autoimmune diseases
 using B cell depleting/immunoregulatory antibody combination
 Muscle,disease...
 stiff-man syndrome; combination therapy for treatment of autoimmune
 diseases using B cell depleting/immunoregulatory antibody combination
 CAS REGISTRY NUMBERS:
 192391-48-3 79217-60-0 104987-11-3 174722-31-7 206181-63-7 82707-54-8
 combination therapy for treatment of autoimmune diseases using B cell
 depleting/immunoregulatory antibody combination

6/7/22 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136101076 CA: 136(7)101076m PATENT
Methods for abrogating a cellular immune response
INVENTOR(AUTHOR): Albert, Matthew L.; Jegathesan, Mithila; Darnell,
Robert B.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20020004041 A1 DATE: 20020110
APPLICATION: US 804584 (20010312) *US 251896 (19990219) *US 545958
(20000505)
PAGES: 35 pp., Cont.-in-part of U.S. Ser. No. 545,958. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424093210; A61K-048/00A; A61K-045/00B; A61K-031/739B;
A61K-038/19B
SECTION:
CA215001 Immunochemistry
IDENTIFIERS: dendritic cell maturation stimulatory mol tolerance,
monoclonal antibody TNF superfamily ligand receptor
DESCRIPTORS:
Immune tolerance...
energy, T cell; dendritic cell maturation-stimulatory mols. for
abrogating cellular immune response and inducing immune tolerance
Transplant and Transplantation... Animal virus...
antigen; dendritic cell maturation-stimulatory mols. for abrogating
cellular immune response and inducing immune tolerance
Antigens...
autoantigens; dendritic cell maturation-stimulatory mols. for
abrogating cellular immune response and inducing immune tolerance
Chemokine receptors...
β chemokine receptor CCR6, ligand; dendritic cell
maturation-stimulatory mols. for abrogating cellular immune response
and inducing immune tolerance
Glycoproteins...
CD40-L (antigen CD40 ligand); dendritic cell maturation-stimulatory
mols. for abrogating cellular immune response and inducing immune
tolerance
Immunity...
cell-mediated, redn.; dendritic cell maturation-stimulatory mols. for
abrogating cellular immune response and inducing immune tolerance
Infection...
chronic; dendritic cell maturation-stimulatory mols. for abrogating
cellular immune response and inducing immune tolerance
DNA...
CpG-contg.; dendritic cell maturation-stimulatory mols. for abrogating
cellular immune response and inducing immune tolerance
T cell(lymphocyte)...
cytotoxic, redn.; dendritic cell maturation-stimulatory mols. for
abrogating cellular immune response and inducing immune tolerance
Transplant rejection... CD4-positive T cell... Dendritic cell... Antibodies
... CD40 (antigen)... Autoimmune disease... Psoriasis... Multiple sclerosis
... Rheumatoid arthritis... Lupus erythematosus... Immunotherapy...
Pathogen... Mycobacterium... Human immunodeficiency virus... Molecules...
Epitopes... Chemotactic factors... Lipopolysaccharides... Monocyte...
Mammalia... Apoptosis... Invariant chain(class II antigen)... Signal
transduction,biological...
dendritic cell maturation-stimulatory mols. for abrogating cellular

immune response and inducing immune tolerance

Cytokine receptors...
 DR3 (death receptor 3); dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

T cell(lymphocyte)...
 effector cell, redn.; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

Proteins...
 FK-binding; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

T cell(lymphocyte)...
 helper cell/inducer, TH2, redn.; dendritic cell maturation-stimulatory
 mols. for abrogating cellular immune response and inducing immune
 tolerance

Histocompatibility antigens...
 HLA, HLA-DM; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Histocompatibility antigens...
 HLA-A; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Histocompatibility antigens...
 HLA-B; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Histocompatibility antigens...
 HLA-C; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Histocompatibility antigens...
 HLA-DR; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Immune tolerance...
 induction; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Diabetes mellitus...
 insulin-dependent; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

T cell(lymphocyte)...
 killer cell, redn.; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

Histocompatibility antigens...
 MHC (major histocompatibility complex), class I; dendritic cell
 maturation-stimulatory mols. for abrogating cellular immune response
 and inducing immune tolerance

Histocompatibility antigens...
 MHC (major histocompatibility complex), class II; dendritic cell
 maturation-stimulatory mols. for abrogating cellular immune response
 and inducing immune tolerance

Culture media...
 monocyte-conditioned; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

Cytokine receptors...
 OX40 ligand; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Cytokines...
 OX40; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance

Skin,disease...
 pemphigus vulgaris; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

Mononuclear cell(leukocyte)...
 peripheral blood; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

Blood...
 peripheral mononuclear cells; dendritic cell maturation-stimulatory
 mols. for abrogating cellular immune response and inducing immune
 tolerance
 CD8-positive T cell...
 redn.; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance
 Chemokines...
 SLC (secondary lymphoid tissue chemokine); dendritic cell
 maturation-stimulatory mols. for abrogating cellular immune response
 and inducing immune tolerance
 Tumor necrosis factors... Tumor necrosis factor receptors...
 superfamily; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance
 Antigens...
 tumor-assocd.; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance
 Cytokines...
 TWEAK; dendritic cell maturation-stimulatory mols. for abrogating
 cellular immune response and inducing immune tolerance
 CAS REGISTRY NUMBERS:
 147171-40-2 antagonists; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance
 9001-92-7 cathepsin D-alternative; dendritic cell maturation-stimulatory
 mols. for abrogating cellular immune response and inducing immune
 tolerance
 363-24-6 9025-26-7 104987-11-3 53123-88-9 207621-35-0 dendritic cell
 maturation-stimulatory mols. for abrogating cellular immune response
 and inducing immune tolerance
 2382-65-2D derivs., DNA contg.; dendritic cell maturation-stimulatory
 mols. for abrogating cellular immune response and inducing immune
 tolerance
 9004-08-4 inhibitors; dendritic cell maturation-stimulatory mols. for
 abrogating cellular immune response and inducing immune tolerance

6/7/23 (Item 16 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT
 Methods for regulating a cell-mediated immune response by blocking
 lymphocytic signals and by blocking LFA-1 mediated adhesion
 INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach,
 Robert J.
 LOCATION: USA
 ASSIGNEE: Bristol-Myers Squibb Company
 PATENT: PCT International ; WO 200195928 A2 DATE: 20011220
 APPLICATION: WO 2001US18619 (20010608) *US PV210671 (20000609)
 PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: A61K-038/17A; A61K-039/395B; A61P-037/00B; C07K-014/705B;
 C07K-016/28B; A61K-039/395B; A61K-038/17B
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
 CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
 GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
 LV; MA; MD; MG; MK; MN; MW; MX; NZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
 SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;
 KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ
 ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;
 NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA215003 Immunochemistry

IDENTIFIERS: lymphocytic signal blocker cellular immune response, immunol
disease allograft rejection antibody CD28, soluble CD40 CD154 B7 CTLA4
LFA1

DESCRIPTORS:

Transplant rejection...

allotransplant; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Actinins...

α -; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Integrins...

antigens CD11a; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Stomach,disease...

atrophic gastritis, autoimmune; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Stomach,disease...

autoimmune gastritis, atrophic; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Anemia(disease)...

autoimmune hemolytic anemia; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Thyroid gland,disease...

autoimmune thyroiditis; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Eye,disease...

autoimmune uveitis; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Integrins...

β 2; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Health products...

biologicals; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Cell adhesion molecules...

blocker; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Tumor necrosis factors...

blockers or antagonists; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Glycoproteins...

CD40-L (antigen CD40 ligand); cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Transplant rejection... Ligands... CD28(antigen)... CD40(antigen)...

CD80(antigen)... CTLA-4(antigen)... LFA-1(antigen)... Filamin... Rodentia
... Antibodies... Fusion proteins(chimeric proteins)... Psoriasis... Lupus

erythematosus... Graves' disease... Autoimmune disease... Addison's disease
... Diabetes mellitus... Myasthenia gravis... Multiple sclerosis...
Sjogren's syndrome... Rheumatic diseases... Rheumatoid arthritis... Human
... Monkey... Ape... Dog(Canis familiaris)... Cat(Felis catus)... Cattle...
Horse(Equus caballus)... Rabbit... Mouse... Rat... Immunosuppressants...
Corticosteroids,biological studies... Drugs... Molecular cloning... DNA
sequences... Protein sequences...
 cell adhesion-blocking and lymphocytic signal-blocking agents for
 regulating cellular immunity and treating immunol. diseases and
 allograft rejection
Immunity...
 cell-mediated; cell adhesion-blocking and lymphocytic signal-blocking
 agents for regulating cellular immunity and treating immunol. diseases
 and allograft rejection
Immunoglobulins...
 chimeric CTLA4; cell adhesion-blocking and lymphocytic signal-blocking
 agents for regulating cellular immunity and treating immunol. diseases
 and allograft rejection
Intestine,disease...
 Crohn's; cell adhesion-blocking and lymphocytic signal-blocking agents
 for regulating cellular immunity and treating immunol. diseases and
 allograft rejection
Integrins...
 cytohesin 1; cell adhesion-blocking and lymphocytic signal-blocking
 agents for regulating cellular immunity and treating immunol. diseases
 and allograft rejection
Immunity...
 disorder; cell adhesion-blocking and lymphocytic signal-blocking agents
 for regulating cellular immunity and treating immunol. diseases and
 allograft rejection
Kidney,disease...
 Goodpasture's syndrome; cell adhesion-blocking and lymphocytic
 signal-blocking agents for regulating cellular immunity and treating
 immunol. diseases and allograft rejection
Transplant and Transplantation...
 graft-vs.-host reaction; cell adhesion-blocking and lymphocytic
 signal-blocking agents for regulating cellular immunity and treating
 immunol. diseases and allograft rejection
Transplant and Transplantation...
 heart; cell adhesion-blocking and lymphocytic signal-blocking agents
 for regulating cellular immunity and treating immunol. diseases and
 allograft rejection
Cell adhesion molecules...
 ICAM-1 (intercellular adhesion mol. 1); cell adhesion-blocking and
 lymphocytic signal-blocking agents for regulating cellular immunity and
 treating immunol. diseases and allograft rejection
Cell adhesion molecules...
 ICAM-2 (intercellular adhesion mol. 2); cell adhesion-blocking and
 lymphocytic signal-blocking agents for regulating cellular immunity and
 treating immunol. diseases and allograft rejection
Cell adhesion molecules...
 ICAM-3 (intercellular adhesion mol. 3); cell adhesion-blocking and
 lymphocytic signal-blocking agents for regulating cellular immunity and
 treating immunol. diseases and allograft rejection
Cytokines...
 inflammatory; cell adhesion-blocking and lymphocytic signal-blocking
 agents for regulating cellular immunity and treating immunol. diseases
 and allograft rejection
Diabetes mellitus...
 insulin-dependent; cell adhesion-blocking and lymphocytic
 signal-blocking agents for regulating cellular immunity and treating

immunol. diseases and allograft rejection

Drug delivery systems...
local; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Signal transduction,biological...
lymphocytic; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Connective tissue...
mixed connective tissue disease; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Antibodies...
monoclonal; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Hypothyroidism...
myxedema; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Kidney,disease...
nephritis, lupus; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Anti-inflammatory agents...
nonsteroidal; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Skin,disease...
pemphigus; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Anemia(disease)...
pernicious anemia; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Muscle,disease...
polymyositis; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Biliary tract...
primary biliary cirrhosis; cell adhesion-blocking and lymphocytic
signal-blocking agents for regulating cellular immunity and treating
immunol. diseases and allograft rejection

Connective tissue...
scleroderma; cell adhesion-blocking and lymphocytic signal-blocking
agents for regulating cellular immunity and treating immunol. diseases
and allograft rejection

Lymphocyte...
signal; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Transplant and Transplantation...
skin; cell adhesion-blocking and lymphocytic signal-blocking agents for
regulating cellular immunity and treating immunol. diseases and
allograft rejection

Antigens...
surface; cell adhesion-blocking and lymphocytic signal-blocking agents
for regulating cellular immunity and treating immunol. diseases and
allograft rejection

Eye,disease...
 sympathetic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Drug delivery systems...
 systemic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Leukemia...
 T-cell; acute; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Lymphoma...
 T-cell; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Disease,animal...
 testicular angiocentric T cell lymphoma; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Platelet(blood)...
 thrombocytopenia, idiopathic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Skin... Heart...
 transplant; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Intestine,disease...
 ulcerative colitis; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Blood vessel,disease...
 vasculitis, benign lymphocytic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

Hepatitis...
 viral, chronic; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

CAS REGISTRY NUMBERS:

382707-61-1P 382707-62-2P amino acid sequence; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

79217-60-0 53-03-2 446-86-6 59-05-2 170277-31-3 118-42-3 599-79-1 185243-69-0 143090-92-0 cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

329900-75-6 inhibitors; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

382707-60-0P 382707-63-3P nucleotide sequence; cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

7440-57-5D salts, cell adhesion-blocking and lymphocytic signal-blocking agents for regulating cellular immunity and treating immunol. diseases and allograft rejection

382711-44-6 382711-45-7 382711-46-8 382711-47-9 382711-48-0 unclaimed sequence; methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking LFA-1 mediated adhesion

6/7/24 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

135370653 CA: 135(26)370653a PATENT
Compositions and methods for achieving immune suppression
INVENTOR(AUTHOR): Strom, Terry B.; Maslinski, Wlodzimierz; Zheng, Xin
Xiao; Kim, Yon Su; Lacraz, Sylvie Ferrari
LOCATION: USA
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.
PATENT: PCT International ; WO 200187330 A2 DATE: 20011122
APPLICATION: WO 2001US15578 (20010514) *US PV203801 (20000512)
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-038/20A; A61K-038/17B; A61K-039/395B; A61P-037/06B;
C07K-014/54B; C07K-014/705B; A61K-038/20B; A61K-038/17B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215005 Immunochemistry
CA203XXX Biochemical Genetics
IDENTIFIERS: interleukin 15 antibody costimulatory signal
immunosuppression, immune tolerance mutant IL15 B7 antigen, autoimmune
disease chimeric CTLA4 Ig IL15
DESCRIPTORS:
Thyroid gland,disease...
autoimmune thyroiditis; interleukin 15 receptor-targeting agent and
costimulatory signal-inhibiting agent for diagnosis and treatment of
immunol. diseases or autoimmune diseases
Thyroid gland,disease...
autoimmune; interleukin 15 receptor-targeting agent and costimulatory
signal-inhibiting agent for diagnosis and treatment of immunol.
diseases or autoimmune diseases
Skin,disease...
Brazilian pemphigus; interleukin 15 receptor-targeting agent and
costimulatory signal-inhibiting agent for diagnosis and treatment of
immunol. diseases or autoimmune diseases
Glycoproteins,specific or class...
CD40-L (antigen CD40 ligand); interleukin 15 receptor-targeting agent
and costimulatory signal-inhibiting agent for diagnosis and treatment
of immunol. diseases or autoimmune diseases
Nervous system...
central, disease, autoimmune; interleukin 15 receptor-targeting agent
and costimulatory signal-inhibiting agent for diagnosis and treatment
of immunol. diseases or autoimmune diseases
CTLA-4(antigen)...
chimeric; interleukin 15 receptor-targeting agent and costimulatory
signal-inhibiting agent for diagnosis and treatment of immunol.
diseases or autoimmune diseases
Signal transduction,biological...
costimulatory mol. inhibitor; interleukin 15 receptor-targeting agent
and costimulatory signal-inhibiting agent for diagnosis and treatment
of immunol. diseases or autoimmune diseases
Immunity...

disorder; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunoglobulins...
 fragments; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunoglobulins...
 G, Fc; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Intestine,disease...
 inflammatory; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Blood vessel,disease...
 injury; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Diabetes mellitus...
 insulin-dependent; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Immunosuppression... Antibodies... T cell(lymphocyte)... Antigen-presenting cell... CD80(antigen)... CD86(antigen)... DNA sequences... Protein sequences... Molecular cloning... Fusion proteins(chimeric proteins)... Immunoglobulins... CD28(antigen)... CD40(antigen)... Autoimmune disease... Rheumatic diseases... Sjogren's syndrome... Dermatomyositis... Behcet's syndrome... Rheumatoid arthritis... Graves' disease... Multiple sclerosis ... Myasthenia gravis... Encephalomyelitis... Psoriasis... AIDS(disease)... Transplant rejection... Neoplasm... Immunosuppressants...

interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Interleukin receptors...
 interleukin 15; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Connective tissue...
 mixed connective tissue disease; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Interleukin 15...
 mutant; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Diabetes mellitus...
 non-insulin-dependent; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...
 pemphigus foliaceus; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...
 pemphigus vegetans; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of immunol. diseases or autoimmune diseases

Skin,disease...
 pemphigus vulgaris; interleukin 15 receptor-targeting agent and costimulatory signal-inhibiting agent for diagnosis and treatment of

immunol. diseases or autoimmune diseases

Skin,disease...
 pemphigus; interleukin 15 receptor-targeting agent and costimulatory
 signal-inhibiting agent for diagnosis and treatment of immunol.
 diseases or autoimmune diseases

Muscle,disease...
 polymyositis; interleukin 15 receptor-targeting agent and costimulatory
 signal-inhibiting agent for diagnosis and treatment of immunol.
 diseases or autoimmune diseases

Arthritis...
 Reiter's syndrome; interleukin 15 receptor-targeting agent and
 costimulatory signal-inhibiting agent for diagnosis and treatment of
 immunol. diseases or autoimmune diseases

Connective tissue...
 scleroderma; interleukin 15 receptor-targeting agent and costimulatory
 signal-inhibiting agent for diagnosis and treatment of immunol.
 diseases or autoimmune diseases

Lupus erythematosus...
 systemic; interleukin 15 receptor-targeting agent and costimulatory
 signal-inhibiting agent for diagnosis and treatment of immunol.
 diseases or autoimmune diseases

CAS REGISTRY NUMBERS:
 199129-26-5 172075-43-3 amino acid sequence; interleukin 15
 receptor-targeting agent and costimulatory signal-inhibiting agent for
 diagnosis and treatment of immunol. diseases or autoimmune diseases
 374585-67-8 172075-42-2 nucleotide sequence; interleukin 15
 receptor-targeting agent and costimulatory signal-inhibiting agent for
 diagnosis and treatment of immunol. diseases or autoimmune diseases
 288797-03-5 288797-02-4 288797-04-6 unclaimed nucleotide sequence;
 comps. and methods for achieving immune suppression

6/7/25 (Item 18 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT
 Human antibodies derived from immunized xenomice
 INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;
 Brenner, Daniel G.; Capon, Daniel J.
 LOCATION: USA
 ASSIGNEE: Cell Genesys, Inc.
 PATENT: PCT International ; WO 9634096 A1 DATE: 19961031
 APPLICATION: WO 95US5500 (19950428)
 PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: C12N-015/00A
 DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ
 DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
 NL; PT; SE
 SECTION:
 CA215003 Immunochemistry
 IDENTIFIERS: human antibody Ig xenomice therapeutic
 DESCRIPTORS:
 Proteins(specific proteins and subclasses)...
 amadori; human antibodies derived from immunized xenomice
 Dermatophagoides... Leukocyte...
 antigen; human antibodies derived from immunized xenomice
 Antigens...
 A7; human antibodies derived from immunized xenomice
 Interferon receptors...

- β; human antibodies derived from immunized xenomice
- Antigens...
 - B7.3; human antibodies derived from immunized xenomice
- CD antigens...
 - CDw52; human antibodies derived from immunized xenomice
- CD antigens...
 - CD27; human antibodies derived from immunized xenomice
- Antigens...
 - CD29 ligand; human antibodies derived from immunized xenomice
- Antigens...
 - CD30 ligand; human antibodies derived from immunized xenomice
- CD antigens...
 - CD6; human antibodies derived from immunized xenomice
- CD antigens...
 - CD72; human antibodies derived from immunized xenomice
- Fc receptors...
 - E; human antibodies derived from immunized xenomice
- Sialoglycoproteins...
 - endosialins; human antibodies derived from immunized xenomice
- Glycoproteins(specific proteins and subclasses)...
 - gcIII; human antibodies derived from immunized xenomice
- Lipids,biological studies...
 - glycated; human antibodies derived from immunized xenomice
- Glycoproteins(specific proteins and subclasses)...
 - gp39; human antibodies derived from immunized xenomice
- Cytokines...
 - Groα; human antibodies derived from immunized xenomice
- Cytokines...
 - Groβ; human antibodies derived from immunized xenomice
- Myelin...
 - growth inhibitor assocd. with; human antibodies derived from immunized xenomice
- Thyroid diseases...
 - Hashimoto's thyroiditis; human antibodies derived from immunized xenomice
- Surface antigens...
 - hepatitis virus; human antibodies derived from immunized xenomice
- Adult respiratory distress syndrome... Allergens... Animal cell line...
 - Animal cells... Antibodies... Antigens... Asthma... Autoimmune diseases...
- B cell(lymphocyte)... Behcet's syndrome... Cachexia... Carcinoembryonic
 - antigen... CD11a(antigen)... CD11b(antigen)... CD11c(antigen)...
- CD14(antigen)... CD19(antigen)... CD20(antigen)... CD22(antigen)...
 - CD28(antigen)... CD2(antigen)... CD30(antigen)... CD3(antigen)... CD40
- ligand... CD40(antigen)... CD44(antigen)... CD45(antigen)... CD4(antigen)
 - ... CD56(antigen)... CD5(antigen)... CD69(antigen)... CD7(antigen)...
- CD80(antigen)... CD86(antigen)... CD8(antigen)... Cell adhesion molecules
 - ... Chemokines... Cholesteryl ester transfer protein... Class I MHC
- antigens... Class II MHC antigens... Coagulation factors(blood)...
 - CTLA-4(antigen)... Cytomegalovirus... Dermatomyositis... Diagnosis... E
- glycoprotein(envelope glycoprotein)... Endotoxins... Enzymes,biological
 - studies... Eosinophil cationic protein... Epidermal growth factor receptors
- ... Erythropoietin receptors... E-selectin... Fas antigen... Fc receptors
 - ... FcεRI receptors... FcεRII receptors... Fibrinogens...
- Fibrins... Fibroblast growth factor receptors... Glomerulonephritis...
 - Glycoprotein B... Glycoprotein H... Graft-vs.-host reaction... Granulocyte
- colony-stimulating factor receptors... Graves' disease... Growth factor
 - receptors... Growth factors(animal)... Hematopoietin receptors... Hepatitis
- virus... Histocompatibility antigens... Human herpesvirus 3... Human
 - herpesvirus 4... Human herpesvirus... Human immunodeficiency virus 1...
- Human papillomavirus... ICAM-1(cell adhesion molecule)... ICAM-2(cell
 - adhesion molecule)... IgE... Immunoglobulins... Insulin-dependent diabetes

mellitus... Integrin $\alpha 1 \beta 1$... Integrin $\alpha 2 \beta 1$...
 Integrin $\alpha 3 \beta 1$... Integrin $\alpha 4 \beta 1$... Integrin
 $\alpha 5 \beta 1$... Integrin $\alpha 6 \beta 1$... Integrin $\beta 1$... Integrin
 $\beta 2$... Interferon receptors... Interferon α receptors...
 Interferon γ receptors... Interferon γ ... Interleukin receptors
 ... Interleukin 1 receptors... Interleukin 10... Interleukin 11...
 Interleukin 12... Interleukin 13... Interleukin 15... Interleukin 1...
 Interleukin 2 receptors... Interleukin 2... Interleukin 3 receptors...
 Interleukin 3... Interleukin 4 receptors... Interleukin 4... Interleukin 5
 receptors... Interleukin 5... Interleukin 6 receptors... Interleukin 6...
 Interleukin 7 receptors... Interleukin 7... Interleukin 8 receptors...
 Interleukin 8... Interleukin 9... Interleukins... Ley antigen...
 LFA-1(antigen)... LFA-3(antigen)... L-selectin... Macrophage inflammatory
 protein 1a... Mac-1 antigen... Major basic protein...
 Metastasis(tumor)... Monoclonal antibodies... Monocyte chemoattractant
 protein-1... Mucins... Multiple myeloma... Multiple sclerosis... Myasthenia
 gravis... Neutrophil-activating peptide-2... Osteopontin... Osteoporosis...
 Oxidized low-density lipoproteins... Paget's disease of bone...
 Platelet-derived growth factor receptors... Platelet-derived growth factors
 ... Polymyositis... Pseudomonas... Psoriasis... p150,95 antigen...
 P-glycoproteins... P-selectin... RANTES(chemokine)... Renal cell carcinoma
 ... Reperfusion injury... Respiratory syncytial virus... Rh blood groups...
 Rheumatoid arthritis... Scleroderma... Septic shock... Sjogren's syndrome
 ... Systemic lupus erythematosus... TCR(T-cell receptors)... Tetanus toxin
 ... Therapy... Thyrotropin receptors... Toxins... Transforming growth
 factor β receptors... Transforming growth factors β ... Tumor
 necrosis factor receptors... Tumor necrosis factor α ...
 Tumor-associated antigen... Type IV collagen... VCAM-1(cell adhesion
 molecule)...
 human antibodies derived from immunized xenomice
 Parathyroid hormone receptors...
 humoral hypercalcemic factor; human antibodies derived from immunized
 xenomice
 Genes(animal)...
 Ig; human antibodies derived from immunized xenomice
 Interleukin receptors...
 interleukin 10 receptors; human antibodies derived from immunized
 xenomice
 Interleukin receptors...
 interleukin 11 receptors; human antibodies derived from immunized
 xenomice
 Interleukin receptors...
 interleukin 13 receptors; human antibodies derived from immunized
 xenomice
 Interleukins... Receptors...
 interleukin 14; human antibodies derived from immunized xenomice
 Interleukin receptors...
 interleukin 15 receptors; human antibodies derived from immunized
 xenomice
 Interleukin receptors...
 interleukin 9 receptors; human antibodies derived from immunized
 xenomice
 Lewis blood groups...
 Leb, synthetic; human antibodies derived from immunized xenomice
 Selectins...
 ligands; human antibodies derived from immunized xenomice
 Proteins(specific proteins and subclasses)...
 LMP-1; human antibodies derived from immunized xenomice
 Membrane proteins...
 LMP-2 (latent-infection membrane protein 2); human antibodies derived
 from immunized xenomice

Allergens...
 Lol p I (Lolium perenne, I); human antibodies derived from immunized xenomice
 Connective tissue diseases...
 mixed; human antibodies derived from immunized xenomice
 Skin diseases...
 Paget disease; human antibodies derived from immunized xenomice
 Breast diseases... Reproductive tract diseases...
 Paget; human antibodies derived from immunized xenomice
 Antibodies...
 pANCA or perinuclear antineutrophil cytoplasm antibodies; human antibodies derived from immunized xenomice
 Skin diseases...
 pemphigus; human antibodies derived from immunized xenomice
 Chemokines...
 PF4; human antibodies derived from immunized xenomice
 c-erbB2 gene(animal)...
 products; human antibodies derived from immunized xenomice
 Virus...
 protein; human antibodies derived from immunized xenomice
 IgE... Interleukin 11... Interleukin 12... Interleukin 13... Interleukin 15
 ... Interleukin 9...
 receptors; human antibodies derived from immunized xenomice
 DNA...
 recombinant; human antibodies derived from immunized xenomice
 Arthritis... Conjunctivitis... Urinary tract diseases...
 Reiter's syndrome; human antibodies derived from immunized xenomice
 Transplant(organ)...
 rejection; human antibodies derived from immunized xenomice
 Ischemia...
 reperfusion; human antibodies derived from immunized xenomice
 Ligands...
 selectin; human antibodies derived from immunized xenomice
 Venoms...
 snake; human antibodies derived from immunized xenomice
 Proteins(specific proteins and subclasses)...
 uropontins; human antibodies derived from immunized xenomice
 Receptors...
 vascular endothelial growth factor; human antibodies derived from immunized xenomice
 Bee... Snake...
 venom; human antibodies derived from immunized xenomice
 Proteins (general),biological studies...
 viral; human antibodies derived from immunized xenomice
 Mouse...
 xeno-; human antibodies derived from immunized xenomice
 Interleukin receptors...
 12; human antibodies derived from immunized xenomice
 CAS REGISTRY NUMBERS:
 90027-15-3 90245-82-3 90546-31-3 196000-12-3 532375-95-3 620103-71-3
 620315-43-3 622295-09-3 800435-34-3 802954-38-3 802955-41-3
 816697-07-3 829868-98-3 924482-21-3 986038-40-3 1162437-33-3
 1274646-02-3 human antibodies derived from immunized xenomice
 90026-46-3 proteins related to; human antibodies derived from immunized xenomice
 ? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR -

CD154 OR GP39 OR CD154)
S4 1 RD S3 (unique items)
S5 37 (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR
CD154)
S6 25 RD S5 (unique items)
? t s6/3/all

6/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0020104725 BIOSIS NO.: 200800151664
T-B cell interaction is crucial for the induction of desmoglein 3-specific
IgG autoantibodies in an HLA-class II transgenic mouse model of
pemphigus vulgaris
AUTHOR: Eming R (Reprint); Hertl M; Schmidt J; Podstawa E; Feliciani C;
Sonderstrup G
AUTHOR ADDRESS: Univ Marburg, Marburg, Germany**Germany
JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT
2007 2007
CONFERENCE/MEETING: 37th Annual Meeting of the
European-Society-for-Dermatological-Research Zurich, SWITZERLAND
September 05 -08, 2007; 20070905
SPONSOR: European Soc Dermatol Res
ISSN: 0022-202X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

6/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019927481 BIOSIS NO.: 200700587222
Increased serum levels of circulating CD40 ligand in patients
with bullous pemphigoid: Preliminary results
AUTHOR: Watanabe R (Reprint); Ishiura N; Nakashima H; Yazawa N; Kuwano Y;
Tada Y; Okochi H; Fujimoto M; Tamaki K
AUTHOR ADDRESS: Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, 13-1
Takaramachi, Kanazawa, Ishikawa 9208641, Japan**Japan
AUTHOR E-MAIL ADDRESS: fujimoto-m@umin.ac.jp
JOURNAL: Dermatology (Basel) 215 (3): p180-186 2007 2007
ITEM IDENTIFIER: doi:10.1159/000106573
ISSN: 1018-8665
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

0019830322 BIOSIS NO.: 200700490063
The CD40/CD40 ligand system is involved in the pathogenesis of
pemphigus
AUTHOR: Caproni Marzia; Antiga Emiliano; Torchia Daniele; Volpi Walter; del
Bianco Elena; Cappetti Alessio; Feliciani Claudio; Fabbri Paolo (Reprint)
AUTHOR ADDRESS: Via Pergola, 58-60, I-50121 Florence, Italy**Italy
AUTHOR E-MAIL ADDRESS: fabbri@unifi.it

JOURNAL: Clinical Immunology (Orlando) 124 (1): p22-25 JUL 2007 2007
ITEM IDENTIFIER: doi:10.1016/j.clim.2007.04.007
ISSN: 1521-6616
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19097585 BIOSIS NO.: 200600442980
Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model
AUTHOR: Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki (Reprint)
AUTHOR ADDRESS: Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan**Japan
AUTHOR E-MAIL ADDRESS: amagai@sc.itc.keio.ac.jp
JOURNAL: Journal of Investigative Dermatology 126 (1): p105-113 JAN 2006 2006
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: A step toward antigen-specific therapy?
AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A
AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel Hill, NC 27599 USA**USA
AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu
JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006 2006
ISSN: 0022-202X
DOCUMENT TYPE: Article; Editorial
RECORD TYPE: Citation
LANGUAGE: English

6/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045
Blockade of CD40/CD40L interaction has therapeutic benefits in the pemphigus vulgaris mouse model
AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T; Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)
AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo, Japan**Japan
JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002 2002

MEDIUM: print
CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative
Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515
ISSN: 0022-202X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

6/3/7 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874
B cells move to centre stage: Novel opportunities for autoimmune disease
treatment
Browning J.L.
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,
MA 02445, United States
AUTHOR EMAIL: Jeff.Browning@biogenidec.com
CORRESP. AUTHOR: Browning J.L.
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12
Cambridge Center, Cambridge, MA 02445, United States
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery (Nat. Rev. Drug Discov.) (United Kingdom)
July 1, 2006, 5/7 (564-576)
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784
PUBLISHER ITEM IDENTIFIER: N2085
DOI: 10.1038/nrd2085
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 173

6/3/8 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148306456 CA: 148(14)306456e PATENT
Methods of identifying a marker of regulatory CD4+ T cells
INVENTOR(AUTHOR): Dromey, James A.; Mannering, Stuart I.; Harrison,
Leonard C.
LOCATION: Australia
ASSIGNEE: The Walter and Eliza Hall Institute of Medical Research
PATENT: PCT International ; WO 200828229 A1 DATE: 20080313
APPLICATION: WO 2007A1302 (20070905) *US 2006PV842548 (20060905)
PAGES: 78pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/8 + Level Value Position Status Version Action Source Office:
C12N-0005/08 A I F B 20060101 H AU
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI;
GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP;
KR; KZ; LA; LC; LK; LR; LS; LI; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY;
MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK;
SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/9 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148055086 CA: 148(3)55086n PATENT
Preparation of pyrrolopyrimidine compounds as protein kinase inhibitors
INVENTOR(AUTHOR): Brain, Christopher Thomas; Thoma, Gebhard; Sung, Moo Je
LOCATION: Switz.
ASSIGNEE: Novartis A.-G.; Novartis Pharma G.m.b.H.
PATENT: PCT International ; WO 2007140222 A2 DATE: 20071206
APPLICATION: WO 2007US69595 (20070524) *US 2006PV808605 (20060526)
PAGES: 213pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/10 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

147534655 CA: 147(26)534655d PATENT
Use of a compound with receptor activator of nuclear factor-kB ligand
(RANKL) activity
INVENTOR(AUTHOR): Penninger, Josef; Loser, Karin; Beissert, Stefan
LOCATION: Austria
ASSIGNEE: Imba-Institut Fuer Molekulare Biotechnologie GmbH
PATENT: PCT International ; WO 2007128564 A2 DATE: 20071115
APPLICATION: WO 2007EP4045 (20070508) *EP 2006450071 (20060508)
PAGES: 44pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/8 + Level Value Position Status Version Action Source Office:
A61K-0031/00 A I F B 20060101 H EP
A61P-0037/00 A I L B 20060101 H EP
A61P-0017/00 A I L B 20060101 H EP
A61K-0038/20 A I L B 20060101 H EP
A61K-0038/16 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA;
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/11 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT
Biomarkers for diagnosis and treatment of diseases having an autoimmune
and/or inflammatory component responsive to anti-CD40 monoclonal
antibodies
INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad
LOCATION: USA
ASSIGNEE: Novartis AG; Xoma Technology
PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123
APPLICATION: WO 2006US19325 (20060518) *US 2005PV682575 (20050518) *US
2005PV749336 (20051209)
PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/8 + Level Value Position Status Version Action Source Office:
G01N-0033/564 A I F B 20060101 H EP
G01N-0033/68 A I L B 20060101 H EP
A61P-0037/00 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MX; MY; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;
TT; TZ; UA; UG; US; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

6/3/12 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

145055995 CA: 145(4)55995w PATENT
Modulation of Fc gamma receptors for optimizing immunotherapy
INVENTOR(AUTHOR): Boruchov, Adam; Young, James W.
LOCATION: USA
ASSIGNEE: Memorial Sloan-Kettering Cancer Center
PATENT: European Pat. Appl. ; EP 1674479 A1 DATE: 20060628
APPLICATION: EP 2005250446 (20050128) *US 2004PV638422 (20041222) *US
2004PV640685 (20041230) *US 2005PV647616 (20050127)
PAGES: 77 pp. CODEN: EPXXDW LANGUAGE: English
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK;
BA; HR; IS; YU

6/3/13 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT
Inhibition of T cell activation in the treatment of immunological disease
by blocking class II MHC antigen function
INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi,
Ki-Wan
LOCATION: S. Korea
ASSIGNEE: Medexgen Inc.
PATENT: PCT International ; WO 200577415 A1 DATE: 20050825

APPLICATION: WO 2005KR457 (20050218) *KR 10835 (20040218)

PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/14 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT

Antagonistic monoclonal antibodies and derivatives specific to human CD40 antigen for treatment of autoimmune and inflammatory diseases

INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,

Isabel

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200544306 A2 DATE: 20050519

APPLICATION: WO 2004US36957 (20041104) *US 2003PV517337 (20031104) *US

2003PV525579 (20031126) *US 2004PV565710 (20040427)

PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/15 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142409698 CA: 142(22)409698r PATENT

Vaccines for cancer, autoimmune disease and infections

INVENTOR(AUTHOR): Mollidrem, Jeffrey

LOCATION: USA

ASSIGNEE: Board of Regents, the University of Texas System

PATENT: PCT International ; WO 200535714 A2 DATE: 20050421

APPLICATION: WO 2004US27792 (20040826) *US 2003PV498238 (20030826)

PAGES: 235 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;

GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA
; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

6/3/16 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

142334937 CA: 142(18)334937g PATENT
Regulatory leukocytes repressing B cell autoantibody secretion
INVENTOR(AUTHOR): Vilen, Barbara J.; Kilmon, Michelle; Rutan, Jennifer A.
LOCATION: USA
ASSIGNEE: University of North Carolina At Chapel Hill
PATENT: PCT International ; WO 200527841 A2 DATE: 20050331
APPLICATION: WO 2004US30325 (20040916) *US 2003PV503534 (20030916)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

6/3/17 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

142259982 CA: 142(14)259982n PATENT
Compositions comprising autoantigen and antigen-specific multivalent
antibody for treating cancer, infection and autoimmune disease
INVENTOR(AUTHOR): Barabas, Arpad Z.
LOCATION: Can.,
ASSIGNEE: The Governors of the University of Calgary
PATENT: PCT International ; WO 200516379 A1 DATE: 20050224
APPLICATION: WO 2004CA1494 (20040812) *US 2003PV495804 (20030815)
PAGES: 104 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A; A61K-039/00B; A61P-037/00B; A61P-037/02B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

6/3/18 (Item 11 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

141122334 CA: 141(8)122334n PATENT
Immunotherapy of B cell malignancies and autoimmune disease using
unconjugated and conjugated antibodies, fragments or fusion proteins
INVENTOR(AUTHOR): Goldenberg, David M.; Hansen, Hans
LOCATION: USA
ASSIGNEE: Immunomedics, Inc.; Mccall, John Douglas
PATENT: PCT International ; WO 200458298 A1 DATE: 20040715
APPLICATION: WO 2003GB5700 (20031231) *US PV437145 (20021231)
PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A; A61K-041/00B; A61K-051/10B; A61K-039/395B;
A61P-005/00B; A61P-037/06B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT;
RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ;
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD
; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG;
CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO;
SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD;
TG

6/3/19 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

139317445 CA: 139(21)317445r PATENT
Remedies for pemphigus containing CD40l antagonist as the active
ingredient
INVENTOR(AUTHOR): Amagai, Masayuki; Nishikawa, Takeji
LOCATION: Japan,
ASSIGNEE: Keio University; Eisai Co., Ltd.
PATENT: PCT International ; WO 200386463 A1 DATE: 20031023
APPLICATION: WO 2003JP4219 (20030402) *JP 2002101886 (20020403)
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: Japanese
PATENT CLASSIFICATIONS:
CLASS: A61K-045/00A; A61K-039/395B; A61P-017/00B; A61P-037/06B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/20 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

137228962 CA: 137(16)228962y PATENT

CD4+CD25+ regulatory T cells from human blood
INVENTOR(AUTHOR): Schuler, Gerold
LOCATION: Germany,
PATENT: European Pat. Appl. ; EP 1241249 A1 DATE: 20020918
APPLICATION: EP 2001106033 (20010312)
PAGES: 26 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-005/06A; A61K-035/14B; G01N-033/50B; A61P-037/06B;
A61P-037/04B
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR

6/3/21 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136246408 CA: 136(16)246408f PATENT
Combination therapy for treatment of autoimmune diseases using B cell
depleting/immunoregulatory antibody combination.
INVENTOR(AUTHOR): Hanna, Nabil
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals
PATENT: PCT International ; WO 200222212 A2 DATE: 20020321
APPLICATION: WO 2001US29026 (20010918) *US PV257147 (20001222)
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61P-037/00; A61K-039/39
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA;
CH; CN; CO; CU; CZ; EE; ES; FI; GB; GE; GM; HU; ID; IL; IN; KP; KR; LK; LR;
MN; MW; MX; NO; NZ; PL; PT; RO; RU DESIGNATED REGIONAL: GH; GM; KE; LS; MW
MZ; SD; SL; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE;
IT; MC; NL; PT; SE; TR; CG; CI; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/22 (Item 15 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136101076 CA: 136(7)101076m PATENT
Methods for abrogating a cellular immune response
INVENTOR(AUTHOR): Albert, Matthew L.; Jegathesan, Mithila; Darnell,
Robert B.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20020004041 A1 DATE: 20020110
APPLICATION: US 804584 (20010312) *US 251896 (19990219) *US 545958
(20000505)
PAGES: 35 pp., Cont.-in-part of U.S. Ser. No. 545,958. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424093210; A61K-048/00A; A61K-045/00B; A61K-031/739B;
A61K-038/19B

6/3/23 (Item 16 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT
Methods for regulating a cell-mediated immune response by blocking
lymphocytic signals and by blocking LFA-1 mediated adhesion

INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach, Robert J.

LOCATION: USA

ASSIGNEE: Bristol-Myers Squibb Company

PATENT: PCT International ; WO 200195928 A2 DATE: 20011220

APPLICATION: WO 2001US18619 (20010608) *US PV210671 (20000609)

PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/17A; A61K-039/395B; A61P-037/00B; C07K-014/705B;
C07K-016/28B; A61K-039/395B; A61K-038/17B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG;
KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ;
; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/24 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

135370653 CA: 135(26)370653a PATENT

Compositions and methods for achieving immune suppression

INVENTOR(AUTHOR): Strom, Terry B.; Maslinski, Wlodzimierz; Zheng, Xin
Xiao; Kim, Yon Su; Lacraz, Sylvie Ferrari

LOCATION: USA

ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.

PATENT: PCT International ; WO 200187330 A2 DATE: 20011122

APPLICATION: WO 2001US15578 (20010514) *US PV203801 (20000512)

PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-038/20A; A61K-038/17B; A61K-039/395B; A61P-037/06B;
C07K-014/54B; C07K-014/705B; A61K-038/20B; A61K-038/17B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/25 (Item 18 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT

Human antibodies derived from immunized xenomice

INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;
Brenner, Daniel G.; Capon, Daniel J.

LOCATION: USA

ASSIGNEE: Cell Genesys, Inc.

PATENT: PCT International ; WO 9634096 A1 DATE: 19961031

APPLICATION: WO 95US5500 (19950428)

PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C12N-015/00A

DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
? t s6/kwic/all		
>>>KWIC option is not available in file(s): 399		

6/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

...of desmoglein 3-specific IgG autoantibodies in an HLA-class II
transgenic mouse model of pemphigus vulgaris

DESCRIPTORS:

DISEASES: ***pemphigus*** vulgaris...
MESH TERMS: Pemphigus (MeSH)
CHEMICALS & BIOCHEMICALS: ...anti- ***CD40L*** antibody...

6/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Increased serum levels of circulating CD40 ligand in patients
with bullous pemphigoid: Preliminary results

...ABSTRACT: cells and autoantibodies are induced. Recent studies have
indicated the importance of the CD40 and CD40 ligand (CD40L)
receptor-ligand pair in the immunopathogenesis of autoimmune
diseases. ***CD40L*** circulates in soluble form, and some reports
suggest that serum soluble CD40L (sCD40L) levels are increased in
various autoimmune diseases. Objectives: To determine serum sCD40L levels
in patients with pemphigus vulgaris (PV) and bullous pemphigoid
(BP), and to determine their correlation with clinical findings and...

DESCRIPTORS:

DISEASES: ***pemphigus*** vulgaris...
MESH TERMS: ***Pemphigus*** (MeSH...
CHEMICALS & BIOCHEMICALS: CD40 ligand

6/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

The CD40/CD40 ligand system is involved in the pathogenesis of
pemphigus

ABSTRACT: The CD40/CD40 ligand (CD40L) system has never
been investigated in autoimmune bullous diseases belonging to the
pemphigus group in humans. Skin biopsy specimens from 21 patients
with pemphigus vulgaris, 10 with pemphigus foliaceus and
healthy volunteers were studied by immunohistochemistry (for CD40 and
CD40L) and reversal transcriptase polymerase-chain reaction (for

CD40L), while sera were analyzed by enzyme-linked immunosorbent assay for soluble ***CD40L***. In all ***pemphigus*** specimens, the basal and suprabasal layers of the epidermis and perivascular infiltrating cells were CD40+. ***CD40L*** + cells moderately infiltrated the perivascular and interstitial dermis of ***pemphigus*** specimens. CD40L mRNA was strongly evident in all pemphigus samples while no signal was detected in the healthy controls. The expression of soluble CD40L was significantly greater in pemphigus sera than in controls. We showed here that the CD40/ ***CD40L*** system is upregulated both in lesional skin and in serum of patients with ***pemphigus***. (c) 2007 Elsevier Inc. All rights reserved.

DESCRIPTORS:

DISEASES: ***pemphigus*** vulgaris...

MESH TERMS: Pemphigus (MeSH)

CHEMICALS & BIOCHEMICALS: ... ***CD40*** ***ligand***

MISCELLANEOUS TERMS: CD40 ligand system

CONCEPT CODES:

6/KWIC/4 (Item 4 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model

ABSTRACT: Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by IgG autoantibodies against desmoglein 3 (Dsg3)...

...from Dsg3(-/-) mice. The purpose of this study was to determine the role of CD40/CD154 interaction in the pathogenic antibody production and development of the disease in PV model mice. When anti- ***CD154*** monoclonal antibody (mAb) was administered to recipient mice prior to adoptive transfer, anti-CD154 mAb almost completely blocked the anti- Dsg3 IgG production and prevented blister formation. The blockade of CD40/CD154 interaction induced tolerance against Dsg3 as the suppression of antibody production was observed through day...

...Dsg3(-/-) splenocytes. Furthermore, the tolerance to Dsg3 was transferable because cotransfer of splenocytes from anti-CD154 mAb-treated mice and naive Dsg3(-/-) splenocytes significantly suppressed anti- Dsg3 IgG production in recipient mice. In contrast, when anti-CD154 mAb was injected after the mice had developed the PV phenotype, no significant suppression of the production of anti- Dsg3 IgG was observed. These findings indicate that the CD40/ ***CD154*** interaction is essential for the induction of pathogenic anti- Dsg3 IgG antibodies and that antigen-specific immune-regulatory cells induced by anti-CD154 mAb would hold a therapeutic option for autoimmune diseases.

...REGISTRY NUMBERS: anti- ***CD154***

DESCRIPTORS:

DISEASES: ***pemphigus*** vulgaris...

MESH TERMS: Pemphigus (MeSH)

CHEMICALS & BIOCHEMICALS: ... ***CD154*** ; ...

...anti- ***CD154*** ;

6/KWIC/5 (Item 5 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Inhibition of pemphigus vulgaris by targeting of the CD40-CD154
co-stimulatory pathway: A step toward antigen-specific therapy?

DESCRIPTORS:

...DISEASES: ***pemphigus*** vulgaris
...MESH TERMS: ***Pemphigus*** (MeSH)
CHEMICALS & BIOCHEMICALS: ... ***CD154*** --

6/KWIC/6 (Item 6 from file: 5)

DIALOG(R)File 5:(c) 2008 The Thomson Corporation. All rts. reserv.

Blockade of CD40/CD40L interaction has therapeutic benefits in the
pemphigus vulgaris mouse model

DESCRIPTORS:

DISEASES: ***pemphigus*** vulgaris...
MESH TERMS: Pemphigus (MeSH)
CHEMICALS & BIOCHEMICALS: ... ***CD40L*** { ***CD40*** ***ligand*** };
MISCELLANEOUS TERMS: CD40/CD40L interaction {CD40/CD40
ligand interaction...
CONCEPT CODES:

6/KWIC/7 (Item 1 from file: 73)

DIALOG(R)File 73:(c) 2008 Elsevier B.V. All rts. reserv.

DRUG DESCRIPTORS:

...endogenous compound--ec; belimumab--drug therapy--dt; belimumab
--pharmacology--pd; CD19 antigen--endogenous compound--ec; CD40
ligand monoclonal antibody--drug therapy--dt; CD40 ligand
monoclonal antibody--pharmacology--pd; complement component C3d receptor
--endogenous compound--ec; epratuzumab--drug therapy--dt...

MEDICAL DESCRIPTORS:

...differentiation; lymphocyte function; monkey; mouse; myelo optic
neuropathy--drug therapy--dt; myositis--drug therapy--dt; nonhuman;
pemphigus vulgaris--drug therapy--dt; polyneuropathy--drug therapy
--dt; priority journal; review; rheumatoid arthritis--drug therapy...
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)

? s (pemphigus) (20n) (inhibit? or suppress? or treat? or therap?) (20n) (cd4? or
t(w)cell? or t(w)lymphocyte?)
>>>File 5 processing for CELL? stopped at CELLULLASE
Processing
Processing
Processing
Processing
Processing
18072 PEMPHIGUS
5242236 INHIBIT?
1100686 SUPPRESS?
8765477 TREAT?
8195076 THERAP?
376008 CD4?

2212549 T
 13302071 CELL?
 815677 T(W)CELL?
 2212549 T
 1329311 LYMPHOCYTE?
 542775 T(W)LYMPHOCYTE?
 S7 185 (PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR
 THERAP?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
 ? rd s7
 S8 139 RD S7 (unique items)
 ? t s8/e/all
 >>>'E' not a valid format name
 ? t s8/3/all

8/3/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2008 The Thomson Corporation. All rts. reserv.

0020104728 BIOSIS NO.: 200800151667
 Suppressive effects of CD4+ CD25+ regulatory T
 cells on the development of phenotypes in a mouse model of
 pemphigus vulgaris
 AUTHOR: Yokoyama T (Reprint); Matsuda S; Takae Y; Amagai M; Koyasu S
 AUTHOR ADDRESS: Keio Univ, Sch Med, Tokyo, Japan**Japan
 JOURNAL: Journal of Investigative Dermatology 127 (Suppl. 2): pS66 OCT
 2007 2007
 CONFERENCE/METING: 37th Annual Meeting of the
 European-Society-for-Dermatological-Research Zurich, SWITZERLAND
 September 05 -08, 2007; 20070905
 SPONSOR: European Soc Dermatol Res
 ISSN: 0022-202X
 DOCUMENT TYPE: Meeting; Meeting Abstract
 RECORD TYPE: Citation
 LANGUAGE: English

8/3/2 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2008 The Thomson Corporation. All rts. reserv.

0019485081 BIOSIS NO.: 200700144822
 Study of the B- and T-lymphocyte responses in pemphigus
 patients treated by anti-CD20 immunotherapy (rituximab)
 AUTHOR: Musette P (Reprint); Mouquet H; Jacquot S; Gilbert D; Gougeon M L;
 Roujeau J C; D'Incan M; Bedane C; Tron F; Joly P
 AUTHOR ADDRESS: CHU Rouen, Serv Dermatol, Rouen, France**France
 JOURNAL: Journal of Investigative Dermatology 126 (Suppl. 3): p23 AUG 2006
 2006
 CONFERENCE/METING: 36th Annual Meeting of the
 European-Society-of-Dermatology-Research (ESDR) Paris, FRANCE September
 06 -07, 2006; 20060906
 SPONSOR: European Soc Dermatol Res
 ISSN: 0022-202X
 DOCUMENT TYPE: Meeting; Meeting Abstract
 RECORD TYPE: Citation
 LANGUAGE: English

8/3/3 (Item 3 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2008 The Thomson Corporation. All rts. reserv.

19097571 BIOSIS NO.: 200600442966

Inhibition of pemphigus vulgaris by targeting of the CD40

-CD154 co-stimulatory pathway: A step toward antigen-specific therapy?

AUTHOR: Liu Zhi (Reprint); Li Ning; Diaz Luis A

AUTHOR ADDRESS: Univ N Carolina, Dept Dermatol, 3100 Thuston Bowles, Chapel Hill, NC 27599 USA**USA

AUTHOR E-MAIL ADDRESS: zhiliu@med.unc.edu

JOURNAL: Journal of Investigative Dermatology 126 (1): p11-13 JAN 2006 2006

ISSN: 0022-202X

DOCUMENT TYPE: Article; Editorial

RECORD TYPE: Citation

LANGUAGE: English

8/3/4 (Item 4 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

18008306 BIOSIS NO.: 200400379095

Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease

AUTHOR: Fimiani M (Reprint); Di Renzo M; Rubegni P

AUTHOR ADDRESS: Policlin ScotteIst Sci Dermatol, Univ Siena, I-53100, Siena, Italy**Italy

AUTHOR E-MAIL ADDRESS: fimiani@unisi.it

JOURNAL: British Journal of Dermatology 150 (6): p1055-1060 June 2004 2004

MEDIUM: print

ISSN: 0007-0963

DOCUMENT TYPE: Article; Literature Review

RECORD TYPE: Abstract

LANGUAGE: English

8/3/5 (Item 5 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

16901534 BIOSIS NO.: 200200495045

Blockade of CD40/CD40L interaction has therapeutic benefits in the pemphigus vulgaris mouse model

AUTHOR: Aoki M (Reprint); Tsunoda K (Reprint); Ota T (Reprint); Iwasaki T; Tanaka S; Koyasu S; Amagai M (Reprint); Nishikawa T (Reprint)

AUTHOR ADDRESS: Dermatology, Keio University of School of Medicine, Tokyo, Japan**Japan

JOURNAL: Journal of Investigative Dermatology 119 (1): p317 July, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002; 20020515

ISSN: 0022-202X

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

8/3/6 (Item 6 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

16399955 BIOSIS NO.: 200100571794

Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro

AUTHOR: Efferth Thomas (Reprint); Fabry Ursula; Osieka Rainhardt

AUTHOR ADDRESS: Virtual Campus Rhineland-Palatinate, 55033, Mainz, Germany
**Germany

JOURNAL: Anticancer Research 21 (4A): p2777-2784 July-August, 2001 2001

MEDIUM: print

ISSN: 0250-7005

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/7 (Item 7 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

15406625 BIOSIS NO.: 200000124938

The use of chlorambucil with prednisone in the treatment of pemphigus

AUTHOR: Shah Neha; Green Andy R; Elgart George W; Kerdell Francisco
(Reprint)

AUTHOR ADDRESS: Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL, 33101, USA**USA

JOURNAL: Journal of the American Academy of Dermatology 42 (1 Part 1): p

85-88 Jan., 2000 2000

MEDIUM: print

ISSN: 0190-9622

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/8 (Item 8 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

15311192 BIOSIS NO.: 200000029505

Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus

AUTHOR: Reich K (Reprint); Brinck U; Letschert M; Blaschke V; Dames K; Braess J; Woermann B; Ruenger T M; Neumann C

AUTHOR ADDRESS: Department of Dermatology, Georg-August-University, von Siebold Strasse 3, D-37075, Goettingen, Germany**Germany

JOURNAL: British Journal of Dermatology 141 (4): p739-746 Oct., 1999 1999

MEDIUM: print

ISSN: 0007-0963

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

8/3/9 (Item 9 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

14702756 BIOSIS NO.: 199800497003

CD44 variant isoform expression in a variety of skin-associated autoimmune diseases

AUTHOR: Seiter Simone (Reprint); Schadendorf Dirk; Tilgen Wolfgang
(Reprint); Zoeller Margot
AUTHOR ADDRESS: Dep. Dermatol., Univ. Homburg, Homburg, Germany**Germany
JOURNAL: Clinical Immunology and Immunopathology 89 (1): p79-93 Oct., 1998
1998
MEDIUM: print
ISSN: 0090-1229
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

14434848 BIOSIS NO.: 199800229095
Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3
specific T cell responses in pemphigus vulgaris patients and normals
AUTHOR: Hertl Michael; Karr Robert W; Amagai Masayuki; Katz Stephen I
AUTHOR ADDRESS: Hautklinik, Universitaetsklinikum der RWTH, Pauwelsstr. 30,
D-52072 Aachen, Germany**Germany
JOURNAL: Journal of Investigative Dermatology 110 (4): p388-392 April,
1998 1998
MEDIUM: print
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13356778 BIOSIS NO.: 199698824611
Therapeutic experience with extracorporeal photophoresis. Technical
aspects, monitoring and clinical results in 41 patients
AUTHOR: Owsianowski M; Garbe C; Ramaker J; Orfanos C E; Gollnick H
(Reprint)
AUTHOR ADDRESS: Universitaetsklin. Dermatol. Venerol., Otto-von-Guericke
Univ., Leipzigstr. 44, D-39120 Magdeburg, Germany**Germany
JOURNAL: Hautarzt 47 (2): p114-123 1996 1996
ISSN: 0017-8470
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: German

8/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13328645 BIOSIS NO.: 199698796478
Investigation of phenotype and T-cell functions in
pemphigus vulgaris patients treated with Sandimmun and
glucocorticoids
AUTHOR: Matushevskaya E V (Reprint); Svirshchevskaya E V; Kubanova A A;
Samsonov V A; Khapilova V I
AUTHOR ADDRESS: Dep. Skin Vener. Dis., Mosc. State Med. Univ., Moscow,
Russia**Russia

JOURNAL: Vestnik Dermatologii i Venerologii 0 (6): p6-11 1995 1995
ISSN: 0042-4609
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Russian

8/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13236989 BIOSIS NO.: 199698704822
Long-term interferon-alpha therapy induces autoantibodies against epidermis
AUTHOR: Fleischmann M; Celerier P; Bernard P; Litoux P; Dreno B (Reprint)
AUTHOR ADDRESS: Dep. Dermatol., Hotel-Dieu, Pl. A. Ricordeau, F-44035
Nantes Cedex 01, France**France
JOURNAL: Dermatology (Basel) 192 (1): p50-55 1996 1996
ISSN: 1018-8665
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

12658117 BIOSIS NO.: 199598125950
Review of immunomodulation by photopheresis: Treatment of cutaneous T-cell
lymphoma, autoimmune disease, and allograft rejection
AUTHOR: Wolfe Jonathan T; Lessin Stuart R; Singh Anjali H; Rook Alain H
(Reprint)
AUTHOR ADDRESS: Dep. Dermatol., Hosp. Univ. Pennsylvania, 3400 Spruce St.,
Philadelphia, PA 19104, USA**USA
JOURNAL: Artificial Organs 18 (12): p888-897 1994 1994
ISSN: 0160-564X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

11844356 BIOSIS NO.: 199396008772
Parenteral administration of 8-methoxypsoralen in photopheresis
AUTHOR: Knobler Robert M (Reprint); Trautinger Franz; Graninger Winfried;
Macheiner Walter; Gruenwald Christian; Neumann Reinhard; Ramer Wolfgang
AUTHOR ADDRESS: Dep. Dermatology, Univ. Vienna Med. Sch., Alserstrasse 4,
A-1090 Vienna, Austria**Austria
JOURNAL: Journal of the American Academy of Dermatology 28 (4): p580-584
1993
ISSN: 0190-9622
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

11133059 BIOSIS NO.: 199243101650
PHOTOPHERESIS A CLINICALLY RELEVANT IMMUNOBIOLOGIC RESPONSE MODIFIER
BOOK TITLE: EDELSON, R. L. (ED.). ANNALS OF THE NEW YORK ACADEMY OF
SCIENCES, VOL. 636. ANTIGEN AND CLONE-SPECIFIC IMMUNOREGULATION; MEETING,
NEW YORK, NEW YORK, USA, OCTOBER 22-24, 1990. XII+410P. NEW YORK ACADEMY
OF SCIENCES: NEW YORK, NEW YORK, USA. ILLUS
AUTHOR: EDELSON R L (Reprint)
AUTHOR ADDRESS: DEP DERMATOLOGY, YALE UNIV SCH MED, 333 CEDAR STREET, 500
LCI, PO BOX 3333, NEW HAVEN, CONN 06510-8059, USA**USA
SERIES TITLE: Annals of the New York Academy of Sciences p154-164 1991
ISSN: 007-8923 ISBN: 0-89766-688-7 (PAPER); 0-89766-687-9 (CLOTH)
DOCUMENT TYPE: Book; Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

8/3/17 (Item 17 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08926693 BIOSIS NO.: 198835023798
A MOLECULAR BASIS FOR MHC CLASS II-ASSOCIATED AUTOIMMUNITY
AUTHOR: TODD J A (Reprint); ACHA-ORBEA H; BELL J I; CHAO N; FRONEK Z; JACOB
C O; MCDERMOTT M; SINHA A A; TIMMERMAN L; ET AL
AUTHOR ADDRESS: DEP MED MICROBIOL, STANFORD UNIV, STANFORD, CALIF 94305,
USA**USA
JOURNAL: Science (Washington D C) 240 (4855): p1003-1009 1988
ISSN: 0036-8075
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: ENGLISH

8/3/18 (Item 18 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08744158 BIOSIS NO.: 198784098307
T AND B-LYMPHOCYTES IN PEMPHIGUS VULGARIS A CLINICO-IMMUNOLOGICAL FOLLOW-UP
STUDY OF FIFTY PATIENTS WITH PEMPHIGUS VULGARIS
AUTHOR: MASHKILLEYSON N (Reprint)
AUTHOR ADDRESS: DEP DERMATOL, HELSINKI UNIV CENTRAL HOSP, SNELLMANINKATU
14, SF-00170 HELSINKI 17, FINLAND**FINLAND
JOURNAL: Acta Dermato-Venereologica 67 (3): p218-224 1987
ISSN: 0001-5555
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/19 (Item 19 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08663040 BIOSIS NO.: 198784017189
PHOTOPHERESIS EXTRACORPOREAL IRRADIATION OF 8 MOP CONTAINING BLOOD A NEW
THERAPEUTIC MODALITY
AUTHOR: KNOBLER R M (Reprint)
AUTHOR ADDRESS: DEP DERMATOL II, UNIV VIENNA, ALSERSTRASSE 4, A-1090

VIENNA, AUSTRIA**AUSTRIA
JOURNAL: Blut 54 (4): p247-250 1987
ISSN: 0006-5242
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08118527 BIOSIS NO.: 198681082418
CUTANEOUS IMMUNOLOGICAL STUDIES IN DIAGNOSIS OF ACUTE GRAFT-VS.-HOST
DISEASE
AUTHOR: DRENO B (Reprint); MILPIED N; HAROUSSEAU J L; STADLER J F; BUREAU B
; MILPIED B; BARRIERE H
AUTHOR ADDRESS: CLIN DERMATOL, HOTEL DIEU 44035, NANTES CEDEX, FR**FRANCE
JOURNAL: British Journal of Dermatology 114 (1): p7-16 1986
ISSN: 0007-0963
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08060161 BIOSIS NO.: 198681024052
IMMUNOLOGICAL STUDIES IN SOME BULLOUS DISEASE
AUTHOR: LEON M (Reprint); VULCAN V; ALECU M; OANA A
AUTHOR ADDRESS: CENTRUL DERMATO-VENEROLOGIC, BUCURESTI**HUNGARY
JOURNAL: Revista de Medicina Interna Neurologie Psihiatrie Neurochirurgie
Dermato-Venerologie Serie Dermato-Venerologia 30 (2): p81-92 1985
ISSN: 0377-4988
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ROMANIAN

8/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

06996601 BIOSIS NO.: 198376088036
PRODUCTION OF PEMPHIGUS ANTIBODY IN-VITRO AND ANALYSIS OF T CELL SUBSETS
AUTHOR: AHMED A R (Reprint); MURAHATA R I; SCHROFF R W; STEVENS R M; SAXON
A S
AUTHOR ADDRESS: DIVISION OF DERMATOLOGY, DEPARTMENT OF MEDICINE, UCLA
SCHOOL OF MEDICINE, LOS ANGELES, CALIFORNIA 90024, USA**USA
JOURNAL: Journal of Clinical Immunology 3 (3): p241-252 1983
ISSN: 0271-9142
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

06199421 BIOSIS NO.: 198171018380
IMMUNOLOGICAL STUDY OF KERATO ACANTHOMAS
AUTHOR: TOSCA A (Reprint); VARELZIDIS A; AVGERINOU G; HATZIS J; PERISSIOS A
; NICOLIS G
AUTHOR ADDRESS: UNIV ATHENS, SCH MED, DEP DERMATOL, "A SYGROS" HOSP, I
DRAGOUMI 5 ATHENS, GREECE**GREECE
JOURNAL: Archives of Dermatological Research 268 (2): p149-156 1980
ISSN: 0340-3696
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

8/3/24 (Item 24 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

06163921 BIOSIS NO.: 198121047884
SUPPRESSOR T CELL FUNCTION IS PRESERVED IN
PEMPHIGUS AND PEMPHIGOID
AUTHOR: KING A J (Reprint); LOPATIN D E; VOORHEES J J; DIAZ L A; SCHWARTZ S
A
AUTHOR ADDRESS: DEP OF DERMATOL, DENTAL RES INST, UNIV OF MICHIGAN, ANN
ARBOR, MICHIGAN, USA**USA
JOURNAL: Clinical Research 29 (2): p283A 1981
CONFERENCE/MEETING: 38TH ANNUAL NATIONAL MEETING OF THE AMERICAN FEDERATION
FOR CLINICAL RESEARCH, SAN FRANCISCO, CALIF., USA, APRIL 25-27, 1981. CLIN
RES.
ISSN: 0009-9279
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

8/3/25 (Item 1 from file: 73)
DIALOG(R)File 73: EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047
The selective immunotherapy of pemphigus
Bystryn J.C.; Czernik A. // Bystryn J.C.
Ronald O. Perelman Department of Dermatology, New York University School
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st
Avenue, New York, NY 10016, United States
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu
CORRESP. AUTHOR: Bystryn J.C.
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY
10016, United States
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia (G. Ital. Dermatol.
Venereol.) (Italy) August 1, 2007, 142/4 (381-390)
CODEN: GIDVD ISSN: 00264741
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English; Italian
NUMBER OF REFERENCES: 63

8/3/26 (Item 2 from file: 73)
DIALOG(R)File 73: EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081949325 EMBASE No: 2007383664

Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone

Scheinfeld N. // Scheinfeld N.

Department of Dermatology, St. Luke's-Roosevelt, New York, NY USA //

Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New York, NY 10025, United States

AUTHOR EMAIL: NSS32@columbia.edu; NSS32@columbia.edu

CORRESP. AUTHOR: Scheinfeld N.

CORRESP. AUTHOR AFFIL: Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New York, NY 10025, United States

CORRESP. AUTHOR EMAIL: NSS32@columbia.edu

Journal of Dermatological Treatment (J. Dermatol. Treat.) (United Kingdom) September 5, 2007, 18/4 (243-245)

CODEN: JDIRE ISSN: 09546634 eISSN: 14711753

PUBLISHER ITEM IDENTIFIER: 779333677

DOI: 10.1080/09546630701287324

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 9

8/3/27 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081810060 EMBASE No: 2007244126

Role of regulatory T cells in the development of skin diseases

Lima H.C. // Lima H.C. // Lima H.C.

Department of Pathology, Universidade Federal do Parana - UFPR, Curitiba

(PR), Brazil // Service of Dermatology and Research Nucleus in Immunodermatology and Clinical Immunology, Universidade Federal do Parana

- UFPR, Curitiba (PR), Brazil // Rua XV de Novembro, 1206, 80060-000 - Curitiba - PR

AUTHOR EMAIL: hclima@ufpr.br; hclima@ufpr.br; hclima@ufpr.br

CORRESP. AUTHOR: Lima H.C.

CORRESP. AUTHOR AFFIL: Rua XV de Novembro, 1206, 80060-000 - Curitiba - PR

CORRESP. AUTHOR EMAIL: hclima@ufpr.br

Anais Brasileiros de Dermatologia (An. Bras. Dermatol.) (Brazil) May 1, 2006, 81/3 (269-281)

CODEN: ABDEB ISSN: 03650596 eISSN: 18064841

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English; Portuguese

NUMBER OF REFERENCES: 121

8/3/28 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0081779408 EMBASE No: 2007213412

Therapy of autoimmune bullous diseases

Mutasim D.F.

Department of Dermatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0592, United States

AUTHOR EMAIL: diya.mutasim@uc.edu

CORRESP. AUTHOR: Mutasim D.F.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0592, United States
CORRESP. AUTHOR EMAIL: diya.mutasim@uc.edu

Therapeutics and Clinical Risk Management (Ther. Clin. Risk Manage.) (New Zealand) May 30, 2007, 3/1 (29-40)
ISSN: 11766336
DOI: 10.2147/tcrm.2007.3.1.29
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 139

8/3/29 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081755259 EMBASE No: 2007189212
Estimation of awareness of corticosteroid induced osteoporosis in patients with chronic skin diseases
Ocena swiadomosci zagrozenia osteoporoza posteroidea u pacjentow z przewleklymi chorobami skory
Kobierzycka M.; Cislo M.; Bialynicki-Birula R.; Nockowski P. // Simon-Blazewicz M. // Kobierzycka M.
Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM we Wroclawiu // Oddzial Dermatologiczny Wojewodzkiego Szpitala Specjalistycznego we Wroclawiu // Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM, ul. Chalubinskiego 1, 50-368 Wroclaw
AUTHOR EMAIL: mkobierz@wp.pl; mkobierz@wp.pl
CORRESP. AUTHOR: Kobierzycka M.
CORRESP. AUTHOR AFFIL: Katedra I Klinika Dermatologii, Wenerologii I Alergologii AM, ul. Chalubinskiego 1, 50-368 Wroclaw
CORRESP. AUTHOR EMAIL: mkobierz@wp.pl

Dermatologia Kliniczna (Dematol. Kliniczna) (Poland) April 30, 2007, 9/1 (29-33)
ISSN: 17307201
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Polish SUMMARY LANGUAGE: English; Polish
NUMBER OF REFERENCES: 27

8/3/30 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081682257 EMBASE No: 2007115834
Complications and Adverse Reactions in the Use of Newer Biologic Agents
ISSUE TITLE: Complications and Adverse Events
Callen J.P.
Division of Dermatology, University of Louisville, Louisville, KY, United States
AUTHOR EMAIL: jefca@aol.com
CORRESP. AUTHOR: Callen J.P.
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville, Louisville, KY, United States
CORRESP. AUTHOR EMAIL: jefca@aol.com

Seminars in Cutaneous Medicine and Surgery (Semin. Cutaneous Med. Surg.

) (United States) March 1, 2007, 26/1 (6-14)
CODEN: SCMSF ISSN: 10855629
PUBLISHER ITEM IDENTIFIER: S108556290600112X
DOI: 10.1016/j.sder.2006.12.002
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
CLINICAL TRIALS NUMBER: NCT00051662--ClinicalTrials.gov; NCT00302445--
ClinicalTrials.gov
NUMBER OF REFERENCES: 84

8/3/31 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081503650 EMBASE No: 2006567099
Paraneoplastic autoimmune multiorgan syndrome: Review of the literature
and support for a cytotoxic role in pathogenesis
ISSUE TITLE: Immunology of Pemphigus and Treatment
Billet S.E.; Pittelkow M.R. // Grando S.A.
Department of Dermatology, Mayo Clinic, Rochester, MN, United States //
University of California Davis, Sacramento, CA, United States
CORRESP. AUTHOR: Pittelkow M.R.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Mayo Clinic, Rochester,
MN, United States

Autoimmunity (Autoimmunity) (United Kingdom) November 1, 2006, 39/7
(617-630)
CODEN: AUIME ISSN: 08916934 eISSN: 1607842X
PUBLISHER ITEM IDENTIFIER: U501856727X93457
DOI: 10.1080/08916930600972099
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 123

8/3/32 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081407991 EMBASE No: 2006470890
Therapeutic modulation of cutaneous autoimmunity by regulatory T cells
Beissert S. // Loser K.
Interdisciplinary Clinical Research Center (IZKF), Munster, Germany //
Department of Dermatology, University of Munster, Von-Esmarch-Strasse 58,
D-48149 Munster, Germany
AUTHOR EMAIL: beisser@uni-muenster.de
CORRESP. AUTHOR: Beissert S.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Munster,
Von-Esmarch-Strasse 58, D-48149 Munster, Germany
CORRESP. AUTHOR EMAIL: beisser@uni-muenster.de

Rheumatology (Rheumatology (UK)) (United Kingdom) October 1, 2006,
45/SUPPL. 3 (iii20-iii22)
CODEN: RUMAF ISSN: 14620324 eISSN: 14620332
DOI: 10.1093/rheumatology/kel286
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 10

8/3/33 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081384356 EMBASE No: 2006447143
Inosine 5prime-monophosphate dehydrogenase inhibitors for the treatment
of autoimmune diseases
Ratcliffe A.J.
UCB, Granta Park, Great Abington, Cambridge CB1 6GS, United Kingdom
AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com
CORRESP. AUTHOR: Ratcliffe A.J.
CORRESP. AUTHOR AFFIL: UCB, Granta Park, Great Abington, Cambridge CB1
6GS, United Kingdom
CORRESP. AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com

Current Opinion in Drug Discovery and Development (Curr. Opin. Drug
Discov. Dev.) (United Kingdom) September 1, 2006, 9/5 (595-605)
CODEN: CODDF ISSN: 13676733
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 55

8/3/34 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874
B cells move to centre stage: Novel opportunities for autoimmune disease
treatment
Browning J.L.
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,
MA 02445, United States
AUTHOR EMAIL: Jeff.Browning@biogenidec.com
CORRESP. AUTHOR: Browning J.L.
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12
Cambridge Center, Cambridge, MA 02445, United States
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery (Nat. Rev. Drug Discov.) (United Kingdom)
July 1, 2006, 5/7 (564-576)
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784
PUBLISHER ITEM IDENTIFIER: N2085
DOI: 10.1038/nrd2085
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 173

8/3/35 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081227105 EMBASE No: 2003062231
Safety of cyclosporin A in the treatment of dermatological diseases [7]
Veller Fornasa C.; Gai F.
Institute of Dermatology, University of Padua, Padua, Italy
AUTHOR EMAIL: cleto.vellerfordasa@UNIPD.IT
CORRESP. AUTHOR: Veller Fornasa C.
CORRESP. AUTHOR AFFIL: Institute of Dermatology, University of Padua,
Padua, Italy

CORRESP. AUTHOR EMAIL: cleto.vellerfordasa@UNIPD.IT

Journal of the European Academy of Dermatology and Venereology (J. Eur.
Acad. Dermatol. Venereol.) (United Kingdom) January 1, 2003, 17/1
(105-107)
CODEN: JEAVE ISSN: 09269959
DOI: 10.1046/j.1468-3083.2003.00519.7.x
DOCUMENT TYPE: Journal; Letter RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 10

8/3/36 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081160155 EMBASE No: 2006222321
Autoimmune Complications of Chronic Lymphocytic Leukemia
ISSUE TITLE: Chronic Lymphocytic Leukemia
Hamblin T.J.
Department of Immunohaematology, University of Southampton, Southampton
General Hospital, London, United Kingdom
AUTHOR EMAIL: terjoha@aol.com
CORRESP. AUTHOR: Hamblin T.J.
CORRESP. AUTHOR AFFIL: Department of Immunohaematology, University of
Southampton, Southampton General Hospital, London, United Kingdom
CORRESP. AUTHOR EMAIL: terjoha@aol.com

Seminars in Oncology (Semin. Oncol.) (United States) April 1, 2006,
33/2 (230-239)
CODEN: SOLGA ISSN: 00937754
PUBLISHER ITEM IDENTIFIER: S0093775406000200
DOI: 10.1053/j.seminoncol.2006.01.011
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 144

8/3/37 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081074574 EMBASE No: 2006134669
Pemphigus: Pathogenic mechanisms and potential therapeutic targets
Powell A.-M.; Black M.M.
Department of Immunodermatology, St. John's Institute of Dermatology, St.
Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
AUTHOR EMAIL: martin.black@kcl.ac.uk
CORRESP. AUTHOR: Black M.M.
CORRESP. AUTHOR AFFIL: Department of Immunodermatology, St. John's
Institute of Dermatology, St. Thomas' Hospital, Lambeth Palace Road,
London SE1 7EH, United Kingdom
CORRESP. AUTHOR EMAIL: martin.black@kcl.ac.uk

Drug Discovery Today: Disease Mechanisms (Drug Discov.Today Dis. Mech.)
(United Kingdom) December 1, 2005, 2/2 (269-274)
ISSN: 17406765
PUBLISHER ITEM IDENTIFIER: S1740676505000301
DOI: 10.1016/j.ddmec.2005.05.023
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 39

8/3/38 (Item 14 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081062976 EMBASE No: 2006123053
The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic
purpura: Reconsideration of treatment with cryopoor plasma
Raife T.J. // Friedman K.D.; Dwyre D.M.
University of Iowa, College of Medicine, C250 GH, 200 Hawkins Drive, Iowa
City, IA 52242, United States // Affiliation unspecified.
AUTHOR EMAIL: thomas-raife@uiowa.edu
CORRESP. AUTHOR: Raife T.J.
CORRESP. AUTHOR AFFIL: University of Iowa, College of Medicine, C250 GH,
200 Hawkins Drive, Iowa City, IA 52242, United States
CORRESP. AUTHOR EMAIL: thomas-raife@uiowa.edu

Transfusion (Transfusion) (United States) January 1, 2006, 46/1
(74-79)
CODEN: TRANA ISSN: 00411132 eISSN: 15372995
DOI: 10.1111/j.1537-2995.2005.00674.x
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 62

8/3/39 (Item 15 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081049234 EMBASE No: 2006109249
Regulatory T cells
Beissert S. // Schwarz A.; Schwarz T. // Schwarz T.
Department of Dermatology, University of Munster, Munster, Germany //
Department of Dermatology, University of Kiel, Kiel, Germany //
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7,
D-24105 Kiel, Germany
AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de;
tschwarz@dermatology.uni-kiel.de
CORRESP. AUTHOR: Schwarz T.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Kiel,
Schittenhelmstrasse 7, D-24105 Kiel, Germany
CORRESP. AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de

Journal of Investigative Dermatology (J. Invest. Dermatol.) (United
States) January 1, 2006, 126/1 (15-24)
CODEN: JIDEA ISSN: 0022202X eISSN: 15231747
PUBLISHER ITEM IDENTIFIER: 5700004
DOI: 10.1038/sj.jid.5700004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 89

8/3/40 (Item 16 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081040121 EMBASE No: 2006100121

Biologic therapies in autoimmune diseases

Penn H. // Penn H.

Royal Free Hospital, London, United Kingdom // Department of
Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom
AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk; h.penn@medsch.ucl.ac.uk

CORRESP. AUTHOR: Penn H.

CORRESP. AUTHOR AFFIL: Department of Rheumatology, Royal Free Hospital,
London NW3 2QG, United Kingdom

CORRESP. AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk

Clinical Medicine, Journal of the Royal College of Physicians of London (
Clin. Med. J. R. Coll. Phys. Lond.) (United Kingdom) January 1, 2006,
6/1 (105-108)

CODEN: CMLUB ISSN: 14702118

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 6

8/3/41 (Item 17 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080905189 EMBASE No: 2005550132

Number V. Oral lichen planus: Clinical features and management

Eisen D. // Carrozzo M. // Sebastian J.-V.B. // Thongprasom K. // Eisen

D.

Dermatology Research Associates, Cincinnati, OH, United States //

Department of Biomedical Sciences and Human Oncology, Oral Medicine,
University of Turin, Turin, Italy // Hospital General Universitario de
Valencia, Valencia, Spain // Oral Medicine Department, Chulalongkorn
University, Bangkok, Thailand // Dermatology Research Associates, 7691
Five Mile Road, Cincinnati, OH 45230, United States

AUTHOR EMAIL: dore@eos.net; dore@eos.net

CORRESP. AUTHOR: Eisen D.

CORRESP. AUTHOR AFFIL: Dermatology Research Associates, 7691 Five Mile
Road, Cincinnati, OH 45230, United States

CORRESP. AUTHOR EMAIL: dore@eos.net

Oral Diseases (Oral Dis.) (Denmark) November 1, 2005, 11/6 (338-349)

CODEN: ORDIF ISSN: 1354523X

DOI: 10.1111/j.1601-0825.2005.01142.x

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 146

8/3/42 (Item 18 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0080904290 EMBASE No: 2005549233

Apoptosis in normal and diseased oral tissues

Loro L.L.; Johannessen A.C. // Vintermyr O.K. // Loro L.L.

Department of Odontology-Oral Pathology and Forensic Odontology,

University of Bergen, Bergen, Norway // Department of Pathology,

Haukeland University Hospital, University of Bergen, Bergen, Norway //

Department of Odontology-Oral Pathology and Forensic Odontology, Gade

Institute, Haukeland University Hospital, N5021 Bergen, Norway

AUTHOR EMAIL: lado.loro@gades.uib.no; lado.loro@gades.uib.no

CORRESP. AUTHOR: Loro L.L.

CORRESP. AUTHOR AFFIL: Department of Odontology-Oral Pathology and
Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021
Bergen, Norway
CORRESP. AUTHOR EMAIL: lado.loro@gades.uib.no

Oral Diseases (Oral Dis.) (Denmark) September 1, 2005, 11/5 (274-287)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01117.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 163

8/3/43 (Item 19 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080904288 EMBASE No: 2005549231
Number IV: Erythema multiforme
Farthing P. // Bagan J.-V. // Scully C. // Scully C.
Charles Clifford Dental School, University of Sheffield, Sheffield,
United Kingdom // University Hospital, University of Valencia, Spain //
Eastman Dental Institute, University College London, London, United
Kingdom // Eastman Dental Institute, University College London, 256 Grays
Inn Road, London WC1X 8LD, United Kingdom
AUTHOR EMAIL: cscully@eastman.ucl.ac.uk; cscully@eastman.ucl.ac.uk
CORRESP. AUTHOR: Scully C.
CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom
CORRESP. AUTHOR EMAIL: cscully@eastman.ucl.ac.uk

Oral Diseases (Oral Dis.) (Denmark) September 1, 2005, 11/5 (261-267)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01141.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 45

8/3/44 (Item 20 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080886863 EMBASE No: 2005531783
Mycophenolate mofetil
Heymann W.R.
Affiliation unspecified.

Journal of the American Academy of Dermatology (J. Am. Acad. Dermatol.)
(United States) December 1, 2005, 53/6 (1045-1046)
CODEN: JAADD ISSN: 01909622
PUBLISHER ITEM IDENTIFIER: S0190962205026782
DOI: 10.1016/j.jaad.2005.08.034
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 8

8/3/45 (Item 21 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080779838 EMBASE No: 2005424454

An approach to the patient with a recalcitrant dermatosis
Callen J.P.
Division of Dermatology, University of Louisville, School of Medicine,
Louisville, KY 40202, United States
AUTHOR EMAIL: jefca@aol.com
CORRESP. AUTHOR: Callen J.P.
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville,
School of Medicine, Louisville, KY 40202, United States
CORRESP. AUTHOR EMAIL: jefca@aol.com

Clinics in Dermatology (Clin. Dermatol.) (United States) September 1,
2005, 23/5 (528-531)
CODEN: CLDEE ISSN: 0738081X
PUBLISHER ITEM IDENTIFIER: S0738081X05000623
DOI: 10.1016/j.clindermatol.2005.04.004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

8/3/46 (Item 22 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080659445 EMBASE No: 2005303751

Auto-immune manifestations in non-Hodgkin's lymphoma
Manifestations dysimmunitaires associees aux lymphomes
Jardin F.; Tilly H. // Levesque H.
Departement d'Hematologie Clinique et Groupe d'Etude des Syndromes
Lymphoproliferatifs, Inserm U164, Centre Henri-Becquerel, 76000 Rouen,
France // Departement de Medecine Interne, Centre Hospitalier
Universitaire de Rouen, Hopital de Bois-Guillaume, Rouen, France
AUTHOR EMAIL: fabrice.jardin@rouen.fncclcc.fr
CORRESP. AUTHOR: Jardin F.
CORRESP. AUTHOR AFFIL: Departement d'Hematologie Clinique et Groupe
d'Etude des Syndromes Lymphoproliferatifs, Inserm U164, Centre
Henri-Becquerel, 76000 Rouen, France
CORRESP. AUTHOR EMAIL: fabrice.jardin@rouen.fncclcc.fr

Revue de Medecine Interne (Rev. Med. Interne) (France) July 1, 2005,
26/7 (557-571)
CODEN: RMEID ISSN: 02488663
PUBLISHER ITEM IDENTIFIER: S024886630400459X
DOI: 10.1016/j.revmed.2004.11.011
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: French SUMMARY LANGUAGE: English; French
NUMBER OF REFERENCES: 169

8/3/47 (Item 23 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080502689 EMBASE No: 2005146848

Mucosal diseases series
Scully C.
Eastman Dental Institute, University College London, 256 Grays Inn Road,
London WC1X 8LD, United Kingdom
AUTHOR EMAIL: c.scully@eastman.ucl.ac.uk
CORRESP. AUTHOR: Scully C.

CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom
CORRESP. AUTHOR EMAIL: c.scully@eastman.ucl.ac.uk

Oral Diseases (Oral Dis.) (Denmark) March 1, 2005, 11/2 (57)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01107.x
DOCUMENT TYPE: Journal; Editorial RECORD TYPE: Citation
LANGUAGE: English

8/3/48 (Item 24 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080301596 EMBASE No: 2004487365
The role of pathogenic B-cell clones in antibody mediated autoimmune
disorders
Wang J.; Zhu X.
Department of Dermatology, Peking University First Hospital, #8, Xishiku
St., Beijing 100034, C.
AUTHOR EMAIL: zhuxj@public.bta.net.cn
CORRESP. AUTHOR AFFIL: Department of Dermatology, Peking University First
Hospital, #8, Xishiku St., Beijing 100034, C.
CORRESP. AUTHOR EMAIL: zhuxj@public.bta.net.cn

Journal of Dermatological Science (J. Dermatol. Sci.) (Ireland)
December 1, 2004, 36/3 (141-148)
CODEN: JDSCE ISSN: 09231811
PUBLISHER ITEM IDENTIFIER: S0923181104001367
DOI: 10.1016/j.jdermsci.2004.07.004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 59

8/3/49 (Item 25 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080038967 EMBASE No: 2004224116
Beneficial effects of topical tacrolimus on recalcitrant erosions of
pemphigus vulgaris
Gach J.E.; Ilchyshyn A. // Gach J.E.
Department of Dermatology, Walsgrave Hospital, Univ. Hospitals Coventry
W., Coventry, United Kingdom // Department of Dermatology, Walsgrave
Hospital, Univ. Hospitals Coventry W., Clifford Bridge Road, Coventry,
CV2 2DX, United Kingdom
AUTHOR EMAIL: asia@jgach.freemove.co.uk; asia@jgach.freemove.co.uk
CORRESP. AUTHOR: Gach J.E.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Walsgrave Hospital,
Univ. Hospitals Coventry W., Clifford Bridge Road, Coventry, CV2 2DX,
United Kingdom
CORRESP. AUTHOR EMAIL: asia@jgach.freemove.co.uk

Clinical and Experimental Dermatology (Clin. Exp. Dermatol.) (United
Kingdom) May 1, 2004, 29/3 (271-272)
CODEN: CEDED ISSN: 03076938
DOI: 10.1111/j.1365-2230.2004.01499.x
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 4

8/3/50 (Item 26 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080018133 EMBASE No: 2004203297
Nicotinamide as a potential addition to the anti-atopic dermatitis
armamentarium
Namazi M.R. // Namazi M.R.
Dermatology Department, Shiraz Univ. of Medical Sciences, Shiraz, Iran,
Islamic Republic of // P.O. Box 71955-687, Shiraz, Iran, Islamic Republic
of
AUTHOR EMAIL: namazi mr@yahoo.com; namazi mr@yahoo.com
CORRESP. AUTHOR: Namazi M.R.
CORRESP. AUTHOR AFFIL: Dermatology Department, Shiraz Univ. of Medical
Sciences, Shiraz, Iran, Islamic Republic of
CORRESP. AUTHOR EMAIL: namazi mr@yahoo.com

International Immunopharmacology (Int. Immunopharmacol.) (Netherlands)
June 1, 2004, 4/6 (709-712)
CODEN: IINMB ISSN: 15675769
PUBLISHER ITEM IDENTIFIER: S156757690300287X
DOI: 10.1016/j.intimp.2003.11.008
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 25

8/3/51 (Item 27 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079923931 EMBASE No: 2004108954
The addition of diuretics to corticosteroids with high mineralocorticoid
activity may lead to the better control of humoral autoimmune disorders
Namazi M.R.
Dermatology Department, Shiraz Univ. of Medical Sciences, P.O. Box
71955-687, Shiraz, Iran, Islamic Republic of
AUTHOR EMAIL: namazi mr@yahoo.com
CORRESP. AUTHOR: Namazi M.R.
CORRESP. AUTHOR AFFIL: Dermatology Department, Shiraz Univ. of Medical
Sciences, P.O. Box 71955-687, Shiraz, Iran, Islamic Republic of
CORRESP. AUTHOR EMAIL: namazi mr@yahoo.com

International Immunopharmacology (Int. Immunopharmacol.) (Netherlands)
February 1, 2004, 4/2 (325)
CODEN: IINMB ISSN: 15675769
PUBLISHER ITEM IDENTIFIER: S1567576903002959
DOI: 10.1016/j.intimp.2003.12.008
DOCUMENT TYPE: Journal; Letter RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 5

8/3/52 (Item 28 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079779998 EMBASE No: 2003490472

CME examination for volume 48

Journal of the American Academy of Dermatology (J. Am. Acad. Dermatol.)
(United States) December 1, 2003, 49/6 (37A-40A)
CODEN: JAADD ISSN: 01909622
DOCUMENT TYPE: Journal; Note RECORD TYPE: Citation
LANGUAGE: English

8/3/53 (Item 29 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079476456 EMBASE No: 2003181862
Cytokines and chemokines in autoimmune disease: An overview
Santamaria P. // Santamaria P.
University of Calgary, Dept. Microbiol./Infect. Disease, Health Sciences
Centre, Calgary, Alta., Canada // Dept. of Microbiol./Infect. Diseases,
Faculty of Medicine, University of Calgary, Calgary, Alta., Canada
CORRESP. AUTHOR: Santamaria P.
CORRESP. AUTHOR AFFIL: Dept. of Microbiol./Infect. Diseases, Faculty of
Medicine, University of Calgary, Calgary, Alta., Canada

Advances in Experimental Medicine and Biology (Adv. Exp. Med. Biol.) (United States) May 17, 2003, 520/- (1-7)
CODEN: AEMBA ISSN: 00652598
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 14

8/3/54 (Item 30 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079378560 EMBASE No: 2003082264
11. Allergic and immunologic diseases of the skin
Blauvelt A.; Hwang S.T.; Udey M.C. // Blauvelt A.
Dermatology Branch, Center for Cancer Research, National Cancer
Institute, Bethesda, MD, United States // Dermatology Branch, Center for
Cancer Research, National Cancer Institute, 10 Center Dr MSC 1908,
Bethesda, MD 20892-1908, United States
CORRESP. AUTHOR: Blauvelt A.
CORRESP. AUTHOR AFFIL: Dermatology Branch, Center for Cancer Research,
National Cancer Institute, 10 Center Dr MSC 1908, Bethesda, MD 20892-1908
, United States

Journal of Allergy and Clinical Immunology (J. Allergy Clin. Immunol.)
(United States) February 1, 2003, 111/2 SUPPL. 2 (S560-S570)
CODEN: JACIB ISSN: 00916749
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 64

8/3/55 (Item 31 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078719601 EMBASE No: 2001325932
Norwegian scabies and immunodeficiency

Gale crouteuse et immunodepression propos de deux observations
Marsit N.; Mokni M.; El Euch D.; Aissa F.; Cherif F.; Azaiez M.I.; Dhahri
A.B.O.

Service de Dermatologie, CHU La Rabta, 1007 Bab Saadoun - Tunis, Tunisia
CORRESP. AUTHOR: Marsit N.
CORRESP. AUTHOR AFFIL: Service de Dermatologie, CHU La Rabta, 1007 Bab
Saadoun - Tunis, Tunisia

Nouvelles Dermatologiques (Nouv. Dermatol.) (France) December 1, 2000
19/9 (675-677)
CODEN: NODEE ISSN: 07525370
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: French SUMMARY LANGUAGE: English; French
NUMBER OF REFERENCES: 14

8/3/56 (Item 32 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078511890 EMBASE No: 2001117978
Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive
stomatitis secondary to CD20 SUP + follicular lymphoma-associated
paraneoplastic pemphigus
Borradori L.; Lombardi T.; Samson J.; Girardet C.; Saurat J.-H.; Hugli A.
Department of Dermatology, University Hospital, Rue Micheli du Crest 24,
CH-1211 Geneve 14, Switzerland
CORRESP. AUTHOR: Borradori L.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University Hospital,
Rue Micheli du Crest 24, CH-1211 Geneve 14, Switzerland
CORRESP. AUTHOR EMAIL: Luca.Borradori@hcuge.ch

Archives of Dermatology (Arch. Dermatol.) (United States) May 12, 2001
137/3 (269-272)
CODEN: ARDEA ISSN: 0003987X
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 23

8/3/57 (Item 33 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078409135 EMBASE No: 2001014946
Recent advances in phototherapy
Simon J.C.; Pflieger D.; Schopf E.
Department of Dermatology, University of Freiburg, Hauptstr. 7, Freiburg
79104, Germany
CORRESP. AUTHOR: Simon J.C.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Freiburg,
Hauptstr. 7, Freiburg 79104, Germany
CORRESP. AUTHOR EMAIL: simonj@haut.ukl.uni-freiburg.de

European Journal of Dermatology (Eur. J. Dermatol.) (France) December
1, 2000, 10/8 (642-644)
CODEN: EJDEE ISSN: 11671122
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 44

8/3/58 (Item 34 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078364443 EMBASE No: 2000414052
Autoimmune skin diseases
Le malattie autoimmuni della cute
Malorgio C.; Panizon F.
Clinica Pediatrica, IRCCS 'Burto Garofolo', Trieste, Italy
CORRESP. AUTHOR: Malorgio C.
CORRESP. AUTHOR AFFIL: Clinica Pediatrica, IRCCS 'Burto Garofolo',
Trieste, Italy

Medico e Bambino (Med. Bambino) (Italy) October 31, 2000, 19/8
(495-503)
CODEN: MBAMF
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Italian SUMMARY LANGUAGE: English; Italian
NUMBER OF REFERENCES: 61

8/3/59 (Item 35 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078048898 EMBASE No: 2000098144
Extracorporeal photopheresis: 4 years of experience in Geneva
Photopherese extracorporelle: Quatre ans d'experience a geneve
Prins C.; Laroutis M.R.; Blondel F.; Bouvier M.; Saurat J.-H.
Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneve 14,
Switzerland
CORRESP. AUTHOR: Prins C.
CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal
Universitaire, 1211 Geneve 14, Switzerland

Medecine et Hygiene (Med. Hyg.) (Switzerland) March 8, 2000, 58/2291
(554-559)
CODEN: MEHGA ISSN: 00256749
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: French SUMMARY LANGUAGE: English; French
NUMBER OF REFERENCES: 11

8/3/60 (Item 36 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077861651 EMBASE No: 1999347983
HLA class II restriction of autoreactive T cell responses in pemphigus
vulgaris: Review of the literature and potential applications for the
development of a specific immunotherapy
Riechers R.; Hertl M. // Grotzinger J.
Department of Dermatology, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen
, Germany // Institute of Biochemistry, RWTH Aachen, Pauwelsstrasse 30,
D-52074 Aachen, Germany
CORRESP. AUTHOR: Riechers R.
CORRESP. AUTHOR AFFIL: Department of Dermatology, RWTH Aachen,
Pauwelsstrasse 30, D-52074 Aachen, Germany

Autoimmunity (Autoimmunity) (United Kingdom) October 19, 1999, 30/3

(183-196)
CODEN: AUIME ISSN: 08916934
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 67

8/3/61 (Item 37 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077306883 EMBASE No: 1998217045
Unresponsive discoid lupus erythematosus successfully controlled by
extracorporeal photopheresis
Extrakorporale Photopherese bei therapieresistentem disseminiert
diskoidem Lupus erythematosus (DDLE)
Richter H.I.; Krutmann J.; Goerz G. // Krutmann J.
Hautklinik, Heinrich-Heine-Universität, Düsseldorf, Germany // Klinische
und Experimentelle Photodermatologie, Hautklinik,
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Düsseldorf,
Germany
CORRESP. AUTHOR: Krutmann J.
CORRESP. AUTHOR AFFIL: Klin./Experimentelle Photodermatol., Hautklinik,
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Düsseldorf,
Germany

Hautarzt (Hautarzt) (Germany) June 1, 1998, 49/6 (487-491)
CODEN: HAUTA ISSN: 00178470
DOI: 10.1007/s001050050775
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English; German
NUMBER OF REFERENCES: 25

8/3/62 (Item 38 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077100015 EMBASE No: 1998008440
T-helper 2 involvement in the pathogenesis of bullous pemphigoid: Role of
soluble CD30 (sCD30)
De Pita O.; Frezzolini A.; Cianchini G.; Ruffelli M.; Teofoli P.; Puddu
P.
Department of Immunodermatology, Ist. Dermatologico dell' Immacolata, IDI,
Via Monti di Creta, 104-00167 Rome, Italy
AUTHOR EMAIL: a.frezzolini@idi.it
CORRESP. AUTHOR: De Pita O.
CORRESP. AUTHOR AFFIL: Department of Immunodermatology, Istituto
Dermatologico dell' Immacolata, IRCCS, Via Monti di Creta, 104-00167 Rome,
Italy

Archives of Dermatological Research (Arch. Dermatol. Res.) (Germany)
December 1, 1997, 289/12 (667-670)
CODEN: ADMFA ISSN: 03403696
DOI: 10.1007/s004030050259
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 27

8/3/63 (Item 39 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0077089535 EMBASE No: 1997382805
Mucocutaneous autoimmune syndrome following fludarabine therapy for
low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL)
Braess J.; Hiddemann W.; Wormann B. // Willert S.; Strutz F. // Reich K.;
Neumann C.
Dept. of Hematology and Oncology, Klinikum Gottingen, Georg August
Universitat, Robert Koch Strasse, D-37075 Gottingen, Germany //
Department of Nephrology, Klinikum Gottingen, Germany // Department of
Dermatology, Klinikum Gottingen, Gottingen, Germany
CORRESP. AUTHOR: Braess J.
CORRESP. AUTHOR AFFIL: Department Hematology and Oncology, Klinikum
Gottingen, Georg August Universitat, Robert Koch Strasse, D-37075
Gottingen, Germany

Annals of Hematology (ANN. HEMATOL.) (Germany) November 1, 1997,
75/5-6 (227-230)
CODEN: ANHEE ISSN: 09395555
DOI: 10.1007/s002770050347
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 25

8/3/64 (Item 40 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075944690 EMBASE No: 1994352172
Extracorporeal photopheresis
EXTRAKORPORALE PHOTOPHERESE
Prinz B.; Plevig G.
Dermatologische Klinik/Poliklinik, Ludwig-Maximilians-Universitat,
Frauenlobstrasse 9-11, D-80337 Munchen, Germany
CORRESP. AUTHOR: Prinz B.
CORRESP. AUTHOR AFFIL: Dermatologische Klinik/Poliklinik,
Ludwig-Maximilians-Universitat, Frauenlobstrasse 9-11, D-80337 Munchen,
Germany

Hautarzt (HAUTARZT) (Germany) December 21, 1994, 45/11 (746-750)
CODEN: HAUTA ISSN: 00178470
DOI: 10.1007/s001050050164
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English; German

8/3/65 (Item 41 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075943261 EMBASE No: 1994360240
Photopheresis: Report of cases and review of the literature
FOTOFERESIS: REPORTE DE CASOS Y REVISION DE LA LITERATURA
Bogaert M.A.; Sisto M.; Kerdel F.A.
Dept. Dermatology/Cutaneous Surgery, University of Miami, School of
Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United States
CORRESP. AUTHOR: Kerdel F.A.
CORRESP. AUTHOR AFFIL: Dept. Dermatology/Cutaneous Surgery, University of
Miami, School of Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United

States

Medicina Cutanea Ibero-Latino-Americana (MED. CUTANEA IBERO-LAT.-AM.) (Spain) December 1, 1994, 22/6 (278-283)
CODEN: MCILB ISSN: 02105187
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Spanish SUMMARY LANGUAGE: English; Spanish

8/3/66 (Item 42 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075922515 EMBASE No: 1994344026
A case of pemphigus vulgaris expired by acute renal failure
Yoo H.D.; Sim W.Y.
Department of Dermatology, College of Medicine, Kyung Hee University,
Seoul, Korea, Republic of
CORRESP. AUTHOR: Yoo H.D.
CORRESP. AUTHOR AFFIL: Department of Dermatology, College of Medicine,
Kyung Hee University, Seoul, Korea, Republic of

Korean Journal of Dermatology (KOREAN J. DERMATOL.) (Korea, Republic of)
November 28, 1994, 32/4 (713-717)
CODEN: TPKCA ISSN: 04944739
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Korean SUMMARY LANGUAGE: English

8/3/67 (Item 43 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651
Autoimmunity as a complication of interleukin 2 immunotherapy: Many
unanswered questions
Gaspari A.A.
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood
Ave, New York, NY 14642, United States
CORRESP. AUTHOR: Gaspari A.A.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States

Archives of Dermatology (ARCH. DERMATOL.) (United States) August 5,
1994, 130/7 (894-897)
CODEN: ARDEA ISSN: 0003987X
DOI: 10.1001/archderm.130.7.894
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

8/3/68 (Item 44 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075803474 EMBASE No: 1994190202
Extracorporeal photopheresis
Gross M.; Boh E.E.; Millikan L.E.
Department of Dermatology, Tulane University Medical Center, 1430 Tulane
Avenue, New Orleans, LA 70112, United States
CORRESP. AUTHOR: Gross M.

CORRESP. AUTHOR AFFIL: Department of Dermatology, Tulane University
Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112, United States

International Journal of Dermatology (INT. J. DERMATOL.) (Canada)
August 8, 1994, 33/6 (407-411)
CODEN: IJDEB ISSN: 00119059
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

8/3/69 (Item 45 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075770590 EMBASE No: 1994205185
The immunological features and pathophysiology of ocular cicatricial
pemphigoid
Elder M.J.; Lightman S.
Moorfields Eye Hospital, City Road, London EC1V 2PD, United Kingdom
CORRESP. AUTHOR: Elder M.J.
CORRESP. AUTHOR AFFIL: Moorfields Eye Hospital, City Road, London EC1V
2PD, United Kingdom

Eye (EYE) (United Kingdom) July 7, 1994, 8/2 (196-199)
CODEN: EYEEE ISSN: 0950222X
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/70 (Item 46 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075676152 EMBASE No: 1994100257
Role of extracorporeal photopheresis in the treatment of cutaneous T-cell
lymphoma, autoimmune disease, and allograft rejection
Rook A.H.; Wolfe J.T.
Department of Dermatology, University of Pennsylvania Hospital, 3400
Spruce Street, Philadelphia, PA 19104, United States
CORRESP. AUTHOR: Rook A.H.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Pennsylvania Hospital, 3400 Spruce Street, Philadelphia, PA 19104, United
States

Journal of Clinical Apheresis (J. CLIN. APHERESIS) (United States)
April 11, 1994, 9/1 (28-30)
CODEN: JCAPE ISSN: 07332459
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/71 (Item 47 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075450186 EMBASE No: 1993229742
Pemphigus vulgaris and vegetans
Becker B.A.; Gaspari A.A.
Department of Dermatology, University of Rochester, School of
Medicine/Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, United
States

CORRESP. AUTHOR: Gaspari A.A.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Rochester, School of Medicine/Dentistry, 601 Elmwood Avenue, Rochester,
NY 14642, United States

Dermatologic Clinics (DERMATOL. CLIN.) (United States) August 23, 1993
11/3 (429-452)

CODEN: DRMCD ISSN: 07338635
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/72 (Item 48 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075326355 EMBASE No: 1993105897
Paraneoplastic pemphigus in a child with a T-cell lymphoblastic lymphoma
Rybojad M.; Leblanc T.; Flageul B.; Bernard Ph.; Morel P.; Schaison G.;
D'Agay M.-F.; Borradori L.
Service Dermatologie, Hopital Cantonal Universitaire, 24, Rue
Micheli-du-Crest, CH-1211 Geneve, Switzerland
CORRESP. AUTHOR: Borradori L.
CORRESP. AUTHOR AFFIL: Service Dermatologie, Hopital Cantonal
Universitaire, 24, Rue Micheli-du-Crest, CH-1211 Geneve, Switzerland

British Journal of Dermatology (BR. J. DERMATOL.) (United Kingdom)
April 28, 1993, 128/4 (418-422)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/73 (Item 49 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075072132 EMBASE No: 1992223805
Photopheresis in the 1990s
Christensen I.; Heald P.
500 LCI, 333 Cedar Street, New Haven, CT 06510, United States
CORRESP. AUTHOR: Christensen I.
CORRESP. AUTHOR AFFIL: 500 LCI, 333 Cedar Street, New Haven, CT 06510,
United States

Journal of Clinical Apheresis (J. CLIN. APHERESIS) (United States)
December 1, 1991, 6/4 (216-220)
CODEN: JCAPE ISSN: 07332459
DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Citation
LANGUAGE: English

8/3/74 (Item 50 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0074873316 EMBASE No: 1992024988
The role of cyclosporine A in the treatment of pemphigus erythematosus
Campolmi P.; Bonan P.; Lotti T.; Palleschi G.M.; Fabbri P.; Panconesi E.
Clinica Dermatologica, Via Alfani 37, 50121 Firenze, Italy
CORRESP. AUTHOR: Bonan P.

CORRESP. AUTHOR AFFIL: Clinica Dermatologica, Via Alfani 37, 50121
Firenze, Italy

International Journal of Dermatology (INT. J. DERMATOL.) (United States
) December 1, 1991, 30/12 (890-892)
CODEN: IJDEB ISSN: 00119059
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/75 (Item 51 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0074446101 EMBASE No: 1990345667
Cyclosporin in dermatology
LA CYCLOSPORINE EN DERMATOLOGIE
Salomon D.; Halioua B.
Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneva 4,
Switzerland
CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal
Universitaire, 1211 Geneva 4, Switzerland

Schweizerische Rundschau fur Medizin/Praxis (SCHWEIZ. RUNDSCH. MED.
PRAX.) (Switzerland) November 22, 1990, 79/42 (1258-1261)
CODEN: SRMPD ISSN: 03698394
DOCUMENT TYPE: Journal; Short Survey RECORD TYPE: Citation
LANGUAGE: French SUMMARY LANGUAGE: English; German

8/3/76 (Item 52 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0074308283 EMBASE No: 1990202296
Photopheresis: A new therapeutic concept
Edelson R.L.
Department of Dermatology, Yale University School of Medicine, New Haven,
CT, United States
CORRESP. AUTHOR AFFIL: Department of Dermatology, Yale University School
of Medicine, New Haven, CT, United States

Yale Journal of Biology and Medicine (YALE J. BIOL. MED.) (United
States) December 1, 1989, 62/6 (565-577)
CODEN: YJBMA ISSN: 00440086
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

8/3/77 (Item 53 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0073492421 EMBASE No: 1987020814
When to discontinue therapy in pemphigus vulgaris?
WANN IST ES MOGLICH, DIE THERAPIE BEIM PEMPHIGUS VULGARIS ABZUSETZEN?
Mashkilleysen N.; Eskelinen A.
Department fur Dermatologie, Stomatologisches Institut Moskau, Moskau,
U.S.S.R.
CORRESP. AUTHOR AFFIL: Department fur Dermatologie, Stomatologisches
Institut Moskau, Moskau, U.S.S.R.

H+G Zeitschrift fur Hautkrankheiten (H G Z. HAUTKR.) (Germany)
December 1, 1986, 61/22 (1596-1602)
CODEN: ZHKRA ISSN: 03010481
DOCUMENT TYPE: Journal RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/78 (Item 54 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0073249693 EMBASE No: 1986058727
Heparin action in pemphigus vulgaris: Clinical and immunologic studies
Mashkilleysen N.A.
Department of Dermatology, Moscow Medical Stomatological Institute,
Moscow, U.S.S.R.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Moscow Medical
Stomatological Institute, Moscow, U.S.S.R.

Acta Dermato-Venereologica (ACTA DERM.-VENEREOL.) (Sweden) December 1,
1985, 65/6 (545-547)
CODEN: ADVEA ISSN: 00015555
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation
LANGUAGE: English

8/3/79 (Item 55 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0073194646 EMBASE No: 1986093680
Deficiency of interleukin-2 in pemphigus vulgaris
INTERLEUKIN-2-MANGEL BEI PEMPHIGUS VULGARIS
Blitstein-Willinger E.; Stuttgart G.
Universitäts-Hautklinik und -Poliklinik im Rudolph-Virchow-Krankenhaus,
FU, D-1000 Berlin 65, Germany
CORRESP. AUTHOR AFFIL: Universitäts-Hautklinik und -Poliklinik im
Rudolph-Virchow-Krankenhaus, FU, D-1000 Berlin 65, Germany

H+G Zeitschrift fur Hautkrankheiten (H G Z. HAUTKR.) (Germany) May 14,
1986, 61/1-2 (82-85)
CODEN: ZHKRA ISSN: 03010481
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/80 (Item 56 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0073173784 EMBASE No: 1986117818
Cutaneous immunological studies in diagnosis of acute graft-versus-host
disease
Dreno B.; Milpied N.; Harousseau J.L.; et-al
Clinique Dermatologique, Hematologie, Hotel Dieu, 44035 Nantes, France
CORRESP. AUTHOR AFFIL: Clinique Dermatologique, Hematologie, Hotel Dieu,
44035 Nantes, France

British Journal of Dermatology (BR. J. DERMATOL.) (United Kingdom)
June 18, 1986, 114/1 (7-15)

CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/81 (Item 57 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0072541205 EMBASE No: 1983026673
Use of monoclonal antibodies specific for T cell subsets in cutaneous disorders: I. Quantitative analysis of peripheral blood lymphocytes
Faure M.; Thivolet J.
Inserm U 209, Lab. Rech. Dermatol. Immunol., Hop. E. Herriot, 69374 Lyon Cedex 2, France
CORRESP. AUTHOR AFFIL: Inserm U 209, Lab. Rech. Dermatol. Immunol., Hop. E. Herriot, 69374 Lyon Cedex 2, France

Journal of Clinical Immunology (J. CLIN. IMMUNOL.) (United States)
December 1, 1982, 2/Suppl. 3 (1035-1105)
CODEN: JCIMD ISSN: 02719142
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/82 (Item 58 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0071805404 EMBASE No: 1981251814
Use of orthoclone monoclonal antibodies in the study of selected dermatologic conditions
Berger C.L.; Kung P.; Goldstein G.; et-al
Dept. Dermatol., Columbia Univ., New York, NY 10032, United States
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Columbia Univ., New York, NY 10032, United States

International Journal of Immunopharmacology (INT. J. IMMUNOPHARMACOL.)
(United Kingdom) December 29, 1981, 3/3 (275-282)
CODEN: IJIMD ISSN: 01920561
DOI: 10.1016/0192-0561(81)90021-7
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/83 (Item 59 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0071256724 EMBASE No: 1978401631
Pemphigus vulgaris and thymoma. A T-lymphocyte defect?
Kavli G.
Dept. Dermatol., Univ. 9012 Tromso, Norway
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Univ. 9012 Tromso, Norway

British Journal of Dermatology (BR. J. DERMATOL.) (United Kingdom)
December 11, 1978, 99/1 (97-98)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/84 (Item 60 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0071200319 EMBASE No: 1978343401
Immunosuppressive effect of serum from patients with skin diseases
DIE IMMUNITÄTSHEMMENDE WIRKUNG DES BLUTSERUMS BEI DERMATOSEN
Somos S.
Hautklin., Univ. Pecs, Hungary
CORRESP. AUTHOR AFFIL: Hautklin., Univ. Pecs, Hungary

Dermatologische Monatsschrift (DERMATOL. MONATSSCHR.) (German
Democratic Republic) August 18, 1978, 164/3 (186-192)
CODEN: DMONB ISSN: 0019083
DOCUMENT TYPE: Journal RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English

8/3/85 (Item 61 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0070779654 EMBASE No: 1977136545
Hodgkin's disease and pemphigus
Naysmith A.; Hancock B.W.
Univ. Dept. Med., Roy. Hosp., Sheffield, United Kingdom
CORRESP. AUTHOR AFFIL: Univ. Dept. Med., Roy. Hosp., Sheffield, United
Kingdom

British Journal of Dermatology (BR. J. DERMATOL.) December 1, 1976,
94/6 (695-696)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/86 (Item 62 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0070392933 EMBASE No: 1975176789
'Opportunistic' auto immune disease and 'opportunistic' malignancy from
impaired cell mediated immunity?
Cairns R.J.
St Bartholomew's Hosp., Rochester, United Kingdom
CORRESP. AUTHOR AFFIL: St Bartholomew's Hosp., Rochester, United Kingdom

British Journal of Dermatology (BR. J. DERMATOL.) December 1, 1974,
91/5 (601-602)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal RECORD TYPE: Citation
LANGUAGE: English

8/3/87 (Item 63 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0070262085 EMBASE No: 1975045851
Pemphigus and Hodgkin's disease

Sood V.D.; Pasricha J.S.
Dept. Dermatol. Venereol., All India Inst. Med. Sch., New Delhi, India
CORRESP. AUTHOR AFFIL: Dept. Dermatol. Venereol., All India Inst. Med.
Sch., New Delhi, India

British Journal of Dermatology (BR. J. DERMATOL.) December 1, 1974,
90/5 (575-578)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

8/3/88 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

17756072 PMID: 17598863
Clinical-scale generation of strongly CD83-expressing dendritic cells
using extracorporeal photopheresis.
Bredberg Anders; Jonsson Svante; Lindblom Anders; Bjork Peter
Department of Medical Microbiology, Malmo University Hospital, Lund
University, Malmo, Sweden.
Photodermatology, photoimmunology & photomedicine (Denmark) Aug 2007,
23 (4) p113-9, ISSN 0905-4383--Print Journal Code: 9013641
Publishing Model Print
Document type: Evaluation Studies; Journal Article; Research Support,
Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/89 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

17458661 PMID: 17097371
Lichenoid paraneoplastic pemphigus in the absence of detectable
antibodies.
Cummins Deborah L; Mimouni Daniel; Tzu Julia; Owens Nicole; Anhalt Grant
J; Meyerle Jon H
Department of Dermatology, Johns Hopkins Hospital, Baltimore, MD 21205,
USA.
Journal of the American Academy of Dermatology (United States) Jan 2007
, 56 (1) p153-9, ISSN 1097-6787--Electronic Journal Code: 7907132
Publishing Model Print-Electronic
Document type: Case Reports; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/90 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

16839443 PMID: 16417225
Tolerance induction by the blockade of CD40/CD154 interaction in
pemphigus vulgaris mouse model.
Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki
Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki

Department of Dermatology, Keio University School of Medicine,
Shinjuku-ku, Tokyo, Japan.

Journal of investigative dermatology (United States) Jan 2006, 126

(1) p105-13, ISSN 0022-202X--Print Journal Code: 0426720

Publishing Model Print; Comment in J Invest Dermatol. 2006
Jan;126(1) 11-3; Comment in PMID 16417211

Document type: Journal Article; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/91 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

15542509 PMID: 14761596

[A clinicopathological study of Castleman's disease]

Na Jia; Liu Ping; Wang Ren-gui; Wang Liang-chun; Zou Wan-zhong

Department of Pathology, Peking University First Hospital, Beijing
100034, China.

Zhonghua bing li xue za zhi Chinese journal of pathology (China) Dec
2003, 32 (6) p521-4, ISSN 0529-5807--Print Journal Code: 0005331

Publishing Model Print

Document type: English Abstract; Journal Article

Languages: CHINESE

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/92 (Item 5 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

12747263 PMID: 9675577

[Extracorporeal photopheresis in therapy-refractory disseminated discoid
lupus erythematosus]

Extrakorporale Photopherese bei therapieresistentem disseminiert
diskoidem Lupus erythematosus (DDLE).

Richter H I; Krutmann J; Goerz G

Hautklinik, der Heinrich-Heine-Universität, Düsseldorf.

Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte
Gebiete (GERMANY) Jun 1998, 49 (6) p487-91, ISSN 0017-8470--Print

Journal Code: 0372755

Publishing Model Print

Document type: Case Reports; English Abstract; Journal Article

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/93 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

11939831 PMID: 8868455

[Therapeutic experiences with extracorporeal photopheresis. Technical
procedure, follow-up and clinical outcome in 31 skin diseases]

Therapeutische Erfahrungen mit der Extrakorporalen Photopherese.
Technisches Vorgehen, Überwachung und klinische Ergebnisse bei 41
Hautkranken.

Owsianowski M; Garbe C; Ramaker J; Orfanos C E; Gollnick H
Universitäts-Hautklinik und Poliklinik, Freie Universität, Berlin.
Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte
Gebiete (GERMANY) Feb 1996, 47 (2) p114-23, ISSN 0017-8470--Print
Journal Code: 0372755
Publishing Model Print
Document type: English Abstract; Journal Article
Languages: GERMAN
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/94 (Item 7 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

11883255 PMID: 8804843
Coexistence of superficial pemphigus and psoriasis.
Panzarella K; Camisa C
Department of Dermatology, Cleveland Clinic Foundation, Ohio 44195, USA.
Cutis; cutaneous medicine for the practitioner (UNITED STATES) Jun 1996
, 57 (6) p414-8, ISSN 0011-4162--Print Journal Code: 0006440
Publishing Model Print
Document type: Case Reports; Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/95 (Item 8 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

10013351 PMID: 1793210
Photopheresis in the treatment of autoimmune disease: experience with
pemphigus vulgaris and systemic sclerosis.
Rook A H
Department of Dermatology, Hospital of the University of Pennsylvania,
Philadelphia 19104.
Annals of the New York Academy of Sciences (UNITED STATES) Dec 30 1991,
636 p209-16, ISSN 0077-8923--Print Journal Code: 7506858
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/96 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

09859874 PMID: 1887157
[The application of photopheresis in the therapy of cancerous and
autoimmune diseases]
Applicazione della fotoforesi nella terapia di malattie oncologiche ed
autoimmuni.
Dall'Amico R; Zacchello G; Heald P
Dipartimento di Pediatria, Università, Padova.
Recenti progressi in medicina (ITALY) May 1991, 82 (5) p294-9,
ISSN 0034-1193--Print Journal Code: 0401271

Publishing Model Print

Document type: Clinical Trial; English Abstract; Journal Article; Review

Languages: ITALIAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/97 (Item 10 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

09261567 PMID: 2636804

Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris--preliminary report.

Rook A H; Heald P W; Nahass G T; Macey W; Witmer W K; Lazarus G S; Jegasothy B V

General Clinical Research Center, Hospital of University of Pennsylvania, Philadelphia 19104.

Yale journal of biology and medicine (UNITED STATES) Nov-Dec 1989, 62

(6) p647-52, ISSN 0044-0086--Print Journal Code: 0417414

Contract/Grant No.: M01 RR00040-29; RR; United States NCRR

Publishing Model Print

Document type: Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/98 (Item 11 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

08747618 PMID: 2460382

Immunohistological study of captopril-induced late cutaneous eruptions.

Bretin N; Dreno B; Bureau B; Litoux P

Department of Dermatology, Nantes, France.

Dermatologica (SWITZERLAND) 1988, 177 (1) p11-5, ISSN 0011-9075--

Print Journal Code: 0211607

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/99 (Item 12 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2008 Dialog. All rts. reserv.

08141983 PMID: 3101298

[When is it possible to discontinue therapy in pemphigus vulgaris?]

Wann ist es möglich, die Therapie beim Pemphigus vulgaris abzusetzen?

Mashkilleysen N; Eskelinen A

Zeitschrift für Hautkrankheiten (GERMANY, WEST) Nov 15 1986, 61 (22) p1596-602, ISSN 0301-0481--Print Journal Code: 0367576

Publishing Model Print

Document type: Case Reports; English Abstract; Journal Article

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

8/3/100 (Item 13 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

07804869 PMID: 3936658
Normalization of defective interleukin 1 and interleukin 2 production in patients with pemphigus vulgaris following chrysotherapy.
Blitstein-Willinger E
Clinical and experimental immunology (ENGLAND) Dec 1985, 62 (3)
p705-14, ISSN 0009-9104--Print Journal Code: 0057202
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/101 (Item 14 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

07255837 PMID: 6422017
Glucocorticosteroids and oral medicine.
Pedersen A; Klausen B
Journal of oral pathology (DENMARK) Feb 1984, 13 (1) p1-15, ISSN
0300-9777--Print Journal Code: 0342050
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/102 (Item 15 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

06495871 PMID: 6974011
Cell-mediated immunity in patients with less than pemphigus vulgaris greater than before, during and after prolonged treatment with steroids.
Shohat B; David M; Feuerman E J
Biomedicine / publiee pour l'A.A.I.C.I.G. (FRANCE) Jul 1981, 35 (3)
p101-3, ISSN 0300-0893--Print Journal Code: 0361342
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/103 (Item 16 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

05608378 PMID: 347546
[Immunological aspects of malignant lymphomas]
Aspetti immunologici dei linfomi maligni.
Hancock B W; Richmond J
Recenti progressi in medicina (ITALY) Feb 1978, 64 (2) p217-29,

ISSN 0034-1193--Print Journal Code: 0401271
Publishing Model Print
Document type: Journal Article; Review
Languages: ITALIAN
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/104 (Item 17 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

05482935 PMID: 144706
Antilymphocyte globulin and its use in skin diseases.
Barrett A J
International journal of dermatology (UNITED STATES) Nov 1977, 16 (9)
p738-9, ISSN 0011-9059--Print Journal Code: 0243704
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/105 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148031934 CA: 148(2)31934m PATENT
Ligands or antibodies capable of binding to CD3 and CD55 for producing
regulatory CD4+ T cells to treat antibody- or cell-mediated autoimmune
disease
INVENTOR(AUTHOR): Spendlove, Ian; Durrant, Linda Gillian
LOCATION: UK,
ASSIGNEE: The University of Nottingham
PATENT: PCT International ; WO 2007135401 A2 DATE: 20071129
APPLICATION: WO 2007GB1864 (20070518) *GB 20069924 (20060519)
PAGES: 65pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395	A	I	F	B	20060101	H	EP
A61P-0037/00	A	I	L	B	20060101	H	EP
A61K-0038/17	A	I	L	B	20060101	H	EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RS; RU; SC; SD; SE; SG; SK; SL; SM;
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/106 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

147446877 CA: 147(21)446877x PATENT
Combination therapy for treating autoimmune diseases

INVENTOR(AUTHOR): Koenig, Scott
LOCATION: USA
ASSIGNEE: MacroGenics, Inc.
PATENT: PCT International ; WO 2007117600 A2 DATE: 20071018
APPLICATION: WO 2007US8579 (20070406) *US 2006PV789899 (20060407) *US
2006PV844095 (20060913)
PAGES: 38pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/107 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

147446856 CA: 147(21)446856q PATENT
Isolation and use of human regulatory T cells
INVENTOR(AUTHOR): Yun, Theodore J.
LOCATION: USA
ASSIGNEE: Biogen Idec Ma Inc.
PATENT: PCT International ; WO 2007117602 A2 DATE: 20071018
APPLICATION: WO 2007US8581 (20070406) *US 2006PV789918 (20060407)
PAGES: 74pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/8 + Level Value Position Status Version Action Source Office:
C12N-0005/08 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA;
NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/108 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

147235154 CA: 147(11)235154w PATENT
Preparation of thiazole and thiadiazole compounds for treating
inflammation, immune disorders, and other diseases
INVENTOR(AUTHOR): Vo, Nha Huu; Chen, Shoujun; Che, Qinglin; Xie, Yu
LOCATION: USA
ASSIGNEE: Synta Pharmaceuticals Corp.
PATENT: PCT International ; WO 200787427 A2 DATE: 20070802
APPLICATION: WO 2007US2121 (20070125) *US 2006PV761974 (20060125) *US

2006PV761933 (20060125)

PAGES: 210pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/433 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/109 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147203924 CA: 147(10)203924f PATENT

Compositions and methods for modulation of suppressor T cell activation

INVENTOR(AUTHOR): Wang, Bin; Greene, Mark I.; Saquaf, Sandra; Li, Bin;

Zhang, Hongtao; Hancock, Wayne W.

LOCATION: USA

ASSIGNEE: The Trustees of the University of Pennsylvania; The Children's Hospital of Philadelphia

PATENT: PCT International; WO 200784775 A2 DATE: 20070726

APPLICATION: WO 2007US1677 (20070122) *US 2006PV760549 (20060120) *US

2006PV794670 (20060424)

PAGES: 77pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0035/14 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/110 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147141190 CA: 147(7)141190c JOURNAL

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients

AUTHOR(S): Goh, M. S. Y.; McCormack, C.; Dinh, H. V.; Welsh, B.; Foley, P.; Prince, H. M.

LOCATION: Dermatology Service and Clinical Cancer Services, Peter MacCallum Cancer Centre, Melbourne, Vic., 8006, Australia

JOURNAL: Br. J. Dermatol. (British Journal of Dermatology) DATE: 2007

VOLUME: 156 NUMBER: 5 PAGES: 990-996 CODEN: BJDEAZ ISSN: 0007-0963

LANGUAGE: English PUBLISHER: Blackwell Publishing Ltd.

8/3/111 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146460616 CA: 146(23)460616x PATENT

Apoptotic cells ex vivo use to generate regulatory T cells (Treg) and disease treatment using Treg

INVENTOR(AUTHOR): Peritt, David; Campbell, Kim; Krutsick, Amy

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20070098686 A1 DATE: 20070503

APPLICATION: US 2006555978 (20061102) *US 2005PV732847 (20051102)

PAGES: 15pp. CODEN: USXXCO LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 424085200

IPC/R/8 + Level Value Position Status Version Action Source Office:

A61K-0038/20 A I F B 20060101 20070503 H US

A61K-0031/366 A I L B 20060101 20070503 H US

A61K-0031/59 A I L B 20060101 20070503 H US

8/3/112 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146357227 CA: 146(18)357227x PATENT

Diastereomeric peptides for modulating T cell immunity

INVENTOR(AUTHOR): Shai, Yechiel; Cohen, Irun R.; Quintana, Francisco;

Gerber, Doron

LOCATION: Israel

ASSIGNEE: Yeda Research and Development Co., Ltd.

PATENT: PCT International ; WO 200734490 A2 DATE: 20070329

APPLICATION: WO 20061L1113 (20060921) *US 2005PV719169 (20050922)

PAGES: 79pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/R/8 + Level Value Position Status Version Action Source Office:

C07K-0014/07 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KN; KP; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/113 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146272528 CA: 146(14)272528w PATENT

Human Ig comprising antigen T cell epitope for activating selective subsets of antigen presenting cells to treat viral infection, cancer and autoimmune disease

INVENTOR(AUTHOR): Wang, Lilin; Smith, Dan; Phillips, Bill; Bot, Adrian

LOCATION: USA

ASSIGNEE: Multicell Immunotherapeutics, Inc.

PATENT: PCT International ; WO 200722477 A2 DATE: 20070222
APPLICATION: WO 2006US32512 (20060817) *US 2005PV708980 (20050817)
PAGES: 197pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

A61K-0039/395 A I F B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA;
LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG;
NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV;
SY; TJ; TM; TR; TT; TZ; UA; UG; US DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/114 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146252109 CA: 146(13)252109g PATENT

Preparation of amino acid and peptide aldehyde imines as inhibitors of
cancer cell, T-cell and keratinocyte proliferation for the treatment of
proliferative diseases

INVENTOR(AUTHOR): Leban, Johann; Kralik, Martin

LOCATION: Germany,

ASSIGNEE: 4SC AG

PATENT: PCT International ; WO 200717284 A2 DATE: 20070215

APPLICATION: WO 2006EP7933 (20060810) *EP 200517391 (20050810)

PAGES: 57pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:

C07K-0005/04 A I F B 20060101 H EP

C07K-0005/06 A I L B 20060101 H EP

C07K-0005/08 A I L B 20060101 H EP

C07K-0005/10 A I L B 20060101 H EP

A61K-0038/04 A I L B 20060101 H EP

C07D-0233/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA;
LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI;
NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ;
TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/115 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT

Biomarkers for diagnosis and treatment of diseases having an autoimmune
and/or inflammatory component responsive to anti-CD40 monoclonal
antibodies

INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad

LOCATION: USA
ASSIGNEE: Novartis AG; Xoma Technology
PATENT: PCT International ; WO 2006125117 A2 DATE: 20061123
APPLICATION: WO 2006US19325 (20060518) *US 2005PV682575 (20050518) *US
2005PV749336 (20051209)

PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

G01N-0033/564 A I F B 20060101 H EP

G01N-0033/68 A I L B 20060101 H EP

A61P-0037/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;
TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/116 (Item 12 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

145437248 CA: 145(22)437248z PATENT

Detection and isolation of immunosuppressive regulatory T cells and uses thereof in treatment of autoimmune disease and prevention of graft rejection

INVENTOR(AUTHOR): Borsellino, Giovanna; Battistini, Luca; Roetzschke, Olaf; Falk, Kirsten

LOCATION: Italy

ASSIGNEE: Fondazione Santa Lucia I.R.C.C.S.

PATENT: PCT International ; WO 2006111986 A1 DATE: 20061026

APPLICATION: WO 2005IT227 (20050419)

PAGES: 18pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

G01N-0033/566 A I F B 20060101 H EP

A61K-0035/00 A I L B 20060101 H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH;
PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA;
UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY;
CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/117 (Item 13 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144312116 CA: 144(17)312116c PATENT

Preparation of piperidinylthiazolecarboxamides as inhibitors of T-cell proliferation

INVENTOR(AUTHOR): Leban, Johann; Schmitt, Harald; Wolf, Kristina
LOCATION: Germany,
ASSIGNEE: 4SC AG

PATENT: European Pat. Appl. ; EP 1637529 A1 DATE: 20060322
APPLICATION: EP 200422363 (20040920)

PAGES: 22 pp. CODEN: EPXXDW LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

C07D-0401/14	A	I	F	B		H	EP
A61K-0031/4535	A	I	L	B		H	EP
C07D-0495/04	A	I	L	B		H	EP
C07D-0401/04	A	I	L	B		H	EP
C07D-0487/04	A	I	L	B		H	EP
A61P-0025/28	A	I	L	B		H	EP
A61P-0035/00	A	I	L	B		H	EP

DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO; MK; CY; AL; TR; BG; CZ; EE; HU; PL; SK;
HR

8/3/118 (Item 14 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144286710 CA: 144(16)286710v PATENT

Methods for restoring immune balance for the treatment of T-cell mediated
diseases with human chorionic gonadotropin

INVENTOR(AUTHOR): Yoon, Ji-Won

LOCATION: S. Korea

ASSIGNEE: Biotech Institute for International Innovation Inc.

PATENT: PCT International ; WO 200629088 A2 DATE: 20060316

APPLICATION: WO 2005US31554 (20050901) *US 2004PV606831 (20040902)

PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

A61K-0038/22	A	I	F	B	20060101	H	US
--------------	---	---	---	---	----------	---	----

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; LC; LK; LR;
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG;
PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ;
UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/119 (Item 15 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144231353 CA: 144(13)231353a JOURNAL

Inhibition of the Transcription Factor Foxp3 Converts Desmoglein

3-Specific Type 1 Regulatory T Cells into Th2-Like Cells

AUTHOR(S): Veldman, Christian; Pahl, Andreas; Beissert, Stefan;
Wiebke, Buer, Jan; Dieckmann, Detlef; Schuler, Gerold; Hertl, Michael

LOCATION: Department of Dermatology, University of Erlangen-Nuernberg,
Erlangen, Germany,

JOURNAL: J. Immunol. (Journal of Immunology) DATE: 2006 VOLUME: 176

NUMBER: 5 PAGES: 3215-3222 CODEN: JOIMA3 ISSN: 0022-1767 LANGUAGE:

English PUBLISHER: American Association of Immunologists

8/3/120 (Item 16 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

144156641 CA: 144(9)156641n PATENT

Use of a steroid for enhancement of skin permeability of agents used to treat inflammation, hyperproliferative disorders, disorders involving T cells, and other disorders

INVENTOR(AUTHOR): Meingassner, Josef Gottfried

LOCATION: Switz.

ASSIGNEE: Novartis AG; Novartis Pharma GmbH

PATENT: PCT International ; WO 200608092 A1 DATE: 20060126

APPLICATION: WO 2005EP7740 (20050715) *GB 200415994 (20040716) *GB 200417205 (20040802) *US 2004PV605328 (20040827)

PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-031/436A; A61K-047/28B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; VZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/121 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

143440276 CA: 143(24)440276w PATENT

Phenanthridine analogues, their preparation, pharmaceutical compositions, and uses as inhibitors of hyperproliferation of T cells and keratinocytes

INVENTOR(AUTHOR): Pegoraro, Stefano; Lang, Martin; Feurle, Juliane;

Krauss, Juergen

LOCATION: Germany,

ASSIGNEE: 4SC AG; Switch Biotech AG

PATENT: PCT International ; WO 2005105752 A1 DATE: 20051110

APPLICATION: WO 2004EP11121 (20041005) *EP 200410341 (20040430) *US 2004PV566820 (20040430)

PAGES: 92 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07D-221/12A; C07D-401/04B; C07D-401/14B; C07D-405/06B;

C07D-405/14B; C07D-409/14B; C07D-405/04B; C07D-233/18B; A61K-031/473B;

A61K-031/55B; A61P-017/00B; C07D-409/04B; C07D-409/12B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/122 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

143241985 CA: 143(14)241985b PATENT
Inhibition of T cell activation in the treatment of immunological disease
by blocking class II MHC antigen function
INVENTOR(AUTHOR): Chung, Yong-Hoon; Cho, Hoon-Sik; Park, Hong-Gyu; Yi,
Ki-Wan
LOCATION: S. Korea
ASSIGNEE: Medexgen Inc.
PATENT: PCT International ; WO 200577415 A1 DATE: 20050825
APPLICATION: WO 2005KR457 (20050218) *KR 10835 (20040218)
PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; GR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU;
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

8/3/123 (Item 19 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

142480777 CA: 142(26)480777w PATENT
Antagonistic anti-human CD40 monoclonal antibodies and fragments for
treating proliferative, cancerous and autoimmune disease
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,
Isabel; Chen, Bao-Lu; Lu, Xiaofeng; Lee, Sang Hoon; Hurst, Deborah
LOCATION: USA
ASSIGNEE: Chiron Corporation
PATENT: PCT International ; WO 200544854 A2 DATE: 20050519
APPLICATION: WO 2004US37152 (20041104) *US 2003PV517337 (20031104) *US
2003PV525579 (20031126) *US 2004PV565710 (20040427)
PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-016/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; GR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LI; LU;
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

8/3/124 (Item 20 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT
Antagonistic monoclonal antibodies and derivatives specific to human CD40
antigen for treatment of autoimmune and inflammatory diseases
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,
Isabel
LOCATION: USA
ASSIGNEE: Chiron Corporation
PATENT: PCT International; WO 200544306 A2 DATE: 20050519
APPLICATION: WO 2004US36957 (20041104) *US 2003PV517337 (20031104) *US
2003PV525579 (20031126) *US 2004PV565710 (20040427)
PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

8/3/125 (Item 21 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142233317 CA: 142(13)233317z PATENT
β-galactosyl ceramide compounds complexed with CD1d peptide for
therapeutic reduction of natural killer T cells in immune disorders or
associated diseases in humans
INVENTOR(AUTHOR): Ortaldo, John; Wiltrout, Robert
LOCATION: USA
ASSIGNEE: The Government of the United States of America, as Represented
by the Secretary Department of Health and Human Services
PATENT: PCT International; WO 200514008 A2 DATE: 20050217
APPLICATION: WO 2004US22913 (20040716) *US 2003PV488339 (20030717)
PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-031/70A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ;
VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA;
SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

8/3/126 (Item 22 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142000710 CA: 142(1)710g PATENT

Use of diketopiperazine derivatives for the treatment of T-cell-mediated diseases
INVENTOR(AUTHOR): Bar-Or, David; Bar-Or, Raphael; Shimonkovitz, Richard
LOCATION: USA
ASSIGNEE: DMI Biosciences, Inc.
PATENT: PCT International ; WO 2004103304 A2 DATE: 20041202
APPLICATION: WO 2004US15340 (20040514) *US 2003PV471017 (20030515) *US
2003PV489270 (20030721) *US 2003PV514930 (20031027) *US 2003PV517338
(20031104)
PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
NE; SN; TD; TG

8/3/127 (Item 23 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

140092608 CA: 140(7)92608q PATENT
Use of CD152 for treating autoimmune diseases and inflammations
INVENTOR(AUTHOR): Brunner-Weinzierl, Monika
LOCATION: Germany,
ASSIGNEE: Universitaetsklinikum Charite Medizinische Fakultat Der
Humboldt-Universitaet Zu Berlin
PATENT: PCT International ; WO 200406950 A2 DATE: 20040122
APPLICATION: WO 2003EP7665 (20030715) *DE 10232697 (20020715)
PAGES: 39 pp. CODEN: PIXXD2 LANGUAGE: German
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU;
SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN;
YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE;
LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/128 (Item 24 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

139336934 CA: 139(22)336934r PATENT
IL-21 mutants and antagonists for modulating IL-21-mediated T cell
response and for diagnosis, prognosis and treatment of autoimmune
diseases and transplant
INVENTOR(AUTHOR): Moll, Thomas; Strom, Terry B.; Zheng, Xin Xiao
LOCATION: USA
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.

PATENT: PCT International ; WO 200387320 A2 DATE: 20031023
APPLICATION: WO 2003US10736 (20030408) *US PV371038 (20020409)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

CLASS: C12N-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI;
FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG;
CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/129 (Item 25 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

139322294 CA: 139(21)322294v PATENT
Treating or preventing autoimmune disease using an IL-16 inhibitor
INVENTOR(AUTHOR): Delovitch, Terry L.
LOCATION: Can.,
ASSIGNEE: The John P. Robarts Research Institute
PATENT: PCT International ; WO 200386457 A2 DATE: 20031023
APPLICATION: WO 2003CA501 (20030407) *US PV370535 (20020408)
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/130 (Item 26 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

138168815 CA: 138(12)168815m PATENT
B7-related nucleic acids and polypeptides useful for immunomodulation
INVENTOR(AUTHOR): Mikesell, Glen E.; Shen, Henry
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20030031675 A1 DATE: 20030213
APPLICATION: US 77023 (20020215) *US PV209811 (20000606) *US PV272107
(20010228) *US 875338 (20010606)
PAGES: 163 pp., Cont.-in-part of U.S. Ser. No. 875,338. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424178100; A61K-039/395A; C07H-021/04B; C12P-021/04B;
C12N-001/21B; C12N-005/04B; C12N-005/06B

8/3/131 (Item 27 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

137321349 CA: 137(22)321349p PATENT
Diagnostic and therapeutic compositions and methods which utilize the
human T cell receptor β gene region
INVENTOR(AUTHOR): Hood, Leroy E.; Rowen, Lee
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20020150891 A1 DATE: 20021017
APPLICATION: US 263959 (19990305) *US 309335 (19940919) *US 531241
(19950919)
PAGES: 164 pp., Cont. of U. S. Ser. No. 531,241, abandoned. CODEN:
USXXCO LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 435006000; C12Q-001/68A; G01N-033/53B; A01N-043/04B

8/3/132 (Item 28 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

137257652 CA: 137(18)257652c PATENT
Method of attenuating reactions to skin irritants
INVENTOR(AUTHOR): Wilson, S. Brian; Dranoff, Glenn; Gillesen, Silke
LOCATION: USA
ASSIGNEE: Dana-Farber Cancer Institute, Inc.
PATENT: PCT International ; WO 200276401 A2 DATE: 20021003
APPLICATION: WO 2002US9378 (20020326) *US PV278837 (20010326)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW
; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

8/3/133 (Item 29 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136278158 CA: 136(18)278158r PATENT
Control of T cell processes using combinations of antagonists of
interleukin-2 and interleukin-15
INVENTOR(AUTHOR): Li, Xian Chang; Strom, Terry; Zheng, Xin Xiao
LOCATION: USA
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.
PATENT: PCT International ; WO 200222805 A2 DATE: 20020321
APPLICATION: WO 2001US28612 (20010914) *US PV232251 (20000914)
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MY; NZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG;
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;

KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN;
TD; TG

8/3/134 (Item 30 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

135206452 CA: 135(15)206452p PATENT
Phage display libraries of the T cell receptor and the selection of T
cell receptor reagents for diagnostic and therapeutic use
INVENTOR(AUTHOR): Nissim, Ahuva
LOCATION: Israel
PATENT: PCT International ; WO 200162908 A2 DATE: 20010830
APPLICATION: WO 2001IL120 (20010205) *US 510361 (20000222)
PAGES: 132 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/10A; C12N-015/11B; C12N-015/13B; C12N-015/62B;
C12N-015/85B; C12N-007/01B; C07K-014/705B; C07K-016/00B; C12Q-001/68B;
G01N-033/68B; A61K-038/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;
; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

8/3/135 (Item 31 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

132075702 CA: 132(7)75702h PATENT
MUC-1 mucin in detecting T-cell activation and treating disorders
INVENTOR(AUTHOR): Agrawal, Babita; Longenecker, B. Michael
LOCATION: Can.,
ASSIGNEE: Biomira Inc.
PATENT: PCT International ; WO 200000828 A1 DATE: 20000106
APPLICATION: WO 99US12820 (19990625) *US 90916 (19980626)
PAGES: 40 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: G01N-033/569A; G01N-033/50B
DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH;
CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; HR; HU; ID; IL; IN; IS; JP; KE;
KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ;
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN;
YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM;
; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;
NE; SN; TD; TG

8/3/136 (Item 32 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

131057772 CA: 131(5)57772f PATENT

Methods to treat undesirable immune responses

INVENTOR(AUTHOR): Conti-Fine, Bianca M.

LOCATION: USA

ASSIGNEE: Regents of the University of Minnesota

PATENT: PCT International ; WO 9930736 A2 DATE: 19990624

APPLICATION: WO 98US26787 (19981216) *US 991143 (19971216)

PAGES: 221 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

8/3/137 (Item 33 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

126130578 CA: 126(10)130578a PATENT

Oral tolerance in skin diseases presenting with T-cell mediated inflammation

INVENTOR(AUTHOR): Weiner, Howard L.; Kupper, Thomas S.; Chen, Youhai

LOCATION: USA

ASSIGNEE: Autoimmune, Inc.

PATENT: PCT International ; WO 9640232 A1 DATE: 19961219

APPLICATION: WO 96US10384 (19960605) *US 486190 (19950607)

PAGES: 28 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/00A; A61K-038/16B; A61K-038/17B; A61K-038/39B; A61K-045/00B; C07K-014/00B; C07K-014/435B; C07K-014/47B; C07K-014/78B; C12N-009/00B

DESIGNATED COUNTRIES: AU; BR; CA; HU; IL; JP; KR; NO

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

8/3/138 (Item 34 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

125026266 CA: 125(3)26266r PATENT

Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases

INVENTOR(AUTHOR): Meruelo, Daniel; Lavie, Gad

LOCATION: USA

ASSIGNEE: New York University

PATENT: United States ; US 5514714 A DATE: 960507

APPLICATION: US 39790 (930330) *US 572085 (900823) *US 784952 (911101)

PAGES: 21 pp. Cont.-in-part of U.S. Ser. No. 784, 952, abandoned.

CODEN: USXXAM LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: 514561000; A61K-031/195A; A61K-031/19B; A61K-031/12B

8/3/139 (Item 35 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

121170550 CA: 121(15)170550p PATENT
Method using Staphylococcus enterotoxin B for treating autoimmune diseases
INVENTOR(AUTHOR): Ochi, Atsuo
LOCATION: Can.,
ASSIGNEE: Mount Sinai Hospital Corp.
PATENT: Canada Pat Appl ; CA 2084120 AA DATE: 940531
APPLICATION: CA 2084120 (921130)
PAGES: 81 pp. CODEN: CPXKEB LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/085A

?
PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
? s s8 and py=2001		
	139	S8
	2343842	PY=2001
S9	3	S8 AND PY=2001
? t s9/7/all		

9/7/1 (Item 1 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

16399955 BIOSIS NO.: 200100571794
Induction of apoptosis, depletion of glutathione, and DNA damage by
extracorporeal photochemotherapy and psoralen with exposure to UV light
in vitro
AUTHOR: Efferth Thomas (Reprint); Fabry Ursula; Osieka Rainhardt
AUTHOR ADDRESS: Virtual Campus Rhineland-Palatinate, 55033, Mainz, Germany
**Germany
JOURNAL: Anticancer Research 21 (4A): p2777-2784 July-August, 2001
2001
MEDIUM: print
ISSN: 0250-7005
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Extracorporeal photochemotherapy (ECPT) is a novel
treatment for disorders caused by aberrant T
lymphocytes. The effects of ECPT were investigated in mononuclear
cells (MNC) of six patients suffering from either Sezary syndrome,
mycosis fungoides, systemic sclerosis, pemphigus vulgaris or
Hodgkin's disease. ECPT caused moderate to severe induction of apoptosis
and depletion of glutathione in the MNC of two out of these six patients.
The MNC were then treated with 8-methoxypsoralen (8-MOP) and UV light in

vitro and analyzed for apoptosis and glutathione levels. 8-MOP and UV light induced a profile of cellular alterations that is similar to ECTP. In addition, we measured DNA damage by means of a PCR-based methodology. As exemplified by the T-cell receptor-delta and glucose-6-phosphate dehydrogenase genes, DNA damage correlated with induction of apoptosis and depletion of glutathione. It is, therefore, reasonable to propose that UV-induced glutathione depletion contributes to DNA lesions which ultimately account for the onset of apoptosis.

9/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078511890 EMBASE No: 2001117978
Anti-CD20 monoclonal antibody (Rituximab) for refractory erosive stomatitis secondary to CD20 SUP + follicular lymphoma-associated paraneoplastic pemphigus
Borradori L.; Lombardi T.; Samson J.; Girardet C.; Saurat J.-H.; Hugli A. Department of Dermatology, University Hospital, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland
CORRESP. AUTHOR: Borradori L.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University Hospital, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland
CORRESP. AUTHOR EMAIL: Luca.Borradori@hcuge.ch

Archives of Dermatology (Arch. Dermatol.) (United States) May 12, 2001
137/3 (269-272)
CODEN: ARDEA ISSN: 0003987X
DOCUMENT TYPE: Journal; Article RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 23

9/7/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

135206452 CA: 135(15)206452p PATENT
Phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use
INVENTOR(AUTHOR): Nissim, Ahuva
LOCATION: Israel
PATENT: PCT International ; WO 200162908 A2 DATE: 20010830
APPLICATION: WO 20011120 (20010205) *US 510361 (20000222)
PAGES: 132 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/10A; C12N-015/11B; C12N-015/13B; C12N-015/62B;
C12N-015/85B; C12N-007/01B; C07K-014/705B; C07K-016/00B; C12Q-001/68B;
G01N-033/68B; A61K-038/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;
ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA203002 Biochemical Genetics
CA215XXX Immunochemistry

IDENTIFIERS: T cell receptor phage display library, Ig TCR fusion protein
 phage display library

DESCRIPTORS:

Spinal column...
 ankylosing spondylitis, TCR variants for diagnosis and treatment of
 autoimmune disease associated with; phage display libraries of T cell
 receptor and selection of T cell receptor reagents for diagnostic

Alopecia...
 areata, TCR variants for diagnosis and treatment of autoimmune disease
 associated with; phage display libraries of T cell receptor and selection
 of T cell receptor reagents for diagnostic and therapeutic

Thyroid gland,disease...
 autoimmune thyroiditis, TCR variants for diagnosis and treatment of
 autoimmune disease associated with; phage display libraries of T cell
 receptor and selection of T cell receptor reagents for diagnostic

Uterus,neoplasm...
 cervix, squamous cell carcinoma, TCR variants for diagnosis and
 treatment of autoimmune disease associated with; phage display libraries
 of T cell receptor and selection of T cell receptor reagents for d

CD8 (antigen)...
 complexes with MHC antigens, ligands of, for increasing avidity of T
 cell receptor derivs.; phage display libraries of T cell receptor and
 selection of T cell receptor reagents for diagnostic and ther

Skin,disease...
 epidermolysis bullosa, TCR variants for diagnosis and treatment of
 autoimmune disease associated with; phage display libraries of T cell
 receptor and selection of T cell receptor reagents for diagnostic

PCR (polymerase chain reaction)... Primers (nucleic acid)...
 for amplification of T cell receptor variable regions; phage display
 libraries of T cell receptor and selection of T cell receptor reagents
 for diagnostic and therapeutic use

DNA... RNA... Peptides,biological studies... Proteins,general,biological
 studies... Enzymes,biological studies... Carbohydrates,biological studies
 ... Glycosphingolipids... Fatty acids,biological studies...
 for increasing avidity of T cell receptor derivs.; phage display
 libraries of T cell receptor and selection of T cell receptor reagents
 for diagnostic and therapeutic use

Genetic vectors...
 for manufacture of T cell receptor variants; phage display libraries of T
 cell receptor and selection of T cell receptor reagents for diagnostic
 and therapeutic use

Immunoglobulins...
 fusion products, with T cell receptor, display libraries of; phage
 display libraries of T cell receptor and selection of T cell receptor
 reagents for diagnostic and therapeutic use

Kidney,disease...
 Goodpasture's syndrome, TCR variants for diagnosis and treatment of
 autoimmune disease associated with; phage display libraries of T cell
 receptor and selection of T cell receptor reagents for diagnostic

Immunoglobulins...
 heavy chains, fusion products with T cell receptor, display libraries
 of; phage display libraries of T cell receptor and selection of T cell
 receptor reagents for diagnostic and therapeutic use

Histocompatibility antigens...
 HLA, class I, TCR variants for diagnosis and treatment of autoimmune
 disease associated with; phage display libraries of T cell receptor and
 selection of T cell receptor reagents for diagnostic and thera

Diagnosis...
 immunodiagnosis, T cell receptor reagents for; phage display libraries
 of T cell receptor and selection of T cell receptor reagents for
 diagnostic and therapeutic use

Diabetes mellitus...
insulin-dependent, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and

Rheumatoid arthritis...
juvenile, pauciarticular, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic

Immunoglobulins...
light chains, fusion products with T cell receptor, display libraries of; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Histocompatibility antigens...
MHC (major histocompatibility complex), complexes with CD8 antigens, ligands of, for increasing avidity of T cell receptor derivs.; phage display libraries of T cell receptor and selection of T cell r

Sleep...
narcolepsy, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic

Nerve,disease...
optic, neuritis, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic

Plasmid vectors...
pCDV, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Skin,disease...
pemphigus vulgaris, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic

TCR(T cell receptors)... Phage display library...
phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...
pJS, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...
pNMV, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Biliary tract...
primary biliary cirrhosis, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic

Plasmid vectors...
pUC19-CK-CH1, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...
pUM19-CK-CH1, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Plasmid vectors...
p1PP12, for manufacture of T cell receptor variants; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use

Arthritis...
Reiter's syndrome, TCR variants for diagnosis and treatment of

autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and Lupus erythematosus...
systemic, TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic Immunotherapy...
T cell receptor variants for; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use
Behcet's syndrome... Rheumatoid arthritis... Sjogren's syndrome... Addison's disease... Graves' disease... Celiac disease... Hodgkin's disease ... Multiple sclerosis... Myasthenia gravis...
TCR variants for diagnosis and treatment of autoimmune disease associated with; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use
Autoimmune disease...
TCR variants for diagnosis and treatment of; phage display libraries of T cell receptor and selection of T cell receptor reagents for diagnostic and therapeutic use
CAS REGISTRY NUMBERS:
358018-07-2 358018-08-3 358018-09-4 358018-10-7 358018-11-8
358018-12-9 358018-13-0 358018-14-1 358018-15-2 358018-16-3
358018-17-4 358018-18-5 358018-19-6 358018-20-9 357141-59-4
357141-60-7 357141-61-8 357141-62-9 358018-21-0 357141-64-1
358018-22-1 357141-66-3 357141-67-4 358018-23-2 357141-69-6
357141-71-0 357141-72-1 357141-73-2 357141-75-4 358018-24-3
357141-77-6 357141-78-7 357141-79-8 358018-25-4 358018-26-5
358018-27-6 357141-83-4 357141-84-5 357141-85-6 357141-86-7
357141-87-8 357141-88-9 357141-89-0 357141-90-3 357141-91-4
357141-92-5 357141-93-6 357141-94-7 357141-95-8 357141-96-9
unclaimed nucleotide sequence; phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use
357141-70-9 357141-74-3 160573-53-5 167731-68-2 unclaimed sequence; phage display libraries of the T cell receptor and the selection of T cell receptor reagents for diagnostic and therapeutic use
? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
S9	3	S8 AND PY=2001
? s s8 and (review? or overview?)		
>>>File 5 processing for REVIEW? stopped at REVIEW MONKEY CAT		
	139	S8
	4910206	REVIEW?
	149848	OVERVIEW?
S10	31	S8 AND (REVIEW? OR OVERVIEW?)
? t s10/3/all		

10/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

12658117 BIOSIS NO.: 199598125950
Review of immunomodulation by photopheresis: Treatment of cutaneous
T-cell lymphoma, autoimmune disease, and allograft rejection
AUTHOR: Wolfe Jonathan T; Lessin Stuart R; Singh Anjali H; Rook Alain H
(Reprint)
AUTHOR ADDRESS: Dep. Dermatol., Hosp. Univ. Pennsylvania, 3400 Spruce St.,
Philadelphia, PA 19104, USA**USA
JOURNAL: Artificial Organs 18 (12): p888-897 1994 1994
ISSN: 0160-564X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

10/3/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047
The selective immunotherapy of pemphigus
Bystryn J.C.; Czernik A. // Bystryn J.C.
Ronald O. Perelman Department of Dermatology, New York University School
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st
Avenue, New York, NY 10016, United States
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu
CORRESP. AUTHOR: Bystryn J.C.
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY
10016, United States
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia (G. Ital. Dermatol.
Venereol.) (Italy) August 1, 2007, 142/4 (381-390)
CODEN: GIDVD ISSN: 00264741
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English; Italian
NUMBER OF REFERENCES: 63

10/3/3 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081949325 EMBASE No: 2007383664
Red blood cell anemia in a patient with pemphigus vulgaris induced by the
use of mycophenolate mofetil and prednisone
Scheinfeld N. // Scheinfeld N.
Department of Dermatology, St. Luke's-Roosevelt, New York, NY USA //
Department of Dermatology, St. Luke's-Roosevelt, 1090 Amsterdam Ave, New
York, NY 10025, United States
AUTHOR EMAIL: NSS32@columbia.edu; NSS32@columbia.edu
CORRESP. AUTHOR: Scheinfeld N.
CORRESP. AUTHOR AFFIL: Department of Dermatology, St. Luke's-Roosevelt,
1090 Amsterdam Ave, New York, NY 10025, United States
CORRESP. AUTHOR EMAIL: NSS32@columbia.edu

Journal of Dermatological Treatment (J. Dermatol. Treat.) (United
Kingdom) September 5, 2007, 18/4 (243-245)
CODEN: JDIRE ISSN: 09546634 eISSN: 14711753

PUBLISHER ITEM IDENTIFIER: 779333677
DOI: 10.1080/09546630701287324
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 9

10/3/4 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081810060 EMBASE No: 2007244126
Role of regulatory T cells in the development of skin diseases
Lima H.C. // Lima H.C. // Lima H.C.
Department of Pathology, Universidade Federal do Parana - UFPR, Curitiba
(PR), Brazil // Service of Dermatology and Research Nucleus in
Immunodermatology and Clinical Immunology, Universidade Federal do Parana
- UFPR, Curitiba (PR), Brazil // Rua XV de Novembro, 1206, 80060-000 -
Curitiba - PR
AUTHOR EMAIL: hclima@ufpr.br; hclima@ufpr.br; hclima@ufpr.br
CORRESP. AUTHOR: Lima H.C.
CORRESP. AUTHOR AFFIL: Rua XV de Novembro, 1206, 80060-000 - Curitiba -
PR
CORRESP. AUTHOR EMAIL: hclima@ufpr.br

Anais Brasileiros de Dermatologia (An. Bras. Dermatol.) (Brazil) May
1, 2006, 81/3 (269-281)
CODEN: ABDEB ISSN: 03650596 eISSN: 18064841
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English; Portuguese
NUMBER OF REFERENCES: 121

10/3/5 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081779408 EMBASE No: 2007213412
Therapy of autoimmune bullous diseases
Mutasim D.F.
Department of Dermatology, University of Cincinnati College of Medicine,
231 Albert Sabin Way, Cincinnati, OH 45267-0592, United States
AUTHOR EMAIL: diya.mutasim@uc.edu
CORRESP. AUTHOR: Mutasim D.F.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH
45267-0592, United States
CORRESP. AUTHOR EMAIL: diya.mutasim@uc.edu

Therapeutics and Clinical Risk Management (Ther. Clin. Risk Manage.) (New Zealand) May 30, 2007, 3/1 (29-40)
ISSN: 11766336
DOI: 10.2147/tcrm.2007.3.1.29
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 139

10/3/6 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081682257 EMBASE No: 2007115834
Complications and Adverse Reactions in the Use of Newer Biologic Agents
ISSUE TITLE: Complications and Adverse Events
Callen J.P.
Division of Dermatology, University of Louisville, Louisville, KY, United States
AUTHOR EMAIL: jefca@aol.com
CORRESP. AUTHOR: Callen J.P.
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville, Louisville, KY, United States
CORRESP. AUTHOR EMAIL: jefca@aol.com

Seminars in Cutaneous Medicine and Surgery (Semin. Cutaneous Med. Surg.
) (United States) March 1, 2007, 26/1 (6-14)
CODEN: SCMSF ISSN: 10855629
PUBLISHER ITEM IDENTIFIER: S108556290600112X
DOI: 10.1016/j.sder.2006.12.002
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
CLINICAL TRIALS NUMBER: NCT00051662--ClinicalTrials.gov; NCT00302445--
ClinicalTrials.gov
NUMBER OF REFERENCES: 84

10/3/7 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081503650 EMBASE No: 2006567099
Paraneoplastic autoimmune multiorgan syndrome: Review of the
literature and support for a cytotoxic role in pathogenesis
ISSUE TITLE: Immunology of Pemphigus and Treatment
Billet S.E.; Pittelkow M.R. // Grando S.A.
Department of Dermatology, Mayo Clinic, Rochester, MN, United States //
University of California Davis, Sacramento, CA, United States
CORRESP. AUTHOR: Pittelkow M.R.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Mayo Clinic, Rochester,
MN, United States

Autoimmunity (Autoimmunity) (United Kingdom) November 1, 2006, 39/7
(617-630)
CODEN: AUIME ISSN: 08916934 eISSN: 1607842X
PUBLISHER ITEM IDENTIFIER: U501856727X93457
DOI: 10.1080/08916930600972099
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 123

10/3/8 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081384356 EMBASE No: 2006447143
Inosine 5prime-monophosphate dehydrogenase inhibitors for the treatment
of autoimmune diseases
Ratcliffe A.J.
UCB, Granta Park, Great Abington, Cambridge CB1 6GS, United Kingdom
AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com
CORRESP. AUTHOR: Ratcliffe A.J.

CORRESP. AUTHOR AFFIL: UCB, Granta Park, Great Abington, Cambridge CB1
6GS, United Kingdom
CORRESP. AUTHOR EMAIL: andrew.ratcliffe@ucb-group.com

Current Opinion in Drug Discovery and Development (Curr. Opin. Drug
Discov. Dev.) (United Kingdom) September 1, 2006, 9/5 (595-605)
CODEN: CODDF ISSN: 13676733
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 55

10/3/9 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081248610 EMBASE No: 2006310874
B cells move to centre stage: Novel opportunities for autoimmune disease
treatment
Browning J.L.
Department of Immunobiology, Biogen Idec, 12 Cambridge Center, Cambridge,
MA 02445, United States
AUTHOR EMAIL: Jeff.Browning@biogenidec.com
CORRESP. AUTHOR: Browning J.L.
CORRESP. AUTHOR AFFIL: Department of Immunobiology USA, Biogen Idec, 12
Cambridge Center, Cambridge, MA 02445, United States
CORRESP. AUTHOR EMAIL: Jeff.Browning@biogenidec.com

Nature Reviews Drug Discovery (Nat. Rev. Drug Discov.) (United Kingdom)
July 1, 2006, 5/7 (564-576)
CODEN: NRDDA ISSN: 14741776 eISSN: 14741784
PUBLISHER ITEM IDENTIFIER: N2085
DOI: 10.1038/nrd2085
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 173

10/3/10 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081074574 EMBASE No: 2006134669
Pemphigus: Pathogenic mechanisms and potential therapeutic targets
Powell A.-M.; Black M.M.
Department of Immunodermatology, St. John's Institute of Dermatology, St.
Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, United Kingdom
AUTHOR EMAIL: martin.black@kcl.ac.uk
CORRESP. AUTHOR: Black M.M.
CORRESP. AUTHOR AFFIL: Department of Immunodermatology, St. John's
Institute of Dermatology, St. Thomas' Hospital, Lambeth Palace Road,
London SE1 7EH, United Kingdom
CORRESP. AUTHOR EMAIL: martin.black@kcl.ac.uk

Drug Discovery Today: Disease Mechanisms (Drug Discov.Today Dis. Mech.)
(United Kingdom) December 1, 2005, 2/2 (269-274)
ISSN: 17406765
PUBLISHER ITEM IDENTIFIER: S1740676505000301
DOI: 10.1016/j.ddmec.2005.05.023
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 39

10/3/11 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081049234 EMBASE No: 2006109249
Regulatory T cells
Beissert S. // Schwarz A.; Schwarz T. // Schwarz T.
Department of Dermatology, University of Munster, Munster, Germany //
Department of Dermatology, University of Kiel, Kiel, Germany //
Department of Dermatology, University of Kiel, Schittenhelmstrasse 7,
D-24105 Kiel, Germany
AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de;
tschwarz@dermatology.uni-kiel.de
CORRESP. AUTHOR: Schwarz T.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Kiel,
Schittenhelmstrasse 7, D-24105 Kiel, Germany
CORRESP. AUTHOR EMAIL: tschwarz@dermatology.uni-kiel.de

Journal of Investigative Dermatology (J. Invest. Dermatol.) (United
States) January 1, 2006, 126/1 (15-24)
CODEN: JIDEA ISSN: 0022202X eISSN: 15231747
PUBLISHER ITEM IDENTIFIER: 5700004
DOI: 10.1038/sj.jid.5700004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 89

10/3/12 (Item 11 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081040121 EMBASE No: 2006100121
Biologic therapies in autoimmune diseases
Penn H. // Penn H.
Royal Free Hospital, London, United Kingdom // Department of
Rheumatology, Royal Free Hospital, London NW3 2QG, United Kingdom
AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk; h.penn@medsch.ucl.ac.uk
CORRESP. AUTHOR: Penn H.
CORRESP. AUTHOR AFFIL: Department of Rheumatology, Royal Free Hospital,
London NW3 2QG, United Kingdom
CORRESP. AUTHOR EMAIL: h.penn@medsch.ucl.ac.uk

Clinical Medicine, Journal of the Royal College of Physicians of London (
Clin. Med. J. R. Coll. Phys. Lond.) (United Kingdom) January 1, 2006,
6/1 (105-108)
CODEN: CMLUB ISSN: 14702118
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 6

10/3/13 (Item 12 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080905189 EMBASE No: 2005550132
Number V. Oral lichen planus: Clinical features and management

Eisen D. // Carrozzo M. // Sebastian J.-V.B. // Thongprasom K. // Eisen D.
Dermatology Research Associates, Cincinnati, OH, United States //
Department of Biomedical Sciences and Human Oncology, Oral Medicine,
University of Turin, Turin, Italy // Hospital General Universitario de
Valencia, Valencia, Spain // Oral Medicine Department, Chulalongkorn
University, Bangkok, Thailand // Dermatology Research Associates, 7691
Five Mile Road, Cincinnati, OH 45230, United States
AUTHOR EMAIL: drore@eos.net; drore@eos.net
CORRESP. AUTHOR: Eisen D.
CORRESP. AUTHOR AFFIL: Dermatology Research Associates, 7691 Five Mile
Road, Cincinnati, OH 45230, United States
CORRESP. AUTHOR EMAIL: drore@eos.net

Oral Diseases (Oral Dis.) (Denmark) November 1, 2005, 11/6 (338-349)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01142.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 146

10/3/14 (Item 13 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080904290 EMBASE No: 2005549233
Apoptosis in normal and diseased oral tissues
Loro L.L.; Johannessen A.C. // Vintermyr O.K. // Loro L.L.
Department of Odontology-Oral Pathology and Forensic Odontology,
University of Bergen, Bergen, Norway // Department of Pathology,
Haukeland University Hospital, University of Bergen, Bergen, Norway //
Department of Odontology-Oral Pathology and Forensic Odontology, Gade
Institute, Haukeland University Hospital, N5021 Bergen, Norway
AUTHOR EMAIL: lado.loro@gades.uib.no; lado.loro@gades.uib.no
CORRESP. AUTHOR: Loro L.L.
CORRESP. AUTHOR AFFIL: Department of Odontology-Oral Pathology and
Forensic Odontology, Gade Institute, Haukeland University Hospital, N5021
Bergen, Norway
CORRESP. AUTHOR EMAIL: lado.loro@gades.uib.no

Oral Diseases (Oral Dis.) (Denmark) September 1, 2005, 11/5 (274-287)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01117.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 163

10/3/15 (Item 14 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080904288 EMBASE No: 2005549231
Number IV: Erythema multiforme
Farthing P. // Bagan J.-V. // Scully C. // Scully C.
Charles Clifford Dental School, University of Sheffield, Sheffield,
United Kingdom // University Hospital, University of Valencia, Spain //
Eastman Dental Institute, University College London, London, United
Kingdom // Eastman Dental Institute, University College London, 256 Gray's
Inn Road, London WC1X 8LD, United Kingdom

AUTHOR EMAIL: cscully@eastman.ucl.ac.uk; cscully@eastman.ucl.ac.uk
CORRESP. AUTHOR: Scully C.
CORRESP. AUTHOR AFFIL: Eastman Dental Institute, University College
London, 256 Grays Inn Road, London WC1X 8LD, United Kingdom
CORRESP. AUTHOR EMAIL: cscully@eastman.ucl.ac.uk

Oral Diseases (Oral Dis.) (Denmark) September 1, 2005, 11/5 (261-267)
CODEN: ORDIF ISSN: 1354523X
DOI: 10.1111/j.1601-0825.2005.01141.x
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 45

10/3/16 (Item 15 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080886863 EMBASE No: 2005531783
Mycophenolate mofetil
Heymann W.R.
Affiliation unspecified.

Journal of the American Academy of Dermatology (J. Am. Acad. Dermatol.)
(United States) December 1, 2005, 53/6 (1045-1046)
CODEN: JAADD ISSN: 01909622
PUBLISHER ITEM IDENTIFIER: S0190962205026782
DOI: 10.1016/j.jaad.2005.08.034
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 8

10/3/17 (Item 16 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080779838 EMBASE No: 2005424454
An approach to the patient with a recalcitrant dermatosis
Callen J.P.
Division of Dermatology, University of Louisville, School of Medicine,
Louisville, KY 40202, United States
AUTHOR EMAIL: jefca@aol.com
CORRESP. AUTHOR: Callen J.P.
CORRESP. AUTHOR AFFIL: Division of Dermatology, University of Louisville,
School of Medicine, Louisville, KY 40202, United States
CORRESP. AUTHOR EMAIL: jefca@aol.com

Clinics in Dermatology (Clin. Dermatol.) (United States) September 1,
2005, 23/5 (528-531)
CODEN: CLDEE ISSN: 0738081X
PUBLISHER ITEM IDENTIFIER: S0738081X05000623
DOI: 10.1016/j.clindermatol.2005.04.004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

10/3/18 (Item 17 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080659445 EMBASE No: 2005303751

Auto-immune manifestations in non-Hodgkin's lymphoma
Manifestations dysimmunitaires associees aux lymphomes
Jardin F.; Tilly H. // Levesque H.
Departement d'Hematologie Clinique et Groupe d'Etude des Syndromes
Lymphoproliferatifs, Inserm U164, Centre Henri-Becquerel, 76000 Rouen,
France // Departement de Medecine Interne, Centre Hospitalier
Universitaire de Rouen, Hopital de Bois-Guillaume, Rouen, France
AUTHOR EMAIL: fabrice.jardin@rouen.fncclcc.fr
CORRESP. AUTHOR: Jardin F.
CORRESP. AUTHOR AFFIL: Departement d'Hematologie Clinique et Groupe
d'Etude des Syndromes Lymphoproliferatifs, Inserm U164, Centre
Henri-Becquerel, 76000 Rouen, France
CORRESP. AUTHOR EMAIL: fabrice.jardin@rouen.fncclcc.fr

Revue de Medecine Interne (Rev. Med. Interne) (France) July 1, 2005,
26/7 (557-571)
CODEN: RMEID ISSN: 02488663
PUBLISHER ITEM IDENTIFIER: S024886630400459X
DOI: 10.1016/j.revmed.2004.11.011
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: French SUMMARY LANGUAGE: English; French
NUMBER OF REFERENCES: 169

10/3/19 (Item 18 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080301596 EMBASE No: 2004487365

The role of pathogenic B-cell clones in antibody mediated autoimmune
disorders
Wang J.; Zhu X.
Department of Dermatology, Peking University First Hospital, #8, Xishiku
St., Beijing 100034, C.
AUTHOR EMAIL: zhuxj@public.bta.net.cn
CORRESP. AUTHOR AFFIL: Department of Dermatology, Peking University First
Hospital, #8, Xishiku St., Beijing 100034, C.
CORRESP. AUTHOR EMAIL: zhuxj@public.bta.net.cn

Journal of Dermatological Science (J. Dermatol. Sci.) (Ireland)
December 1, 2004, 36/3 (141-148)
CODEN: JDSCE ISSN: 09231811
PUBLISHER ITEM IDENTIFIER: S0923181104001367
DOI: 10.1016/j.jdermsci.2004.07.004
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 59

10/3/20 (Item 19 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079476456 EMBASE No: 2003181862

Cytokines and chemokines in autoimmune disease: An overview
Santamaria P. // Santamaria P.
University of Calgary, Dept. Microbiol./Infect. Disease, Health Sciences
Centre, Calgary, Alta., Canada // Dept. of Microbiol./Infect. Diseases,
Faculty of Medicine, University of Calgary, Calgary, Alta., Canada
CORRESP. AUTHOR: Santamaria P.

CORRESP. AUTHOR AFFIL: Dept. of Microbiol./Infect. Diseases, Faculty of Medicine, University of Calgary, Calgary, Alta., Canada

Advances in Experimental Medicine and Biology (Adv. Exp. Med. Biol.) (United States) May 17, 2003, 520/- (1-7)
CODEN: AEMBA ISSN: 00652598
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English
NUMBER OF REFERENCES: 14

10/3/21 (Item 20 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0079378560 EMBASE No: 2003082264
11. Allergic and immunologic diseases of the skin
Blauvelt A.; Hwang S.T.; Udey M.C. // Blauvelt A.
Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States // Dermatology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr MSC 1908, Bethesda, MD 20892-1908, United States
CORRESP. AUTHOR: Blauvelt A.
CORRESP. AUTHOR AFFIL: Dermatology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Dr MSC 1908, Bethesda, MD 20892-1908, United States

Journal of Allergy and Clinical Immunology (J. Allergy Clin. Immunol.) (United States) February 1, 2003, 111/2 SUPPL. 2 (S560-S570)
CODEN: JACIB ISSN: 00916749
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 64

10/3/22 (Item 21 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078409135 EMBASE No: 2001014946
Recent advances in phototherapy
Simon J.C.; Pflieger D.; Schopf E.
Department of Dermatology, University of Freiburg, Hauptstr. 7, Freiburg 79104, Germany
CORRESP. AUTHOR: Simon J.C.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of Freiburg, Hauptstr. 7, Freiburg 79104, Germany
CORRESP. AUTHOR EMAIL: simonj@haut.ukl.uni-freiburg.de

European Journal of Dermatology (Eur. J. Dermatol.) (France) December 1, 2000, 10/8 (642-644)
CODEN: EJDEE ISSN: 11671122
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 44

10/3/23 (Item 22 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078048898 EMBASE No: 2000098144

Extracorporeal photopheresis: 4 years of experience in Geneva
Photopherese extracorporelle: Quatre ans d'experience a geneve
Prins C.; Laroutis M.R.; Blondel F.; Bouvier M.; Saurat J.-H.
Clinique de Dermatologie, Hopital Cantonal Universitaire, 1211 Geneve 14,
Switzerland

CORRESP. AUTHOR: Prins C.

CORRESP. AUTHOR AFFIL: Clinique de Dermatologie, Hopital Cantonal
Universitaire, 1211 Geneve 14, Switzerland

Medecine et Hygiene (Med. Hyg.) (Switzerland) March 8, 2000, 58/2291
(554-559)

CODEN: MEHGA ISSN: 00256749

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: French SUMMARY LANGUAGE: English; French

NUMBER OF REFERENCES: 11

10/3/24 (Item 23 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0077861651 EMBASE No: 1999347983

HLA class II restriction of autoreactive T cell responses in pemphigus
vulgaris: Review of the literature and potential applications for the
development of a specific immunotherapy

Riechers R.; Hertl M. // Grotzinger J.

Department of Dermatology, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen
, Germany // Institute of Biochemistry, RWTH Aachen, Pauwelsstrasse 30,
D-52074 Aachen, Germany

CORRESP. AUTHOR: Riechers R.

CORRESP. AUTHOR AFFIL: Department of Dermatology, RWTH Aachen,
Pauwelsstrasse 30, D-52074 Aachen, Germany

Autoimmunity (Autoimmunity) (United Kingdom) October 19, 1999, 30/3
(183-196)

CODEN: AUIME ISSN: 08916934

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 67

10/3/25 (Item 24 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2008 Elsevier B.V. All rts. reserv.

0077306883 EMBASE No: 1998217045

Unresponsive discoid lupus erythematosus successfully controlled by
extracorporeal photopheresis

Extracorporelle Photopherese bei therapieresistentem disseminiert
diskoidem Lupus erythematosus (DDLE)

Richter H.I.; Krutmann J.; Goerz G. // Krutmann J.

Hautklinik, Heinrich-Heine-Universitat, Dusseldorf, Germany // Klinische
und Experimentelle Photodermatologie, Hautklinik,
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Dusseldorf,
Germany

CORRESP. AUTHOR: Krutmann J.

CORRESP. AUTHOR AFFIL: Klin./Experimentelle Photodermatol., Hautklinik,
Heinrich-Heine-Universitätskliniken, Moorenstrasse 5, D-40225 Dusseldorf,
Germany

Hautarzt (Hautarzt) (Germany) June 1, 1998, 49/6 (487-491)
CODEN: HAUTA ISSN: 00178470
DOI: 10.1007/s001050050775
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English; German
NUMBER OF REFERENCES: 25

10/3/26 (Item 25 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075944690 EMBASE No: 1994352172
Extracorporeal photopheresis
EXTRAKORPORALE PHOTOPHERESE
Prinz B.; Plewig G.
Dermatologische Klinik/Poliklinik, Ludwig-Maximilians-Universitat,
Frauenlobstrasse 9-11, D-80337 Munchen, Germany
CORRESP. AUTHOR: Prinz B.
CORRESP. AUTHOR AFFIL: Dermatologische Klinik/Poliklinik,
Ludwig-Maximilians-Universitat, Frauenlobstrasse 9-11, D-80337 Munchen,
Germany

Hautarzt (HAUTARTZ) (Germany) December 21, 1994, 45/11 (746-750)
CODEN: HAUTA ISSN: 00178470
DOI: 10.1007/s001050050164
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English; German

10/3/27 (Item 26 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075943261 EMBASE No: 1994360240
Photopheresis: Report of cases and review of the literature
FOTOFERESIS: REPORTE DE CASOS Y REVISION DE LA LITERATURA
Bogaert M.A.; Sisto M.; Kerdel F.A.
Dept. Dermatology/Cutaneous Surgery, University of Miami, School of
Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United States
CORRESP. AUTHOR: Kerdel F.A.
CORRESP. AUTHOR AFFIL: Dept. Dermatology/Cutaneous Surgery, University of
Miami, School of Medicine, 1600 N.W. 10th Avenue, Miami, FL 33136, United
States

Medicina Cutanea Ibero-Latino-Americana (MED. CUTANEA IBERO-LAT.-AM.) (Spain)
December 1, 1994, 22/6 (278-283)
CODEN: MCILB ISSN: 02105187
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Spanish SUMMARY LANGUAGE: English; Spanish

10/3/28 (Item 27 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651
Autoimmunity as a complication of interleukin 2 immunotherapy: Many
unanswered questions
Gaspari A.A.
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood

Ave, New York, NY 14642, United States
CORRESP. AUTHOR: Gaspari A.A.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States

Archives of Dermatology (ARCH. DERMATOL.) (United States) August 5,
1994, 130/7 (894-897)
CODEN: ARDEA ISSN: 0003987X
DOI: 10.1001/archderm.130.7.894
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

10/3/29 (Item 28 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075803474 EMBASE No: 1994190202
Extracorporeal photopheresis
Gross M.; Boh E.E.; Millikan L.E.
Department of Dermatology, Tulane University Medical Center, 1430 Tulane
Avenue, New Orleans, LA 70112, United States
CORRESP. AUTHOR: Gross M.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Tulane University
Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112, United States

International Journal of Dermatology (INT. J. DERMATOL.) (Canada)
August 8, 1994, 33/6 (407-411)
CODEN: IJDEB ISSN: 00119059
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

10/3/30 (Item 29 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075450186 EMBASE No: 1993229742
Pemphigus vulgaris and vegetans
Becker B.A.; Gaspari A.A.
Department of Dermatology, University of Rochester, School of
Medicine/Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, United
States
CORRESP. AUTHOR: Gaspari A.A.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Rochester, School of Medicine/Dentistry, 601 Elmwood Avenue, Rochester,
NY 14642, United States

Dermatologic Clinics (DERMATOL. CLIN.) (United States) August 23, 1993
, 11/3 (429-452)
CODEN: DRMCD ISSN: 07338635
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

10/3/31 (Item 30 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0070392933 EMBASE No: 1975176789
'Opportunistic' auto immune disease and 'opportunistic' malignancy from

impaired cell mediated immunity?

Cairns R.J.

St Bartholomew's Hosp., Rochester, United Kingdom

CORRESP. AUTHOR AFFIL: St Bartholomew's Hosp., Rochester, United Kingdom

British Journal of Dermatology (BR. J. DERMATOL.) December 1, 1974,
91/5 (601-602)

CODEN: BJDEA ISSN: 00070963

DOCUMENT TYPE: Journal RECORD TYPE: Citation

LANGUAGE: English

? ds

Set	Items	Description
S1	209	E2,E3
S2	267	E1,E2
S3	2	(S1 OR S2) AND (PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR - CD154 OR GP39 OR CD154)
S4	1	RD S3 (unique items)
S5	37	(PEMPHIGUS) AND (CD40L OR CD40(W)LIGAND OR CD154 OR GP39 OR CD154)
S6	25	RD S5 (unique items)
S7	185	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP- ?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?)
S8	139	RD S7 (unique items)
S9	3	S8 AND PY=2001
S10	31	S8 AND (REVIEW? OR OVERVIEW?)
? s (pemphigus) (20n) (inhibit? or suppress? or treat? or therap?) (20n) (cd4? or t(w)cell? or t(w)lymphocyte?) (20n) (antibod?)		
>>>File 5 processing for CELL? stopped at CELLULLASE		
Processing		
Processing		
Processing		
Processing		
Processing		
Processing		
	18072	PEMPHIGUS
	5242236	INHIBIT?
	1100686	SUPPRESS?
	8765477	TREAT?
	8195076	THERAP?
	376008	CD4?
	2212549	T
	13302071	CELL?
	815677	T(W)CELL?
	2212549	T
	1329311	LYMPHOCYTE?
	542775	T(W)LYMPHOCYTE?
	2323344	ANTIBOD?
S11	51	(PEMPHIGUS) (20N) (INHIBIT? OR SUPPRESS? OR TREAT? OR THERAP?) (20N) (CD4? OR T(W)CELL? OR T(W)LYMPHOCYTE?) (20N) (ANTIBOD?)

? rd s11

S12 34 RD S11 (unique items)

? t s12/3/all

12/3/1 (Item 1 from file: 5)

DIALOG(R)File 5: Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rts. reserv.

19227223 BIOSIS NO.: 200600572618

Polymorphism of the promoter region and exon 1 of the CTLA4 gene in endemic

pemphigus foliaceus (fogo selvagem)
AUTHOR: Pavoni D P; Cerqueira L B; Roxo V M M S; Petzl-Erler M L (Reprint)
AUTHOR ADDRESS: Univ Fed Parana, Dept Genet, Lab Genet Mol Humana,
BR-81531990 Curitiba, Parana, Brazil**Brazil
AUTHOR E-MAIL ADDRESS: perler@ufpr.br
JOURNAL: Brazilian Journal of Medical and Biological Research 39 (9): p
1227-1232 SEP 2006 2006
ISSN: 0100-879X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

18897249 BIOSIS NO.: 200600242644
Serum antidesmoglein-3 antibodies in patients with pemphigus before and
after therapy
AUTHOR: Matushevskaya E V; Svirshchevskaya E V; Dzutseva I R; Togoeva L T;
Lapshina T P
JOURNAL: Vestnik Dermatologii i Venerologii (6): p12-16 2005 2005
ISSN: 0042-4609
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: Russian

12/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

17781306 BIOSIS NO.: 200400147967
Immune reconstitution after autologous CD34 cell transplantation for
autoimmune diseases.
AUTHOR: Storek Jan (Reprint); Zhao Zhao (Reprint); Dawson Monja A (Reprint)
; Sunderhaus Julie (Reprint); McSweeney Peter A (Reprint); Nash Richard A
(Reprint); Sullivan Keith M (Reprint); Furst Daniel E (Reprint); Kraft
George H (Reprint); Wener Mark H (Reprint); Lu Hailing (Reprint); Maloney
David G (Reprint)
AUTHOR ADDRESS: Fred Hutchinson Cancer Research Center and University of
Washington, Seattle, WA, USA**USA
JOURNAL: Blood 102 (11): p715a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

12/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

15406625 BIOSIS NO.: 200000124938
The use of chlorambucil with prednisone in the treatment of pemphigus
AUTHOR: Shah Neha; Green Andy R; Elgart George W; Kerdel Francisco

(Reprint)

AUTHOR ADDRESS: Department of Dermatology and Cutaneous Surgery, University
of Miami School of Medicine, Miami, FL, 33101, USA**USA
JOURNAL: Journal of the American Academy of Dermatology 42 (1 Part 1): p
85-88 Jan., 2000 2000
MEDIUM: print
ISSN: 0190-9622
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

14434848 BIOSIS NO.: 199800229095

Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3
specific T cell responses in pemphigus vulgaris patients and normals
AUTHOR: Hertl Michael; Karr Robert W; Amagai Masayuki; Katz Stephen I
AUTHOR ADDRESS: Hautklin., Universitaetsklinikum der RWTH, Pauwelsstr. 30,
D-52072 Aachen, Germany**Germany
JOURNAL: Journal of Investigative Dermatology 110 (4): p388-392 April,
1998 1998
MEDIUM: print
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13932220 BIOSIS NO.: 199799566280

Gelatinases A and B are expressed in late lesions in autoimmune bullous
disorders
AUTHOR: Feliciani C (Reprint); Toto P; Coscione G; Pour S Mohammad;
Allegretti T; Proietto G; Amerio P
AUTHOR ADDRESS: Clinica Dermatol., Universita "G.d'Annunzio", 66013 Chieti,
Italy**Italy
JOURNAL: International Journal of Immunopathology and Pharmacology 10 (1):
p103-105 1997 1997
ISSN: 0394-6320
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

13236989 BIOSIS NO.: 199698704822

Long-term interferon-alpha therapy induces autoantibodies against epidermis
AUTHOR: Fleischmann M; Celerier P; Bernard P; Litoux P; Dreno B (Reprint)
AUTHOR ADDRESS: Dep. Dermatol., Hotel-Dieu, Pl. A. Ricordeau, F-44035
Nantes Cedex 01, France**France
JOURNAL: Dermatology (Basel) 192 (1): p50-55 1996 1996
ISSN: 1018-8665

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

12/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

09634928 BIOSIS NO.: 198987082819
THE MECHANISMS OF THE THERAPEUTIC ACTION OF EXTRACORPOREAL DETOXIFICATION
IN AUTOIMMUNE BULLOUS DERMATOSES
AUTHOR: GRANDO S A (Reprint); GLUKHEN'KII B T; ROMANENKO A B; CHAYUN O A;
DOLYA S V
AUTHOR ADDRESS: DIV DERMATOL VENEROL, KIEV INST POSTGRAD MED, KIEV, USSR**
USSR
JOURNAL: Vestnik Dermatologii i Venerologii (7): p6-11 1988
ISSN: 0042-4609
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: RUSSIAN

12/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08744158 BIOSIS NO.: 198784098307
T AND B-LYMPHOCYTES IN PEMPHIGUS VULGARIS A CLINICO-IMMUNOLOGICAL FOLLOW-UP
STUDY OF FIFTY PATIENTS WITH PEMPHIGUS VULGARIS
AUTHOR: MASHKILLEYSON N (Reprint)
AUTHOR ADDRESS: DEP DERMATOL, HELSINKI UNIV CENTRAL HOSP, SNELLMANINKATU
14, SF-00170 HELSINKI 17, FINLAND**FINLAND
JOURNAL: Acta Dermato-Venereologica 67 (3): p218-224 1987
ISSN: 0001-5555
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

12/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

08618769 BIOSIS NO.: 198783097660
MONONUCLEAR CELL INFILTRATES IN BULLOUS DISEASE
AUTHOR: NESTOR M S (Reprint); COCHRAN A J; AHMED A R
AUTHOR ADDRESS: DIV SURG ONCOL, 9-267 LOUIS FACTOR BUILD, UCLA SCH MED, LOS
ANGELES, CALIF 90024, USA**USA
JOURNAL: Journal of Investigative Dermatology 88 (2): p172-175 1987
ISSN: 0022-202X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

12/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2008 The Thomson Corporation. All rts. reserv.

06996601 BIOSIS NO.: 198376088036

PRODUCTION OF PEMPHIGUS ANTIBODY IN-VITRO AND ANALYSIS OF T CELL SUBSETS
AUTHOR: AHMED A R (Reprint); MURAHATA R I; SCHROFF R W; STEVENS R M; SAXON
A S
AUTHOR ADDRESS: DIVISION OF DERMATOLOGY, DEPARTMENT OF MEDICINE, UCLA
SCHOOL OF MEDICINE, LOS ANGELES, CALIFORNIA 90024, USA**USA
JOURNAL: Journal of Clinical Immunology 3 (3): p241-252 1983
ISSN: 0271-9142
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

12/3/12 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0082112095 EMBASE No: 2007548047
The selective immunotherapy of pemphigus
Bystryn J.C.; Czernik A. // Bystryn J.C.
Ronald O. Perelman Department of Dermatology, New York University School
of Medicine, New York, NY, United States // NYU Medical Center, 560 1st
Avenue, New York, NY 10016, United States
AUTHOR EMAIL: bystryn@nyu.edu; bystryn@nyu.edu
CORRESP. AUTHOR: Bystryn J.C.
CORRESP. AUTHOR AFFIL: NYU Medical Center, 560 1st Avenue, New York, NY
10016, United States
CORRESP. AUTHOR EMAIL: bystryn@nyu.edu

Giornale Italiano di Dermatologia e Venereologia (G. Ital. Dermatol.
Venereol.) (Italy) August 1, 2007, 142/4 (381-390)
CODEN: GIDVD ISSN: 00264741
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English; Italian
NUMBER OF REFERENCES: 63

12/3/13 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0081441538 EMBASE No: 2006504612
Polymorphism of the promoter region and exon 1 of the CLTA4 gene in
endemic pemphigus foliaceus (fogo selvagem)
Favoni D.P.; Cerqueira L.B.; Roxo V.M.M.S.; Petzl-Erler M.L.
Laboratorio de Genetica Molecular Humana, Universidade Federal do Parana,
81531-990 Curitiba, PR, Brazil
AUTHOR EMAIL: perler@ufpr.br
CORRESP. AUTHOR: Petzl-Erler M.L.
CORRESP. AUTHOR AFFIL: Departamento de Genetica, Universidade Federal do
Parana, 81531-990 Curitiba, PR, Brazil
CORRESP. AUTHOR EMAIL: perler@ufpr.br

Brazilian Journal of Medical and Biological Research (Braz. J. Med.
Biol. Res.) (Brazil) September 1, 2006, 39/9 (1227-1232)
CODEN: RBPMB ISSN: 0100879X eISSN: 16784510
DOI: 10.1590/S0100-879X2006000900010
URL: <http://www.scielo.br/scielo.php?script=sciarttext&pid=S0100-879X2006000900010&lng=en&nrm=iso&tling=en>
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 26

12/3/14 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080639138 EMBASE No: 2005283430

The role of cytokines in the pathogenesis of autoimmune bullous skin disease

Rola cytokin w patomechanizmie chorob pecherzowych
Waszczykowska E.; Wysoczanska K.; Zebrowska A.
Katedra Dermatologii i Wenerologii, Uniwersytetu Medycznego, ul.
Krzemieńska 5, 94-017 Łódź, Poland
CORRESP. AUTHOR: Waszczykowska E.
CORRESP. AUTHOR AFFIL: Katedra Dermatologii i Wenerologii, Uniwersytetu
Medycznego, ul. Krzemieniecka 5, 94-017 Łódź, Poland

Alergia Astma Immunologia (Alergia Astma Immunol.) (Poland) December
1, 2004, 9/4 (179-186)
CODEN: AAIMF ISSN: 14273101
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: Polish SUMMARY LANGUAGE: English; Polish
NUMBER OF REFERENCES: 48

12/3/15 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0080278996 EMBASE No: 2004458124

Management of autoimmune skin disorders in the elderly
Loo W.J.; Burrows N.P. // Loo W.J.
Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, United
Kingdom // Department of Dermatology, Addenbrooke's NHS Trust, Hills
Road, Cambridge, CB2 2QQ, United Kingdom
AUTHOR EMAIL: wjl00@hotmail.com; wjl00@hotmail.com
CORRESP. AUTHOR: Loo W.J.
CORRESP. AUTHOR AFFIL: Department of Dermatology, Addenbrooke's NHS
Trust, Hills Road, Cambridge, CB2 2QQ, United Kingdom
CORRESP. AUTHOR EMAIL: wjl00@hotmail.com

Drugs and Aging (Drugs Aging) (New Zealand) November 9, 2004, 21/12
(767-777)
CODEN: DRAGE ISSN: 1170229X
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 50

12/3/16 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0078364443 EMBASE No: 2000414052

Autoimmune skin diseases
Le malattie autoimmuni della cute
Malorgio C.; Panizon F.
Clinica Pediatrica, IRCCS 'Burto Garofolo', Trieste, Italy
CORRESP. AUTHOR: Malorgio C.
CORRESP. AUTHOR AFFIL: Clinica Pediatrica, IRCCS 'Burto Garofolo',
Trieste, Italy

Medico e Bambino (Med. Bambino) (Italy) October 31, 2000, 19/8
(495-503)
CODEN: MBAMF
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: Italian SUMMARY LANGUAGE: English; Italian
NUMBER OF REFERENCES: 61

12/3/17 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0075806162 EMBASE No: 1994232651
Autoimmunity as a complication of interleukin 2 immunotherapy: Many
unanswered questions
Gaspari A.A.
Department of Dermatology, University of Rochester, Box 697, 601 Elmwood
Ave, New York, NY 14642, United States
CORRESP. AUTHOR: Gaspari A.A.
CORRESP. AUTHOR AFFIL: Department of Dermatology, University of
Rochester, Box 697, 601 Elmwood Ave, New York, NY 14642, United States

Archives of Dermatology (ARCH. DERMATOL.) (United States) August 5,
1994, 130/7 (894-897)
CODEN: ARDEA ISSN: 0003987X
DOI: 10.1001/archderm.130.7.894
DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation
LANGUAGE: English

12/3/18 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0073492421 EMBASE No: 1987020814
When to discontinue therapy in pemphigus vulgaris?
WANN IST ES MOGLICH, DIE THERAPIE BEIM PEMPHIGUS VULGARIS ABZUSETZEN?
Mashkilleysen N.; Eskelinen A.
Department fur Dermatologie, Stomatologisches Institut Moskau, Moskau,
U.S.S.R.
CORRESP. AUTHOR AFFIL: Department fur Dermatologie, Stomatologisches
Institut Moskau, Moskau, U.S.S.R.

H+G Zeitschrift fur Hautkrankheiten (H G Z. HAUTKR.) (Germany)
December 1, 1986, 61/22 (1596-1602)
CODEN: ZHKRA ISSN: 03010481
DOCUMENT TYPE: Journal RECORD TYPE: Abstract
LANGUAGE: German SUMMARY LANGUAGE: English

12/3/19 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0071805404 EMBASE No: 1981251814
Use of orthoclone monoclonal antibodies in the study of selected
dermatologic conditions
Berger C.L.; Kung P.; Goldstein G.; et-al
Dept. Dermatol., Columbia Univ., New York, NY 10032, United States
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Columbia Univ., New York, NY

10032, United States

International Journal of Immunopharmacology (INT. J. IMMUNOPHARMACOL.)
(United Kingdom) December 29, 1981, 3/3 (275-282)
CODEN: IJIMD ISSN: 01920561
DOI: 10.1016/0192-0561(81)90021-7
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

12/3/20 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2008 Elsevier B.V. All rts. reserv.

0071256724 EMBASE No: 1978401631
Pemphigus vulgaris and thymoma. A T-lymphocyte defect?
Kavli G.
Dept. Dermatol., Univ. 9012 Tromsø, Norway
CORRESP. AUTHOR AFFIL: Dept. Dermatol., Univ. 9012 Tromsø, Norway

British Journal of Dermatology (BR. J. DERMATOL.) (United Kingdom)
December 11, 1978, 99/1 (97-98)
CODEN: BJDEA ISSN: 00070963
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English

12/3/21 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

16839443 PMID: 16417225
Tolerance induction by the blockade of CD40/CD154 interaction in
pemphigus vulgaris mouse model.
Aoki-Ota Miyo; Kinoshita Mari; Ota Takayuki; Tsunoda Kazuyuki; Iwasaki
Toshiro; Tanaka Sigeru; Koyasu Shigeo; Nishikawa Takeji; Amagai Masayuki
Department of Dermatology, Keio University School of Medicine,
Shinjuku-ku, Tokyo, Japan.
Journal of investigative dermatology (United States) Jan 2006, 126
(1) p105-13, ISSN 0022-202X--Print Journal Code: 0426720
Publishing Model Print; Comment in J Invest Dermatol. 2006
Jan;126(1) 11-3; Comment in PMID 16417211
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

12/3/22 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

08141983 PMID: 3101298
[When is it possible to discontinue therapy in pemphigus vulgaris?]
Wann ist es möglich, die Therapie beim Pemphigus vulgaris abzusetzen?
Mashkilleysen N; Eskelinen A
Zeitschrift für Hautkrankheiten (GERMANY, WEST) Nov 15 1986, 61 (22)
p1596-602, ISSN 0301-0481--Print Journal Code: 0367576
Publishing Model Print
Document type: Case Reports; English Abstract; Journal Article
Languages: GERMAN

Main Citation Owner: NLM
Record type: MEDLINE; Completed

12/3/23 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

06809937 PMID: 6215423
Use of monoclonal antibodies specific for T cell subsets in cutaneous disorders: I. Quantitative analysis of peripheral blood lymphocytes.
Faure M; Thivolet J
Journal of clinical immunology (UNITED STATES) Jul 1982, 2 (3 Suppl)
p103S-110S, ISSN 0271-9142--Print Journal Code: 8102137
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

12/3/24 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2008 Dialog. All rts. reserv.

05608378 PMID: 347546
[Immunological aspects of malignant lymphomas]
Aspetti immunologici dei linfomi maligni.
Hancock B W; Richmond J
Recenti progressi in medicina (ITALY) Feb 1978, 64 (2) p217-29,
ISSN 0034-1193--Print Journal Code: 0401271
Publishing Model Print
Document type: Journal Article; Review
Languages: ITALIAN
Main Citation Owner: NLM
Record type: MEDLINE; Completed

12/3/25 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

148031934 CA: 148(2)31934m PATENT
Ligands or antibodies capable of binding to CD3 and CD55 for producing regulatory CD4+ T cells to treat antibody- or cell-mediated autoimmune disease
INVENTOR(AUTHOR): Spendlove, Ian; Durrant, Linda Gillian
LOCATION: UK,
ASSIGNEE: The University of Nottingham
PATENT: PCT International ; WO 2007135401 A2 DATE: 20071129
APPLICATION: WO 2007GB1864 (20070518) *GB 20069924 (20060519)
PAGES: 65pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC8/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H EP
A61P-0037/00 A I L B 20060101 H EP
A61K-0038/17 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA;

NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM;
SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/26 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

147446877 CA: 147(21)446877x PATENT
Combination therapy for treating autoimmune diseases
INVENTOR(AUTHOR): Koenig, Scott
LOCATION: USA
ASSIGNEE: Macrogenics, Inc.
PATENT: PCT International; WO 2007117600 A2 DATE: 20071018
APPLICATION: WO 2007US8579 (20070406) *US 2006PV789899 (20060407) *US
2006PV844095 (20060913)
PAGES: 38pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:
A61K-0039/395 A I F B 20060101 H US
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB;
GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR;
KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ;
NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL;
SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA DESIGNATED REGIONAL: AT; BE; BG; CH
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/27 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

146006355 CA: 146(1)6355z PATENT
Biomarkers for diagnosis and treatment of diseases having an autoimmune
and/or inflammatory component responsive to anti-CD40 monoclonal
antibodies
INVENTOR(AUTHOR): Aukerman, Sharon Lea; Jallal, Bahija; Luqman, Mohammad
LOCATION: USA
ASSIGNEE: Novartis AG; Xoma Technology
PATENT: PCT International; WO 2006125117 A2 DATE: 20061123
APPLICATION: WO 2006US19325 (20060518) *US 2005PV682575 (20050518) *US
2005PV749336 (20051209)
PAGES: 145pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:

IPCR/8 + Level Value Position Status Version Action Source Office:
G01N-0033/564 A I F B 20060101 H EP
G01N-0033/68 A I L B 20060101 H EP
A61P-0037/00 A I L B 20060101 H EP
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LK;
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;

TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

12/3/28 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

145025794 CA: 145(2)25794n JOURNAL
Inhibition of pemphigus vulgaris by targeting of the CD40-CD154
co-stimulatory pathway: a step toward antigen-specific therapy?
AUTHOR(S): Liu, Zhi; Li, Ning; Diaz, Luis A.
LOCATION: Department of Dermatology, University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA
JOURNAL: J. Invest. Dermatol. (Journal of Investigative Dermatology)
DATE: 2006 VOLUME: 126 NUMBER: 1 PAGES: 11-13 CODEN: JIDEAE ISSN:
0022-202X LANGUAGE: English PUBLISHER: Nature Publishing Group

12/3/29 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480777 CA: 142(26)480777w PATENT
Antagonistic anti-human CD40 monoclonal antibodies and fragments for
treating proliferative, cancerous and autoimmune disease
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,
Isabel; Chen, Bao-Lu; Lu, Xiaofeng; Lee, Sang Hoon; Hurst, Deborah
LOCATION: USA
ASSIGNEE: Chiron Corporation
PATENT: PCT International ; WO 200544854 A2 DATE: 20050519
APPLICATION: WO 2004US37152 (20041104) *US 2003PV517337 (20031104) *US
2003PV525579 (20031126) *US 2004PV565710 (20040427)
PAGES: 176 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-016/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MK; MG; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

12/3/30 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2008 American Chemical Society. All rts. reserv.

142480770 CA: 142(26)480770p PATENT
Antagonistic monoclonal antibodies and derivatives specific to human CD40
antigen for treatment of autoimmune and inflammatory diseases
INVENTOR(AUTHOR): Long, Li; Luqman, Mohammad; Yabannavar, Asha; Zaror,
Isabel
LOCATION: USA

ASSIGNEE: Chiron Corporation
PATENT: PCT International ; WO 200544306 A2 DATE: 20050519
APPLICATION: WO 2004US36957 (20041104) *US 2003PV517337 (20031104) *US
2003PV525579 (20031126) *US 2004PV565710 (20040427)
PAGES: 114 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SJ; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ
; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LU; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

12/3/31 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

139322294 CA: 139(21)322294v PATENT
Treating or preventing autoimmune disease using an IL-16 inhibitor
INVENTOR(AUTHOR): Delovitch, Terry L.
LOCATION: Can.,
ASSIGNEE: The John P. Roberts Research Institute
PATENT: PCT International ; WO 200386457 A2 DATE: 20031023
APPLICATION: WO 2003CA501 (20030407) *US PV370535 (20020408)
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PH; PL; PT; RO; RU; SC;
SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA;
ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

12/3/32 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

138168815 CA: 138(12)168815m PATENT
B7-related nucleic acids and polypeptides useful for immunomodulation
INVENTOR(AUTHOR): Mikesell, Glen E.; Shen, Henry
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20030031675 A1 DATE: 20030213
APPLICATION: US 77023 (20020215) *US PV209811 (20000606) *US PV272107
(20010228) *US 875338 (20010606)
PAGES: 163 pp., Cont.-in-part of U.S. Ser. No. 875,338. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424178100; A61K-039/395A; C07H-021/04B; C12P-021/04B;
C12N-001/21B; C12N-005/04B; C12N-005/06B

12/3/33 (Item 9 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

136278158 CA: 136(18)278158r PATENT
Control of T cell processes using combinations of antagonists of
interleukin-2 and interleukin-15
INVENTOR(AUTHOR): Li, Xian Chang; Strom, Terry; Zheng, Xin Xiao
LOCATION: USA
ASSIGNEE: Beth Israel Deaconess Medical Center, Inc.
PATENT: PCT International ; WO 200222805 A2 DATE: 20020321
APPLICATION: WO 2001US28612 (20010914) *US PV232251 (20000914)
PAGES: 80 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C12N-015/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH; PL; PT; RO; RU; SD; SE; SG;
SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY;
KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL
; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN;
TD; TG

12/3/34 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2008 American Chemical Society. All rts. reserv.

131057772 CA: 131(5)57772f PATENT
Methods to treat undesirable immune responses
INVENTOR(AUTHOR): Conti-Fine, Bianca M.
LOCATION: USA
ASSIGNEE: Regents of the University of Minnesota
PATENT: PCT International ; WO 9930736 A2 DATE: 19990624
APPLICATION: WO 98US26787 (19981216) *US 991143 (19971216)
PAGES: 221 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP;
KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO;
NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ;
VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM
; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE;
SN; TD; TG
?